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CHAPTER I  
 
BACKGROUND AND LITERATURE REVIEW 
 
Introduction 
Positive-sense RNA viruses are the cause of a large percentage of severe human infections. 
Many positive-sense RNA ((+)RNA) viruses (such as Chikungunya, Dengue, Zika, West Nile, 
SARS-CoV and MERS-CoV viruses) have recently emerged in human populations (Bolles et al., 
2011; Hilgenfeld and Peiris, 2013; Murray et al., 2010; Shuaib et al., 2016; Tsetsarkin et al., 
2007). SARS-CoV and MERS-CoV viruses belong to the group of viruses called coronaviruses 
(CoVs). Beyond these well-known, highly pathogenic, human CoVs, four CoVs are endemic in 
human populations, often resulting in symptoms of the “common cold”, bronchiolitis, or 
pneumonia (Graham et al., 2013). CoVs are enveloped, (+)RNA viruses belonging to the order 
Nidovirales in the family Coronaviridae. CoVs are named for their crown-like appearance in 
electron microscopy (EM) images caused by the protrusion of spike fusion proteins across the 
surface of virions (Masters, 2006) (Figure 1). CoVs encode the largest genomes of any known 
(+)RNA virus, with genomes ranging from 27-34kb (Gorbalenya et al., 2006; Stenglein et al., 
2014). This size is striking since most (+)RNA viruses encode genomes of 12kb and below 
(Gorbalenya et al., 2006), and the only known (+)RNA viruses with genomes >20kb are in the 
order Nidovirales. Similar to all other (+)RNA viruses, CoVs must encode an RNA-dependent 
RNA polymerase (RdRp) to facilitate genome replication. Replication fidelity is the relative 
number of correct vs. incorrect nucleotides incorporated into nascent viral genomes during 
replication. RdRps – as well as other polymerases without encoded proofreading – incorporate 
nucleotides with low-fidelity, resulting in high viral mutation rates. However, in contrast to all 
other (+)RNA viruses, coronaviruses and the other large nidoviruses encode a proofreading 3′-5′ 
exoribonuclease (ExoN) (Eckerle et al., 2010; Minskaia et al., 2006; Smith et al., 2013). In 
addition to ExoN, non-structural protein 10 (nsp10), a small non-enzymatic protein, is involved 
in CoV replication fidelity (Bouvet et al., 2014; Smith et al., 2015). All biochemical and genetic 
data over the past decade support the hypothesis that CoVs encode a multi-component 
polymerase-fidelity complex and regulate their fidelity by mechanisms in addition to the RdRp.  
	 2	
 
 
 
 
 
Figure 1. Coronavirus virion structure and EM  
Coronaviruses are enveloped viruses that encode and package structural proteins in the virions they 
release. A. A representative coronavirus particle where S is the spike fusion protein, M is the 
membrane protein and E is the envelope protein. Within the particle is the (+)RNA genome coated 
with nucleocapsid protein, N. Image modified from Clint Smith. B. Representative negative-contrast 
electron microscopic (EM) images of HCoV-229E, top, and Murine Hepatitis virus (MHV), bottom 
(from (Murphy, 2012) with permission). The particle decoration with spike protein results in the 
appearance of crown, giving coronaviruses their name.	
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For most (+)RNA viruses the RdRp has been the only protein implicated in regulation of fidelity. 
However, in work published since this dissertation research began, a viral helicase has also been  
shown to be capable of influencing the fidelity of Chikungunya virus (Stapleford et al., 2015). 
This study demonstrates the potential for other virus-encoded proteins to be involved in fidelity 
regulation. Similarly, in Mycobacterium tuberculosis the β2 clamp, which is a processivity 
factor, encodes determinants of fidelity (Gu et al., 2016). In CoVs, like other (+)RNA viruses, 
the RdRp is essential to nucleotide incorporation and therefore necessarily functions in fidelity 
regulation. However, in the presence of the proofreading ExoN and putative multi-protein 
replication-transcription complex (RTC) an important question is how the RdRp participates in 
replication fidelity. In this dissertation research, I investigate the phenotypic relationship 
between the proofreading ExoN and the RdRp of CoVs. I identify RdRp determinants that 
regulate nucleotide selectivity and, for one determinant, support increased overall fidelity. I 
demonstrate that proofreading by the murine hepatitis virus (MHV) ExoN, encoded in 
nonstructural protein 14 (nsp14-ExoN), is epistatic to nucleotide selectivity by the RdRp, defined 
here as a situation where the phenotype of one viral protein masks the phenotype of genetic 
variants of another viral protein. I provide evidence that determinants of fidelity within the CoV 
RdRp can be predicted based on RdRp structure-function studies from other (+)RNA families, 
and thus may be common across viral orders. Additionally, I demonstrate that selection for 
resistance to a specific nucleotide in the CoV RdRp can occur while maintaining baseline 
susceptibility, or even increased susceptibility, to other nucleotides, demonstrating that 
nucleotide selectivity by the CoV RdRp is quite adaptable. Finally, I present progress toward the 
development of a quantitative assay to define the fidelity of CoVs during replication in cells 
without exogenous nucleoside analogs.  
Coronavirus genome organization and replication strategy 
Coronaviruses possess the largest known RNA genomes ranging from 27-34kb (Gorbalenya et 
al., 2006; Stenglein et al., 2014). Upon entering a host cell the genome functions as messenger 
RNA (mRNA), complete with a 5′ cap and a polyA tail (Shi and Lai, 2005). These features 
protect the genome from degradation by the cell and allow use of host translational machinery. 
At either end of the genome are untranslated regions (UTRs), which include highly structured 
regions of RNA (Goebel et al., 2007; Hsue and Masters, 1997; Kang et al., 2006). The remainder 
of the genome can be divided into nonstructural proteins (nsps) and structural proteins. CoVs 
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Figure 2. Coronavirus genome organization, replication and transcription 
A. The genomes of coronaviruses can be divided into nonstructural and structural proteins. The 
nonstructural proteins (nsps) are encoded in the first Orf, which is expressed as either Orf1a including 
nsps1-11 or Orf1ab including nsps 1-10 and 12-16. Coronavirus genomes are complete mRNAs with 
5′-caps and polyA tails. The RdRp of coronaviruses in encoded in nsp12 and is responsible for 
transcription and replication of genomic and sub-genomic RNAs. B. Genomes are replicated by 
continuous transcription and through negative-sense anti-genome intermediates. Sub-genomic mRNAs 
are generated by discontinuous transcription linking body TRS’s to the 5′-leader TRS. This results in 
identical 5′ and 3′ ends for all viral RNAs of the same polarity. Amplification of positive-sense sub-
genomic mRNAs occurs from the negative-sense sub-genomic RNAs. This figure is adapted from 
(Perlman and Netland, 2009; Raaben et al., 2008) and (Smith et al., 2014).	
	 5	
encode 16 nsps all within the first open reading frame (Orf) (Figure 2a). The first Orf (Orf1ab) is 
further broken into Orf1a and Orf1b and requires use of a programmed -1 ribosomal frameshift 
guided by a structured RNA region in order to express all 16 nsps (Bredenbeek et al., 1990). This 
slippery sequence results in a frameshift roughly 40% of the time it is translated (Irigoyen et al., 
2016), thereby allowing for around 2.5 times as many protein products of Orf1a as Orf1b. In 
either instance the full Orf1a or Orf1ab is translated as one large polyprotein. The next step in 
replication is the proteolytic maturation of intermediate and mature nsps from the replicase 
polyprotein by CoV encoded proteases within the polyprotein. The specific number of proteases 
is virus specific. In the case of MHV - the most well studied of the coronaviruses, three separate 
proteases are required to process all 16 nsps (Shi and Lai, 2005).  
Structural proteins are encoded within the remaining Orfs, the number of which varies by virus. 
Functionally, this provides both a temporal delay in the expression of these proteins, as the 
subgenomic mRNAs are not immediately available to the host machinery for translation, as well 
as differential expression levels (Irigoyen et al., 2016). Once the Orf1ab nonstructural proteins 
are expressed and processed they form RTCs, which transcribe subgenomic mRNAs and 
replicate the full-length genome. Transcription occurs in two forms, continuous and 
discontinuous, the result of which is both full-length negative-sense RNA genomes and a nested 
set of sub-genomic negative-sense RNAs with lengths corresponding to various portions of 
sequence downstream of Orf1ab (Perlman and Netland, 2009). Many specific details of the 
mechanism behind the generation of sub-genomic RNA require further study. What is known is 
that a transcriptional regulator sequence (TRS) is present in the 5′-UTR and at the beginning of 
each Orf. During the process of generating subgenomic RNA, discontinuous replication occurs 
producing negative-sense RNAs which all possess identical 5′-UTRs and one TRS (Figure 2b). 
Therefore, both genomic and subgenomic RNAs have identical 5′ and 3′ ends. The CoV RNA-
dependent RNA polymerase encoded in nsp12 is responsible for both transcription and 
replication of viral RNA (Ahn et al., 2012). However, some early evidence suggested that there 
are two separate polymerase activities, one that mainly resulted in negative RNA synthesis and 
one in positive (Brayton et al., 1982). Therefore, the RdRp may function within complexes of 
two different compositions and/or may be present in two different forms during replication (Ahn 
et al., 2012; Cheng et al., 2005). 
	 6	
The nonstructural proteins of coronaviruses are mainly involved in transcription and replication 
of the genome and protecting these viral processes from cellular innate sensing of viral 
components. In contrast, the structural proteins are mainly involved in packaging and 
dissemination of viral particles. Spike is the receptor-binding and fusion protein of CoVs, which 
largely defines host species and tropism within a host. CoVs utilize a wide range of cellular 
receptors. The MHV spike has a receptor-binding domain (RBD) that recognizes the murine 
CEACAM1 protein (Dveksler et al., 1991), which is required and sufficient for MHV infection 
of cells in culture. Similarly, the RBD of MERS-CoV spike recognizes human DPP4 and the 
presence of cell surface DPP4 is necessary and sufficient for infection of various cell types (Raj 
et al., 2013). However, additional factors can enhance infection, as is the case during MHV or 
MERS-CoV infections (Chan et al., 2016; Thorp and Gallagher, 2004), and these cofactors may 
be important for infections in vivo. 
Coronavirus diversity and emergence 
Coronaviruses infect a wide array of species and have emerged as highly virulent human 
pathogens twice in this century. In humans, symptoms range from the common cold to severe 
acute respiratory syndromes, resulting in severe morbidity and death. Currently, five CoVs are 
known to circulate in humans (HCoVs): HCoV-NL63, -229E, -OC43, -HKU1 and MERS-CoV. 
The sixth HCoV, SARS-CoV, is no longer circulating in human populations. However, a bat 
SARS-like CoV that utilizes the SARS-CoV receptor, ACE2, was discovered in Chinese 
horseshoe bats (Rhinolophus sinicus) (Ge et al., 2013), showing that an ancestral virus is still 
circulating in bats. CoVs are adept at transcending species barriers and thriving in new host 
environments. All HCoVs are proposed to have emerged as zoonotic infections. Molecular clock 
analysis predicts that HCoV-NL63 emerged in the human population between 1190 and 1449 CE 
(Huynh et al., 2012), HCoV-229E between 1501-1883 CE (Pfefferle et al., 2009) (or more 
recently (Crossley et al., 2012)), and OC43 between 1866-1918 CE (Vijgen et al., 2005). The 
date of emergence for HKU1 is unknown (Woo et al., 2005). SARS-CoV was identified in 2003 
(Peiris et al., 2003) and MERS-CoV in 2012 (Zaki et al., 2012), both within a year of entering 
the human population (Figure 3). This demonstrates that emergence of novel CoVs into the 
human population is not an uncommon phenomenon; although, it may be a (relatively) recent 
trend correlating with the beginning of the most recent era of human population expansion. 
However, the mechanisms behind CoV evolution and adaption have not been fully elucidated.  
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Figure 3. Timeline for the emergence of human coronaviruses  
Molecular clock analysis suggests that all current HCoVs emerged in human populations with the last 
millennium, roughly corresponding to the most dramatic human population expansion. SARS-CoV 
and MERS-CoV emerged during the time of surveillance and so have specific years ascribed to their 
entry into the human population. HKU1 is the only HCoV for which a timeframe of zoonotic 
transmission has yet to be identified. All HCoVs have been linked to bats except for HCoV-OC43. 
Several have evidence for transmission to humans through intermediate hosts such as camels for 
MERS-CoV, civet cats for SARS-CoV and alpacas for HCoV-NL63.	
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Coronaviruses are found in a plethora of species from birds to bats to humans (Woo et al., 2009). 
The majority of the diversity of Alphacoronavirus and Betacoronavirus species, which 
exclusively infect mammals, exists in bats (Drexler et al., 2013). CoVs are predicted to have co-  
evolved with bats for millions of years, possibly since their evolutionary split from birds 
(Wertheim et al., 2013). Bats are optimal species for the emergence of novel viruses into humans 
and other mammalian species for several reasons including their long life spans, social structure, 
ability to fly and proximity to the base of the mammalian phylogenetic tree (Calisher et al., 
2006). All of the known HCoVs have proposed bat origins with the exception of HCoV-OC43, 
which emerged from a bovine CoV (Huynh et al., 2012). However, emergence into the human 
population often requires passage through an intermediate host. This was the case for SARS-
CoV, whose transmission pattern is well documented (thoroughly reviewed in (Hilgenfeld and 
Peiris, 2013)), and involved cyclical passage between civet cats and humans. Similarly, the 
closest known relative of 229E was recently discovered in alpacas, suggesting interspecies 
transmission to humans might have been through alpacas (Crossley et al., 2012) instead of 
directly through bats (Pfefferle et al., 2009). Finally, MERS-CoV likely infects humans through 
dromedary camels as intermediate hosts (Reusken et al., 2016) (Figure 3). 
MERS-CoV was originally isolated in June 2012 from a 60-year-old male Saudi Arabian. He 
presented with acute respiratory distress syndrome (ARDS) and multiple organ dysfunction 
syndrome (MODS) (van Boheemen et al., 2012), which eventually resulted in death. As of 
December 5th, 2016, there have been 1841 WHO laboratory-confirmed cases with 652 known 
deaths, resulting in a case fatality rate of 35%. Interestingly, the case fatality rate for secondary 
cases is closer to 20% (Cauchemez et al., 2014). Therefore, it is possible that there are many 
symptomatic cases that have occurred, but have not been recorded. The R0 (the number of 
individuals likely to be infected by a single infected individual) for uninterrupted MERS-CoV 
infections is between 0.7-1.5; however, with current intervention protocols in place, R0 is 
predicted to remain below 1, indicating human-to-human transmission is not currently 
sustainable (Breban et al., 2013; Cauchemez et al., 2014). Supporting this, human cases have 
been sporadic, originating from diverse foci within the Middle East, with abruptly terminating 
transmission cycles. Imported cases have been reported throughout Europe and in Tunisia, also 
with only very limited spread (to close family members and healthcare workers) (Penttinen et al., 
2013). An outbreak of MERS-CoV in South Korea was the only exception to this, which resulted 
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in 186 laboratory-confirmed cases during 2015. However, this outbreak spread almost entirely by 
nosocomial transmission, with 178 cases contracted in the healthcare setting (Lee et al., 2016). 
Together, these observations suggest a recurrent introduction to the human population through 
alternative hosts. 
Current evidence suggests that dromedary camels are an intermediate host in the transmission of 
MERS-CoV to humans (Reusken et al., 2016). It was first noticed that multiple individuals 
infected with MERS-CoV infections were associated with close contact with dromedary camels. 
Antibodies to MERS-CoV and MERS-CoV infectious genomes have been found in dromedary 
camels throughout the Middle East (Briese et al., 2014; Hemida et al., 2013). However, bats may 
also be involved in some cases where interaction with camels or sick humans is not identified; 
partial MERS-CoV sequences with 100% sequence identity to human MERS-CoV have been 
identified in Taphozous perforatus bats in Saudi Arabia (Memish et al., 2013). No evidence has 
been collected that suggests close contact with bats for any human MERS-CoV case to date. 
However, some evidence has been provided that suggests oral-fecal transmission could be a 
route of spread (Goh et al., 2013); when combined with demonstrated high environmental 
stability (van Doremalen et al., 2013), contact with guano becomes a potential source of 
infection. Further investigation is needed to fully define transmission patterns of MERS-CoV. 
With infections continuing to be identified in 2016, it is likely that MERS-CoV will be a 
persistent problem in the Middle East until an intervention can be identified and implemented. 
The case of MERS-CoV demonstrates that the emergence of a highly pathogenic HCoV was not 
a one-time event and that understanding the history of CoV evolution and identifying universal 
CoV targets for prevention and treatment are critically important goals.  
Generation of RNA virus diversity through mutation rates and population sizes 
RNA viruses are proposed to be among the most diverse replicative units currently in existence 
(Mokili et al., 2012). They infect an exceptional range of hosts, and regularly cross species 
barriers to further expand this range. An example of this was described in a previous section with 
MERS-CoV. RNA virus replication results in the incorporation of a relatively high number of 
mutations, ranging from 10-4 to 10-6 mutations per site per round of replication (µ) (Castro et al., 
2005; Crotty et al., 2001; Sanjuán et al., 2010; Schaaper, 1993; Smith and Denison, 2012). This 
is low-fidelity replication when compared with the DNA replication of cellular life forms, which 
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are observed to be between 10-9 to 10-11 µ (Drake et al., 1998; Schaaper, 1993) (Figure 4). It is 
often stated that the low-fidelity replication of RNA viruses is due to the poor nucleotide 
selectivity of RNA-dependent RNA polymerases (RdRps) vs. that of DNA polymerases. 
Although the mutation rate of RNA viruses is driven mainly by the fidelity of nucleotide 
incorporation by the RdRp, data suggest that this base misincorporation rate is on average 
equivalent to that of DNA polymerases (Sanjuán et al., 2010; Schaaper, 1993). The difference 
between the observed mutation rates of RNA and DNA replication is instead accounted for by 
the availability of proofreading and mismatch repair in DNA based organisms. No known RdRp 
has a proofreading domain as part of the protein and only coronaviruses, along with the other 
large nidoviruses, are known or predicted to encode a proofreading exoribonuclease (Gorbalenya 
et al., 2006). Arenaviruses encode exoribonucleases; however, to date the activity of these 3′-5′ 
exoribonucleases has only been implicated in immune regulation (Hastie et al., 2011; Huang et 
al., 2015). Studies from our lab show that CoVs display increased fidelity, in the range of 10-6 to 
10-7µ comparable to DNA replication with proofreading but lacking mismatch repair (Eckerle et 
al., 2010; 2007; Smith et al., 2014) (Figure 4). 
Mutations provide the raw material for adaptation and emergence, so low-fidelity replication is 
likely responsible for the capacity of RNA viruses to adapt to new host species and ever 
changing environmental pressures (Domingo, 2010; Eigen, 1993; Sanjuán, 2012). Considering 
the mutation rates described along with genome sizes averaging around 12,000 base pairs, RNA 
viruses generally incorporate between 0.4 and 1.1 mutation per genome (Domingo et al., 1996; 
Drake et al., 1998). Adding to this source of variation, RNA viruses rarely exist as individuals. 
Instead, RNA viruses undergo logistic growth, resulting in large genetically diverse populations 
that could, theoretically, include a substitution at every site in their genome (Lauring and 
Andino, 2010). Therefore, RNA viruses exist as a population of heterogeneous yet related 
viruses (mutant swarms) rather than a group of genetically identical clones. Mutant swarms have 
been shown to display phenotypes that differ from that of their consensus sequence alone 
(Ojosnegros et al., 2011). In other words, mutant swarms seem to be more than a simple sum of 
their parts. Increasing fidelity results in decreased pathogenesis and spread, either through a 
decrease in replication speed, the ability to adapt, or both (Lauring and Andino, 2010; Pfeiffer 
and Kirkegaard, 2005; Regoes et al., 2012; Vignuzzi et al., 2008). One of the most notable 
examples of this phenomenon was described in poliovirus. Wild type poliovirus is neurovirulent 
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Figure 4. Comparison of mutation rates between RNA viruses and cellular DNA polymerases 
All forms of nucleic acid-based replication result in errors. RNA or DNA polymerases generally 
manifest incorporation errors of roughly 10-4 to 10-6 mutations per site per round of replication (µ). 
Coronaviruses, and the other large nidoviruses, are unique among RNA viruses in encoding a 
proofreading 3′-5′ exoribonuclease, which decreases the error rate to between 10-6 to 10-7 µ. Cellular 
DNA replication results in the lowest number of misincorporations. 10-9 to 10-11 µ: mismatch-excision 
repair pathways in addition to proofreading permit these low mutation rates. Adapted from (Smith et 
al., 2014).	
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in mice but high-fidelity poliovirus populations were unable to target the brains of mice. 
However, the identical high-fidelity poliovirus strain forced toward greater population diversity  
(through the use of mutagens) was able to infect the brain (Vignuzzi et al., 2005b). No single 
mutation was identified that conferred this expanded tropism. The ability of populations of 
viruses to act collectively is likely dependent on the fact that multiple viruses often infect a 
single cell (Cheng et al., 2005). Multi-particle infections can allow genomic products to be 
shared during infection (Combe et al., 2015; Lauring et al., 2013; Ojosnegros et al., 2011). In 
some cases this may lead to novel functions by mutated proteins that are normally intolerant to 
mutation because of their essential role in viral replication. Overall, mutations and large 
population sizes combine to enhance the adaptability of viruses.  
Lethal mutagenesis and error catastrophe 
Although the generation of mutations is essential for adaptation, one of the prevailing 
misconceptions regarding viral mutation rates is that increasing the number of mutations 
proportionally enhances the rate at which viral populations adapt (Elena and Sanjuán, 2005; 
Furio et al., 2005). This belief has contributed to a perceived danger of mutator variants that 
contradicts the evidence; instead, what is observed is that increasing the mutation rate beyond 
that of the wild type virus often results in a decrease in fitness (Gnädig et al., 2012; Graham et 
al., 2012; Lee et al., 1997). There are two main reasons for this decrease in fitness: 1) the 
majority of viral mutations are deleterious (Drake and Holland, 1999; Lauring and Andino, 2010; 
Lee et al., 1997), and 2) RNA viruses seem to replicate at or around the error threshold. The error 
threshold is the maximum mutations a replicating entity can tolerate before no longer being able 
to replicate resulting in lethal mutagenesis (Lauring and Andino, 2010). Marginal increases in 
mutation rates could result in too many deleterious mutations within the population (Domingo et 
al., 2012). The error threshold was first demonstrated by treatment of poliovirus with 5-FU 
which resulted in a set increase in mutation frequency no matter the amount of mutagen applied 
but with decreasing surviving virus (Holland et al., 1990). This suggested that the virus could 
only tolerate increased mutations up to the error threshold before ceasing to replicate. This has 
also been demonstrated for coronaviruses with an inactivated nsp14-ExoN (nsp14-ExoN(-)) 
(Smith et al., 2013). Thus, RNA viruses exist within a narrow sequence space where fidelity and 
infidelity are balanced. The enzymatic functions of RNA viruses must be balanced to achieve 
optimal replication, spread and survival.  
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As stated previously, CoVs encode the largest (+)RNA genomes, and increased fidelity in CoVs 
is likely required for maintenance of these large genomes (Smith et al., 2014). These extensive 
genomes encode for an array of virus-specific proteins, which direct the mechanisms CoVs use 
to enter cells and usurp the metabolic machinery. Larger genomes are accompanied by 
fundamental difficulties not present for organisms of smaller size. First, there is a limit to the 
number of mutations that are tolerable within a single genome while maintaining function (Chen 
and Shakhnovich, 2009; Crotty and Andino, 2002; Graci et al., 2012), and given a similar 
propensity for mutations by the polymerase, errors increase as the length of a genome increases. 
Next, polymerases have inherent limits to processivity, and replication requires generation of full 
genomes. The generation of full genomes is impeded when length increases beyond the 
processivity of a polymerase. Transcription of the genome similarly requires mechanisms for 
efficiently replicating RNA through all genes. Additionally, products of viral replication are 
potential targets of the innate immune system, which the virus must regulate in order to optimize 
replication. So, as the size of the genome increases so do the substrates that must be managed. 
However, many of these issues are directly addressed through the increased genome size of 
CoVs. Models have been proposed that envision large CoV replication-transcription complexes 
(RTCs) including nsp7-14 (Ma et al., 2015; Smith et al., 2014). Many of these proteins may 
directly address the size of the CoV genome. For instance nsp7 and nsp8 likely function together 
as a processivity clamp and nsp14-ExoN, with enhancement from the non-enzymatic nsp10 
protein, is able to correct errors introduced by the polymerase. Interestingly, these models - 
based on a combination of available structural, biochemical and biological data - more closely 
resemble the replication complexes observed in DNA-based organisms rather than those of other 
RNA-encoded viruses. 
Structures of, and nucleotide selection by, the RdRps of RNA viruses 
The RdRp is central to the replication of RNA viruses and is generally the key regulator of 
nucleotide selectivity and fidelity (Arnold et al., 2005; Campagnola et al., 2015). The CoV RdRp 
must similarly be essential to the regulation of nucleotide selectivity and overall fidelity of CoV 
replication. However, CoVs, and other large nidoviruses, replicate with higher fidelity than all 
other known (+)RNA viruses (Eckerle et al., 2010; Smith et al., 2013) and this is attributed to 
proofreading by nsp14-ExoN. All known RNA viruses encode for RdRps, and most also encode 
for a helicase. Generally, the replication complexes of RNA viruses are limited in size. However, 
	 14	
CoVs encode larger RTCs with their extensive genomes. Some of the encoded proteins are 
ubiquitous throughout the RNA virus world such as the RdRp. Others are unique to members of 
the Nidovirales – including CoVs – such as nsp14-ExoN and nsp10, a modulator of nsp14-ExoN 
activity (Bouvet et al., 2012; Smith and Denison, 2013). Still, others have functions that are not 
yet fully understood within the context of infection such as the uridylate-specific endonuclease 
activity of nsp15. With so many CoV-specific proteins involved in replication, it is possible that 
selective pressures acting on the CoV RdRp differ compared to the RdRps of other RNA viruses.  	All described polymerase structures (including RdRps) resemble a “cupped right hand” with 
fingers, palm and thumb domains (Ng et al., 2008) (Figure 5). The fingers form a channel that 
allows entry of the template RNA and ribonucleoside triphosphates (rNTPs) and assist in proper 
positioning of incoming nucleotides in the active site (Ferrer-Orta et al., 2007). The palm 
contains the active site, and the thumb functions in contacting exiting nascent RNA (Ferrer-Orta 
et al., 2007; 2015; Gong and Peersen, 2010). The characteristic Gly-Asp-Asp (GDD) active site 
sequence of RdRps sits within the palm domain; CoVs instead encode SDD. All polymerases 
have “open” and “closed” conformations that are essential to polymerization and processivity. In 
most polymerases, transition from one to the other involves separation of the fingers and thumb 
domain while the palm domain remains in an active conformation. Conversely, all RdRps with 
solved structures display strong interactions between the fingers and thumb domains that are not 
released during polymerization (Ferrer-Orta et al., 2007). This is likely the case for CoV as well, 
although there are no solved structures for any CoV RdRps to date. Supporting this, CoV RdRp 
core domains can be modeled against solved structures of other viral RdRps (Sexton et al., 2016; 
Xu et al., 2003) (Figure 5).  
Structural studies have begun to elucidate the mechanisms of ribonucleotide addition by RdRps. 
Residues around the active site are responsible for correct selection of nucleotide bases and 
sugars. They are also responsible for coordinating the cations required for catalyzing new 
phosphodiester bonds and catalysis itself. However, ribonucleotide addition is not a static 
process; as stated above, the active site is found in both open and closed conformations (Gong 
and Peersen, 2010). Active site closure involves shifting amino acid positions throughout the 
RdRp structure providing a mechanism by which residues distant from the active site alter 
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Figure 5. Model of the MHV RdRp core domain 
All RdRps share a structurally homologous core that can be subdivided into fingers, palm and thumb 
domains. Unique to RdRps is a strong interaction between the fingers and thumb domains, which 
prevents the two domains from separating during shifts from open to closed conformations. The active 
site of all RdRps is located in the palm domain and typically contains a central catalytic GDD motif; 
however, CoVs instead encode an SDD catalytic triad, highlighted in the above structural model.	
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elongation rates and nucleotide selection (Arnold et al., 2005). The extensive interactions 
between the fingers and thumb domains of RdRps prevent the fingers from swinging out when 
transitioning between open and closed conformations, as is the case for other polymerases (Gong 
and Peersen, 2010). Therefore, any residue in the fingers or thumb that alters the flexibility 
required for shifting between conformations can affect fidelity. Additionally, residues of the 
fingertips make first contact with incoming nucleotides so substitutions in these residues can 
alter fidelity of nucleotide selection (Curti and Jaeger, 2013).  
The CoV replication-transcription complex (RTC) 
All RdRps share the above characteristics, however, there is also diversity among RdRps. 
Additional domains are often present that encode a variety of functions such as 
methyltransferase, endonuclease, polyribonucleotidyl-transferase, guanylyltransferase, 
membrane targeting, protein-protein binding or protein-RNA binding activities (Ferrer-Orta et 
al., 2007; 2015; Gong and Peersen, 2010; Perlman and Netland, 2009). CoVs similarly encode a 
CoV-specific domain within the same protein as the RdRp core domain. This CoV-specific 
domain has low predicted structural homology to known proteins, so, cannot be modeled with 
high confidence (data not shown). However, the CoV-specific domain is highly conserved across 
all currently sequenced CoVs suggesting an important role in CoV biology. Currently, little is 
known about the role the CoV-specific domain plays in the virus life cycle. However, a 
conserved and essential nucleotidylating activity was elucidated within the CoV-specific domain. 
This sub-domain was coined the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) and 
has no known viral or cellular homologs (Lehmann et al., 2015). The NiRAN sub-domain could 
be involved in capping or other RTC functions; however, more data are required to determine it’s 
specific role. Additionally, a small sequence within the CoV-specific domain of the RdRp 
protein is essential for localizing the protein to the replication complexes (Brockway et al., 2003) 
In many (+)RNA viruses, the RdRp is the only protein required for replication of a template in 
vitro, and the core of the CoV RdRp can be modeled with strong agreement on solved structures 
of other viral RdRps (Sexton et al., 2016). However, unlike the RdRps of most other (+)RNA 
viruses, the CoV RdRp directly interacts with, and requires the presence of certain ancillary 
factors, nsp7 and nsp8, for efficient binding of RNA (Subissi et al., 2014). Together with nsp7 
and nsp8 the CoV RdRp demonstrates high processivity, further supporting the cooperative 
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function of nsp7 and nsp8 as a processivity clamp reminiscent of DNA-based systems as 
suggested previously (Smith et al., 2014; Subissi et al., 2014). An additional function of nsp8 
may be primase activity, and nsp12-RdRp likely requires the presence of primers for replication 
and transcription (Imbert et al., 2006; Sevajol et al., 2014; Xiao et al., 2012). Finally, although 
not essential for replication in a biochemical setting, nsp13 encodes the viral helicase/NTPase, 
and is likely essential for replication in the context of infection (Ahn et al., 2012; Seybert et al., 
2005; Subissi et al., 2014; Velthuis et al., 2009). Interaction studies demonstrate direct 
interactions between nsp12 and nsp13, and most RNA viruses encode helicases (Adedeji et al., 
2012; Imbert et al., 2008). Therefore, the core replication complex for CoVs may legitimately be 
defined as the combination of nsp7, 8, 12 and 13 (Figure 6).  
Fidelity proteins of the replication-transcription complex 
Additional proteins are present in the replication complex beyond those directly essential to 
RNA replication. One of the most intriguing functions conferred by these additional proteins is 
the ability to increase the fidelity of replication over that of the polymerase alone. This 
proofreading activity is attributed to the 3′-5′ exoribonuclease (ExoN) encoded in the 
nonstructural protein 14 (nsp14) of CoVs (Figure 2). The role of nsp14-ExoN proofreading in 
regulating fidelity has been extensively reviewed in (Smith et al., 2014). Many studies to date 
have demonstrated the ability of CoV nsp14-ExoN to remove mismatched nucleotides and 
increase the overall fidelity of CoVs up to 20-fold (Bouvet et al., 2012; Eckerle et al., 2010; 
Graham et al., 2012; Smith et al., 2013). Additionally, the small non-enzymatic protein nsp10 
interacts with nsp14-ExoN and increases the activity of nsp14-ExoN by up to 35-fold in vitro 
(Bouvet et al., 2012). Enhancement of nsp14-ExoN proofreading by nsp10 has also been 
demonstrated in vitro and during viral replication (Bouvet et al., 2014; Smith et al., 2015; Subissi 
et al., 2014). Mutations in nsp10 at the site of interaction between nsp10 and nsp14 increase 
susceptibility of CoVs to a panel of nucleoside analogs, and this sensitivity is increased with 
elevated temperatures during viral replication. However, ExoN-inactivated viruses are not 
subject to fidelity modulation mediated by nsp10 (Smith et al., 2015). Enhancement of ExoN 
activity is likely a combination effect of direct stimulation of activity by nsp10 as well as the 
ability of nsp10 to stabilize nsp14, reminiscent of the E. coli DNA polymerase III holoenzyme 
(Maki and Kornberg, 1987; Scheuermann and Echols, 1984; Smith et al., 2014). Regardless, 
binding of nsp10 to nsp14 seems to directly correlate with increased ExoN activity 
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Figure 6. Model of the CoV replication-transcription complex (RTC) 
CoVs encode a large replication-transcription complex (RTC). Evidence suggests that the core 
replicase is composed of the nsp12-RdRp (which also encodes the NiRAN domain), nsp13-helicase 
(Hel, which has an attached NTPase activity) and the nsp7/8-processivity factor. Nsp14-ExoN and 
nsp10 (co-factor) function to increase fidelity of replication. However, nsp10-cofactor is also a 
binding partner for the 2′-O-methyltransferase (2′-OMT) encoded in nsp16 and, thus, 2′-OMT may 
alter the composition of the RTC by binding more or less nsp10. Finally, nsp9 functions as a single-
stranded RNA-binding protein (ssRBP), and evidence suggests it directly interacts with nsp8. All 
interactions in this model are supported by published data and cited in the text. So far, nsp10, nsp14-
ExoN and nsp12-RdRp have evidence supporting their direct involvement in fidelity regulation. 
Nsp10, nsp14-N7-MT (the N7 methyltransferase) and nsp16-2′-OMT are known to participate in 
genome capping. 	
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(Bouvet et al., 2014). Similar to the case with E. coli, CoV nsp14 required the presence of nsp10 
for crystallization. Interestingly, an nsp10-nsp14 co-crystal structure demonstrated that the active 
site residues for nsp14-ExoN are DEEDh instead of the previously presumed DEDDh. However, 
the overall structural elements of nsp14-ExoN still suggest it should be categorized with the 
DEDD superfamily of exonucleases (Ma et al., 2015). Previously, nsp10 was co-crystalized with 
nsp16, the 2′-O-methytransferase, and it was determined that the sites of interaction between 
nsp10-nsp16 and nsp10-nsp14 were similar (Chen et al., 2011). More recent data demonstrated 
that the interaction face between nsp10-nsp14 is more extensive than that of the nsp10-nsp16 
interface, and the two interfaces do overlap (Bouvet et al., 2014; Ma et al., 2015).  
Nsp14-ExoN and nsp10 are key proteins for CoV replication fidelity; however, in other RNA 
viruses the RdRp is the main determinant of fidelity. Other viral RdRps can be mutated resulting 
in up to a 4-fold change in fidelity while still producing viable viruses (Smith et al., 2014). For 
CoVs, it could easily be imagined that that the presence or absence of nsp14-ExoN activity alters 
the phenotypic outcome of mutations in the RdRp domain, considering the much larger fold 
change in fidelity ensuing from mutations in nsp14-ExoN (Eckerle et al., 2007; 2010; Smith et 
al., 2013). Additionally, CoV nsp12 directly interacts with nsp14, bringing the RdRp and ExoN 
domains into close contact (Subissi et al., 2014). Together, these data suggest that at minimum 
nsp12-RdRp, nsp14-ExoN and nsp10 are determinants of fidelity for CoVs. Additionally, with 
known interactions between nsp7/nsp8 with nsp12, nsp13 with nsp12, and nsp10 with nsp16, it is 
certainly possible that additional replication complex proteins alter fidelity in CoVs either on a 
host-species basis or potentially even with changes in the cellular environment.  
Additional functions of coronavirus replication-transcription complex proteins 
Many CoV proteins are multi-functional. RNA capping is important for efficient translation in 
the absence of an alternative mechanism such as an internal ribosome entry site (IRES) and for 
escape from host innate immune responses. Capping in CoVs is well reviewed in (Sevajol et al., 
2014). In addition to encoding ExoN proofreading activity at the N-terminal end, an N7-guanine 
methyltransferase (N7-MTase) is encoded at the C-terminal end of nsp14 (Subissi et al., 2014). 
The interface between the two domains of nsp14 is highly conserved, hydrophobic and 
extensive, suggesting the subunits function largely in concert with each other and that 
manipulation of one domain may affect the other (Ma et al., 2015). In vitro, when in complex 
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with nsp7/8, nsp12 and nsp10, nsp14 maintains N7-MTase activity, demonstrating that N7-
MTase activity is potentially occurring within the context of the full complex (Subissi et al., 
2014). Interestingly, this context may influence the activity of N7-MTase as both the aspartate 
and glycine of the DxG motif of the S-adenosyl-L-methionine binding pocket appear to be 
essential to binding in vitro but aspartate appears have no effect on viral replication (Chen et al., 
2009). In contrast the glycine residue of the DxG motif was shown to regulate sensitivity to IFN-
β as well as translation efficiency in the context of viral infection (Case et al., 2016). Altering 
nsp14-N7-MT activity does not appear to affect nsp14-ExoN activity. Nsp10 additionally plays a 
dual role in fidelity and capping by interacting with the nsp16 the 2′-O-methytransferase, and 
nsp13 contains NTPase activity in addition to helicase activity (Decroly et al., 2011; Sevajol et 
al., 2014). It is possible that nsp16 itself is also a member of the RTC but experimental evidence 
is needed to support this conjecture.  
Involvement in capping may not be the only mechanism by which nsp14 influences innate 
immune sensing. Using transmissible gastroenteritis virus (TGEV), an Alphacoronavirus, it was 
determined that a mutation in the N-terminal-most zinc finger of ExoN (ZF1) resulted in 
decreased plaque size, decreased activation of IFN-β, and decreased accumulation of dsRNA 
intermediates (Becares et al., 2016). With the complex nature of nsp14 it is difficult to determine 
by what specific mechanism the decreased IFN-β response to TGEV is occurring. However, it is 
conceivable that nsp14-ExoN may serve a function outside of proofreading. Interestingly, so far 
no Alphacoronavirus has been successfully recovered with an inactivated nsp14-ExoN. In fact, 
only Betacoronavirus species have been observed to tolerate this inactivation to date. It will be 
interesting to see whether inactivation of nsp14-ExoN in a Betacoronavirus will similarly result 
in altered innate immune responses. Future research in this area may elucidate additional 
functions of nsp14-ExoN.  
Co-evolution of interactions within the RTC and potential for additional determinants of 
fidelity 
The RTC of CoVs contains at minimum nsp7-14 and may include nsp15 and nsp16 as well 
(Brunn et al., 2007; Imbert et al., 2008; Smith et al., 2014). Many of these proteins have multiple 
domains with disparate functions involved in the production of complete viral RNAs. Due to the 
extensive interactions between these proteins, the members of the complex must co-evolve in a 
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cooperative manner. It would be expected that there would be heavy overall negative, or 
purifying, selection exerted on these proteins in order to maintain essential functions, not only in 
individual proteins but also in their co-factors and binding partners. This has been observed for 
lineage C Betacoronavirus species with greater than 25 percent of the residues in nsps 7, 8, 12, 
13 and 14 undergoing negative selection (Forni et al., 2016). With close interactions among the 
proteins of the RTC, it is conceivable that mutations outside of nsp12-RdRp, nsp14-ExoN and 
nsp10 could also influence fidelity and nucleotide selectivity. This has been demonstrated for 
other organisms. For instance, a mutation in the helicase of Chikungunya virus was shown to 
increase the overall fidelity of that virus in an RdRp-independent manor (Stapleford et al., 2015). 
The Mycobacterium tuberculosis DNA polymerase III holoenzyme replication complex, a 
proposed analogue of the CoV RTC, is composed of α, the polymerase subunit (containing 
exonuclease activity); ε, an additional exonuclease; and β2, a processivity clamp. The β2 clamp of 
M. tuberculosis DNA polymerase III, was demonstrated to increase the exonuclease activity in 
the α subunit. Interestingly, in contrast, the β2 clamp reduced the exonuclease activity of the full 
αεβ2 complex, which includes the external exonuclease (Gu et al., 2016). Similarly, increased 
DNA binding by the processivity factor of Herpes Simplex virus resulted in an increase in 
mutation frequencies (Jiang et al., 2009). Together, these data suggest that nsp7/nsp8 in complex 
could modulate fidelity in CoVs. However, in distinction to CoVs and E. coli, the α and ε 
subunits of M. tuberculosis likely function together through an intermediate interaction with the 
β2 clamp instead of directly with one another (Gu et al., 2016; Smith et al., 2014). Finally, one 
could imagine that the 2′-O-methyltransferase affects fidelity by altering its interaction with 
nsp10, thus controlling availability of this stimulatory co-factor to nsp14-ExoN. Overall, altering 
individual functions of proteins in the RTC likely has a reverberating effect, altering interactions 
and functions of other proteins. These adjustments may serve to balance fidelity under a variety 
of conditions in vitro and in vivo.  
Conclusion 
Currently, there are no available vaccines or antiviral treatments against any human CoV. Many 
of the non-structural proteins encoded by coronaviruses are present only among members of the 
Nidovirales. Therefore, understanding these proteins, specifically those of the RTC could lead to 
identification of novel drug targets. Additionally, altering viral replication fidelity is attenuating 
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in most circumstances. Understanding the proteins involved in maintaining viral fidelity may 
foster development of vaccine candidates for CoVs.  
At the start of this dissertation research, evidence had been presented implicating only nsp14-
ExoN in fidelity regulation in the context of viral replication. In this dissertation, I present data 
demonstrating for the first time the involvement of nsp12, particularly nsp12-RdRp, in the 
regulation of fidelity for CoVs. Moreover, I demonstrate that the functional relationship between 
the activities of nsp14-ExoN and nsp12-RdRp is complex. There are many proteins functioning 
together within the RTC and these likely also play a role in fidelity regulation. Since this 
research began, nsp10 has been shown to influence replication fidelity during viral infection, 
supporting the previous biochemical evidence. Additionally, other proteins and processes have 
been implicated in the regulation of fidelity of other RNA viruses beyond simply nucleotide 
selection and proofreading. Therefore, it is possible that other members of the RTC contribute to 
the overall fidelity of CoVs. CoVs offer a unique platform to interrogate the contributions of 
different replication components to overall fidelity. However, due to size and complexity of 
CoVs, fidelity studies have not been amenable to many of the techniques used in other viral 
systems. Therefore, in this dissertation I also present data toward the development of novel 
techniques for investigating fidelity in CoVs that also should be applicable to other viral systems. 
This is important, as another current limitation to viral fidelity research is the inability to 
accurately compare data across viruses. 
In Chapter II, I present work identifying and characterizing residues in the CoV RdRp with 
predicted involvement in nucleotide selectivity by homology to picornaviruses (Sexton et al., 
2016). In Chapter III, I describe the identification of fidelity-regulating mutations in nsp12 and 
nsp14 of CoVs through adaptive selection methods as a complement to work in Chapter II. In 
Chapter IV, I present results from different techniques designed to investigate fidelity and 
demonstrate the potential for a novel approach. Chapter V summarizes the materials and methods 
used throughout this dissertation. Chapter VI explores the implications and future direction of 
this work.  
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CHAPTER II  
 
HOMOLOGY-BASED IDENTIFICATION OF A MUTATION IN THE CORONAVIRUS 
RNA-DEPENDENT RNA POLYMERASE THAT CONFERS RESISTANCE TO 
MULTIPLE MUTAGENS 
 
Introduction 
At the start of this dissertation research, coronavirus fidelity had been investigated only in 
regards to the 3′-5′ exoribonuclease, encoded in non-structural protein 14 (nsp14-ExoN). It had 
been demonstrated that inactivation of nsp14-ExoN activity by mutating the DE of the DEED 
active site to AA resulted in an increase in mutations and increased susceptibility to multiple 
mutagens. The data suggested that inactivation of nsp14-ExoN resulted in up to a 20-fold 
decrease in fidelity (Denison et al., 2011; Eckerle et al., 2007; 2010; Graham et al., 2012). Up to 
this discovery, all fidelity determinants in positive-sense RNA ((+)RNA) viruses had mapped to 
the RNA-dependent RNA polymerase. Studies of CVB3, polio, HIV-1 and other viruses 
demonstrate that viable viruses are only recoverable within a four-fold range of RdRp fidelity 
(Dapp et al., 2013; Gnädig et al., 2012; Smith et al., 2014; Vignuzzi et al., 2005a). In most cases 
altered RdRp fidelity decreases fitness relative to WT viruses; this has been demonstrated for 
changes as small as a 1.2 fold difference in the accumulation of mutations (Pfeiffer and 
Kirkegaard, 2005; Severson et al., 2003; Smith et al., 2014; Vignuzzi et al., 2005a). There are no 
solved structures for any CoV nsp12-RdRp, but the presence of conserved RdRp motifs and 
modeling of the C-terminal half of nsp12 predicts an RdRp domain that is structurally similar to 
other RNA viruses (Lehmann et al., 2015; Xu et al., 2003).  
The demonstrated function of nsp14-ExoN in high fidelity CoV replication raised the question of 
whether and how nsp12-RdRp participates in fidelity regulation. I sought to determine whether 
nsp12-RdRp could modulate nucleotide selectivity independently or in association with the 
proofreading nsp14-ExoN. I modeled the RdRp domain of CoV nsp12 on coxsackievirus virus 
B3 (CVB3) and poliovirus polymerase structures and predicted residues important for fidelity 
based on prior results from those virus systems. Substitution mutations at these residues were 
introduced in the isogenic recombinant genome of the β-CoV, murine hepatitis virus (MHV-
A59). In this chapter I demonstrate that two of these mutations, nsp12-V553I and nsp12-M611F, 
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confer resistance to the mutagen 5-fluorouracil (5-FU) and one, nsp12-V553I, also results in 
resistance to the mutagen 5-azacytidine (5-AZC) and demonstrates a decreased accumulation of 
mutations. Increased mutagen resistance and decreased accumulation of mutations was only 
observed in viruses with an inactivated nsp14-ExoN, demonstrating that nsp14-ExoN 
proofreading activity is epistatic to the nucleotide selectivity of nsp12-RdRp. For the project I 
define epistasis as a situation where the phenotype of one gene or viral protein masks the 
phenotype of genetic variants of another viral protein. This result is consistent with a primary 
role for nsp14-ExoN in error recognition and removal. However, introduction of RdRp mutations 
within the WT-MHV background decreased fitness relative to WT. Together the results suggest 
that nsp12-RdRp shares common determinants of nucleotide selectivity with RdRps from other 
RNA virus families. Further, the CoV RdRp has likely evolved to function in cooperation with 
nsp14-ExoN rather than independently. I performed all experiments and final analysis for the 
data in this chapter. My coauthors provided assistance in the following experiments: Clint Smith 
developed the qRT-PCR protocol used in the specific infectivity assays, Hervé Blanc in Marco 
Vignuzzi’s lab prepared the samples I sent them for deep sequencing, ran the samples and sent 
the data through the ViVan bioinformatics pipeline for initial cleanup and analysis, and Olve 
Peersen provided guidance on the homology modeling. 
Homology modeling of MHV nsp12-RdRp polymerase core domain predicts putative 
fidelity determinants 
Mutations that alter nucleotide selectivity have been identified across multiple RNA virus RdRps 
(Castro et al., 2005; Gnädig et al., 2012; Levi et al., 2010; Pfeiffer and Kirkegaard, 2003; 
Verdaguer and Ferrer-Orta, 2012); however, whether these residues are conserved across virus 
families is unknown. I sought to determine whether residues within nsp12-RdRp that are 
structurally homologous to known RNA virus fidelity determinants would have similar effects on 
nucleotide selectivity when introduced into the MHV background. To do this, we modeled the 
structure of MHV nsp12-RdRp using Phyre2 software (Kelley et al., 2015). A series of nsp12-
RdRp truncations was assessed, and the highest confidence model was used for further study. 
This region corresponded with a published model for the SARS-CoV nsp12-RdRp (Xu et al., 
2003) and included residues 385-887 of the MHV nsp12 protein, referred to here as the RdRp 
core domain (Figure 7a, b). Deletion of the CoV-specific domain (residues 1-384), and a small 
C-terminal portion of the thumb domain (888-928), was required to establish this high- 
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Figure 7. Homology modeling of CoV nsp12-RdRp and identification of residues that potentially 
regulate fidelity based on CVB3 structure 	
Phyre2 software was used to model A. a subsection of the MHV nsp12-RdRp core domain (expanded 
from nsp12-RdRp full schematic). This B. modeled MHV RdRp structure was aligned with the C. 
solved CVB3 RdRp structure. Residues chosen for site-directed mutagenesis (A and B) were selected 
by comparing previously determined fidelity altering mutations of picornavirus RdRps. Amino acid 
alignments D. across CoVs show residues are almost completely conserved.	
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confidence model (Figure 7a). The model was resolved by highest probability similarity to 
human rhinovirus serotype 1b (PDB ID: 1XR5a), rabbit hemorrhagic disease virus (PDB ID: 
1KHV) and EV71 (PDB ID: 3N6M). The Phyre2 confidence, i.e. the probability of true 
homology, for the RdRp core domain to these structures was >99% while the percent identity 
was only 14-20%. Having generated a structural model for the MHV nsp12-RdRp core domain I 
next sought to predict residues involved in nucleotide selectivity. The nsp12-RdRp core domain 
model was aligned with the solved structure of coxsackievirus B3 (CVB3, PDB ID: 3DDK) 
using PyMol (Figure 7c). A series of CVB3 RdRp mutations have been shown to result in 
decreased fidelity (Campagnola et al., 2015; Gnädig et al., 2012; Yang et al., 2012). The CVB3 
fidelity determinants were compared with the MHV nsp12-RdRp core domain model. Those that 
aligned well structurally and by amino acid similarity were further investigated: MHV nsp12-
V553, M611, W613, A621, Y649 and K794 (Figure 7). Finally, the nsp12 amino acid sequences 
of 27 different α−, β− and γ-CoVs were aligned, including SARS-CoV and MERS-CoV. All six 
identified residues were conserved across these CoVs (Figure 7d). Analysis of similarity and 
types of residues in the picornaviruses were then used to determine the specific amino acid 
changes that would be introduced at the identified MHV residues. The resulting substitution 
mutations were engineered in the isogenic cloned MHV genome: nsp12-V553A/I, M611F, 
W613Y, A621G, Y694H/W and K794R (Table 1).  
Recovery of mutant viruses in the MHV nsp14-ExoN(+) and nsp14-ExoN(-) isogenic 
backgrounds 
I next tested whether viable viruses could be recovered with substitutions at the identified 
residues. Virus recovery was attempted a maximum of 3 times, resulting in recovery of 6 of the 8 
mutant viruses in the WT background: nsp12-V553I, M611F, W613Y, A621G, Y649H, and 
K794R. The time required for recovery of mutant viruses in the WT background ranged from 24 
to 48 hours. No other mutations were identified across nsp12 sequences in recovered viruses. 
The A621G mutant was not further studied as it demonstrated rapid primary reversion even in 
the recovery (P0) supernatant. Since our goal was to understand the relationship of nsp12-RdRp 
and nsp14-ExoN in fidelity regulation, I additionally attempted recovery of the WT background 
viable mutants in the setting of inactivated nsp14-ExoN (nsp14-ExoN(-)). As nsp14-ExoN(-) 
results in delays in replication and decreased titers we did not attempt recovery of mutant viruses 
with mutation non-recoverable in the WT background. In contrast to mutant viruses recovered in 
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the WT background, I only recovered 2 of the 5 mutants in the nsp14-ExoN(-) background: 
nsp12-V553I/nsp14-ExoN(-) and nsp12-M611F/nsp14-ExoN(-) (Table 1). The time to recovery 
for nsp12-V553I/nsp14-ExoN(-) was 84 hours and for nsp12-M611F/nsp14-ExoN(-) was 96 
hours. Working stocks of all viruses were made by infecting D9s with an MOI of 0.01 and 
recovering stocks at around 24 h.p.i for WT viruses, or between 32 and 48 h.p.i for mutant 
viruses in the nsp14-ExoN(-) background. Therefore 4-10 replication cycles were required to 
generate stocks. Working stocks were sequenced to verify that the introduced mutations were 
still present.	
 
 
Table 1. Recovery of mutant viruses using site-directed mutagenesis 
 
 
 
Resistance of recovered mutant viruses to the base analog 5-fluorouracil 
I next tested our panel of recovered mutant viruses for resistance to the RNA mutagen 5-
fluorouracil (5-FU). 5-FU selectivity has been used to reveal changes in fidelity based on 
increased or decreased sensitivity to incorporation and virus inhibition for picornaviruses, 
influenza viruses, vesicular stomatitis viruses and others (Gnädig et al., 2012; Holland et al., 
1990; Pauly and Lauring, 2015; Smith et al., 2013). WT CoVs (MHV, SARS-CoV) are resistant 
to 5-FU, while nsp14-ExoN(-) mutants are profoundly sensitive to 5-FU inhibition, consistent 
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with nsp14-ExoN-mediated removal of misincorporated 5-FU. The effect of 5-FU on DBT cell 
viability was previously tested with no effect observed up to 400uM (Smith et al., 2013). I 
compared WT-MHV with the nsp12 mutants in both the WT and nsp14-ExoN(-) backgrounds. 
There was no significant change in sensitivity to 5-FU compared to WT for any of the nsp12-
RdRp mutant viruses in the WT background at up to 120uM 5-FU although the mutation Y649H 
does appear to decrease resistance slightly (Figure 8a). In contrast, the nsp12-M611F/nsp14-
ExoN(-) and nsp12-V553I/nsp14-ExoN(-) mutant viruses both were significantly less sensitive to 
5-FU than nsp14-ExoN(-) alone, with both populations persisting when treated with 120uM 5-
FU where nsp14-ExoN(-) was not detectable beyond 80uM 5-FU (Figure 8b). These data 
demonstrate that both nsp12-RdRp mutations V553I and M611F confer resistance to 5-FU. This 
suggests a couple possibilities: that it is not possible to increase the exclusion of 5-FU beyond 
the high level dictated by nsp14-ExoN or that selectivity for native nucleotides over 5-FU is in 
fact increased by nsp12 mutations, but at a low level that is not detectable by changes in virus 
titer.  
Three of the mutations (nsp12-Y649H, W613Y, and K794R) were viable in the nsp14-ExoN(+) 
background, but failed to grow in the absence of proofreading. The observation that they only 
grew in an nsp14-ExoN(+) background indicates that the mutations retained sufficient 
polymerase function to support virus replication, but it was critically dependent on having 
proofreading functionality, suggesting these mutations may have given rise to low fidelity 
variants. Unfortunately, the low titer from the nsp14-ExoN(-) background precluded direct 
sequencing analysis and I therefore cannot definitively show this is the case.  
 
Replication kinetics of nsp12-V553I and nsp12-M611F mutant viruses in the WT and 
nsp14-ExoN(-) backgrounds 
Since I was interested in mutations that potentially confer altered fidelity, I prioritized the nsp12-
V553I and nsp12-M611F mutant viruses for further analysis. I next sought to determine how the 
nsp12-V553I and nsp12-M611F viruses replicated in comparison to their isogenic background 
(Figure 9). In the wild-type background both mutant viruses had slightly delayed exponential 
replication, but eventually reached similar peak titers comparable to WT. In contrast, in the 
nsp14-ExoN(-) background both nsp12-V553I and nsp12-M611F mutant viruses displayed 
similar replication kinetics to the isogenic nsp14-ExoN(-) background. I also assessed RNA 
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Figure 8. Resistance of MHV nsp12-RdRp mutant viruses to 5-fluorouracil in the WT and 
nsp14-ExoN(-) background  
Domain location of mutations is indicated by: fingers (blues) and palm (reds). DBT cells were pre-
treated with different concentrations of 5-FU for 30 min. Treatment was removed and cells were 
infected with indicated viruses in the A. WT background or B. nsp14-ExoN(-) background at an MOI 
of 0.01 PFU/cell. Media containing 5-FU was replaced 30 min p.i. Virus samples were taken at 24 
(WT) or 32 (nsp14-ExoN(-)) h.p.i and titer was determined by plaque assay. Data represents 3 
independent experiments, each with 2 replicates. Error bars represent SEM (*P < 0.05 by Wilcoxon 
test and are relative to nsp14-ExoN(-)).	
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Figure 9. Replication kinetics of MHV nsp12-RdRp mutant viruses  
Mutation location is indicated by: fingers (blue) and palm (red). DBT cells were infected with the 
viruses indicated in the A, C and E. WT background or B, D and F. nsp14-ExoN(-) background at an 
MOI of 0.01 PFU/cell. Supernatant aliquots were taken at indicated times p.i. and titer determined by 
plaque assay. Total RNA was taken at indicated times p.i. and RT-qPCR was performed. Data 
represents 3 independent experiments. Error bars represent SEM.	
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synthesis for nsp12-V553I and nsp12-M611F by RT-qPCR. Measured genomic RNA levels were 
consistent with the virus replication kinetics data, and I observed delayed and decreased genome 
RNA levels in the WT background after multiple rounds of replication (Figure 9e). However, at 
early time points there was no difference in RNA accumulation suggesting that decreased RNA 
is a result of steps post RNA synthesis (Figure 9c). In the nsp14-ExoN(-) background, RNA 
synthesis levels were indistinguishable from the nsp14-ExoN(-) background for both nsp12-
V553I and nsp12-M611F, with no additional RNA synthesis defects detectable (Figure 9d and f). 
The results, along with my  recovery of several of the nsp12-RdRp mutants only in the nsp14-
ExoN(+) background, support the hypothesis that nsp14-ExoN and nsp12-RdRp may have an 
epistatic relationship. However, for replication kinetics the effects of nsp12-V553I and nsp12-
M611F are not observable in the presence of an inactive nsp14-ExoN, demonstrating that the 
replication phenotype of an inactive nps14-ExoN is epistatic to replication variants encoded in 
nsp12-RdRp.  
Specific infectivity of nsp12-V553I and nsp12-M611F 
Having identified two mutant viruses with resistance to 5-FU I wanted to further test whether 
resistance was due to decreased incorporation of the mutagen. Measurement of specific 
infectivity has been useful for determining lethal mutagenesis for MHV and other RNA viruses 
(Rozen-Gagnon et al., 2014; Smith et al., 2013). I tested the nsp12-M611F and nsp12-V553I 
mutants, in both the WT and nsp14-ExoN(-) backgrounds, for changes in specific infectivity 
when infected at an MOI of 0.01 and treated with 5-FU (Figure 10). Both nsp12-M611F and 
nsp12-V553I resulted in an increased ratio of infectious particles (PFU/ml) to total particles 
(RNA genomes) in the nsp14-ExoN(-) background (Figure 10b). Similarly, in the WT 
background nsp12-M611F demonstrated an increase in the ratio of infectious particles to RNA 
genomes (Figure 10a). Thus specific infectivity may be a more sensitive measure of lower level 
changes in nucleotide selectivity in the setting of nsp14-ExoN(-). 
Fitness cost of nsp12-V553I and nsp12-M611F in WT and nsp14-ExoN(-) backgrounds 
In multiple RNA viruses, including CoVs, both increased and decreased fidelity have been 
reported to have a fitness cost (Smith et al., 2014). I therefore sought to determine whether 
nsp12-V553I or nsp12-M611F conferred any cost in fitness, defined as the ability to directly 
compete during co-infection. In the WT background, both nsp12-V553I and nsp12-M611F 
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Figure 10. Specific infectivity is increased in both nsp12-V553I and nsp12-M611F mutants  
DBT cells were pre-treated with increasing concentrations of 5-FU for 30 min. Treatment was 
removed and cells were infected with indicated viruses in the A. WT background or B. nsp14-ExoN(-) 
background at an MOI of 0.01. Media containing 5-FU was replaced 60 min p.i. Virus samples were 
taken at 20 and 24 h.p.i respectively. Titer was determined by plaque assay and number of supernatant 
genomes was determined using one-step RT-qPCR. Data represents 2 independent experiments, each 
with 3 replicates. Error bars represent SEM (*P < 0.05 by 2way ANOVA using the Bonferroni 
correction for multiple comparisons).	
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demonstrated delays in replication and impaired RNA accumulation. However, since there were  
not any observed additional defects in replication or RNA synthesis for nsp12-V553I and nsp12-
M611F when introduced in the nsp14-ExoN(-) background (Figure 9b, d), I tested for any 
additional fitness cost of nsp12-V553I/nsp14-ExoN(-) or nsp12-M611F/nsp14-ExoN(-) viruses 
compared with nsp14-ExoN(-) alone. When co-infected with nsp14-ExoN(-) at ratios from 1:9 to 
9:1, nsp12-V553I/nsp14-ExoN(-) maintained the input ratio compared with nsp14-ExoN(-) 
(Figure 11a). A small advantage to nsp12-V553I/nsp14-ExoN(-) was observed when the co-
infected cultures were treated with 60uM 5-FU, consistent with a conferred advantage for 5-FU 
resistance (Figure 11a). Thus there appeared to be no additional fitness cost of nsp12-
V553I/nsp14-ExoN(-) compared to nsp14-ExoN(-) alone. In contrast, nsp12-M611F/nsp14-
ExoN(-) was not able to compete with nsp14-ExoN(-) at any ratio (Figure 11b). Treatment with 
60uM 5-FU again favored nsp12-M611F/nsp14-ExoN(-); however, even then the percent of the 
population made up of nsp12-M611F/nsp14-ExoN(-) only remained at around 30% of the 
population when initially given a 9-fold advantage (Figure 11b). 
I next tested whether the relative differences in fitness cost resulted in selective pressure for 
reversion of nsp12-V553I and nsp12-M611F (Figure 12). DBT cells were infected with nsp12-
V553I, nsp12-V553I/nsp14-ExoN(-), nsp12-M611F, or nsp12-M611F/nsp14-ExoN(-) at an 
initial MOI of 0.01. After 5 passages the viruses were analyzed for retention of original 
mutations using di-deoxy (Sanger) sequencing. The nsp12-V553I mutation was stable after 
passage in both WT and nsp14-ExoN(-) backgrounds, maintaining the mutated AUU codon 
(Figure 12a), suggesting minimal selective pressure on that nucleotide, codon, or amino acid. In 
contrast, the nsp12-M611F mutation demonstrated significant change over passage in both the 
WT and the nsp14-ExoN(-) backgrounds. The original mutation, UUC, was no longer the 
majority codon in the nsp14-ExoN(-) background and was less than 52% of the population in all 
WT background lineages (Figure 12b). The nsp12-M611F/nsp14-ExoN(-) population resulted in 
a mix of two nucleotide changes resulting in reversion to AUG (methionine) (≤68% of the 
population), single nucleotide changes that result in mutation it to Leu (≤55% of the population), 
a somewhat smaller but still hydrophobic residue, or retaining a Phe substitution (≤27% of the 
population). Thus the fitness cost of nsp12-M611F results in significant selective pressure for 
changes at that residue during passage in absence of 5-FU.  
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Figure 11. Competitive fitness analysis in the nsp14-ExoN(-) background  
DBT cells were pre-treated with media alone or containing 60uM 5-FU for 30 min. Treatment was 
removed and cells were co-infected, at total MOI of 0.01 PFU/cell, with nsp14-ExoN(-) and A. nsp12-
V553I/nsp14-ExoN(-) or B. nsp12-M611F/nsp14-ExoN(-) at a ratio of 9:1, 1:1 or 1:9. Media alone or 
containing 60uM or 300uM 5-FU was replaced 30 min p.i. Total RNA was taken at 24 h.p.i 
Sequencing was performed across a 1.7kb region of nsp12-RdRp that included both mutations. Data 
represents 3 independent experiments, each with 2 replicates. Error bars represent SEM.	
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Figure 12. The nsp12-V553I mutation is stable across passage; however, nsp12-M611F is 
vulnerable to reversion  
DBT cells were infected with an initial MOI of 0.01 then blind passaged in triplicate for 5 passages. 
Total RNA was taken and sequencing was performed across a 1.7kb region of nsp12-RdRp that 
included both mutations. Percentage of each nucleotide present in each of the triplicate lineages after 5 
passages is shown. Mutant viruses in the WT (solid bars) and nsp14-ExoN(-) (slashed bars) 
backgrounds are both shown. The original mutation for each of the viruses is shown above the graph 
and the likely majority, secondary and tertiary codons present in the population are shown below the 
graph.  
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Resistance of recovered mutant viruses to the base analog 5-azacytidine 
Having shown that both nsp12-M611F and nsp12-V553I mutations conferred resistance to 5-FU 
in the nsp14-ExoN(-) background but that nsp12-M611F reverted quickly and was at a fitness 
disadvantage in both the WT and nsp14-ExoN(-) background, I next wanted to test whether the 
mutations conferred resistance specifically to 5-FU or broadly to base analogs and therefore were 
likely determinants of fidelity. A study by Arias et al demonstrated that for foot-and-mouth 
disease virus (FMDV) resistance to a specific mutagen can result from a point mutation while 
conferring the opposite overall fidelity (Arias et al., 2008). I therefore tested for resistance to the 
additional mutagen 5-azacytidine (5-AZC). Similar to the 5-FU results, the nsp12-V553I/nsp14-
ExoN(-) mutant virus was more resistant to 5-AZC than nsp14-ExoN(-) alone, maintaining 
approximately one log higher titers from 20-50uM 5-AZC (Figure 13). However, the nsp12-
M611F/nsp14-ExoN(-) mutant virus showed no difference in resistance to 5-AZC compared with 
nsp14-ExoN(-) alone (Figure 13). These data suggest that nsp12-V553I is likely a fidelity 
determinant where as nsp12-M611F confers specific resistance to 5-FU and has an unknown 
overall fidelity. This result is also consistent with the rapid reversion observed for the nsp12-
M611F mutation.  
The nsp12-V533I mutation results in a decrease in the accumulation of mutations 
Having shown that the nsp12-V553I and nsp12-M611F mutations resulted in resistance to 5-FU, 
and that nsp12-V553I additionally conferred resistance to 5-AZC, I sought to directly determine 
whether either of these mutations resulted in a change in the number of mutations accumulated in 
viral RNA. DBT cells were infected with wild type, nsp12-V553I, nsp12-M611F, nsp14-ExoN(-
), nsp12-V553I/nsp14-ExoN(-) or nsp12-M611F/nsp14-ExoN(-) at an MOI of 0.01 and RNA 
was collected at 20 h. pi. My collaborators in Marco Vignuzzi’s laboratory then prepared these 
samples for Illumina next generation sequencing (NGS) across the full genome and analyzed 
them using the ViVan analysis pipeline (Isakov et al., 2015). I graphed mutations present as 1% 
or more of the population by frequency and position in the genome. Engineered mutations are 
depicted with colored dots. Most non-engineered new mutations were present at 10% or less of 
the population and were distributed across the genome with no detectable “hot-spots” (Figure 
14a-f). For nsp12-V553I in the WT background, no difference was observed in the number of 
mutations accumulated to 1% or greater of the population compared to WT alone. In contrast, in 
the nsp14-ExoN(-) background, nsp12-V553I was associated with a 1.7-fold decrease in the 
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Figure 13. Resistance of MHV nsp12-RdRp V553I and M611F mutant viruses to 5-azacytidine in 
the nsp14-ExoN(-) background  
Domain location of mutations is indicated by: fingers (blues) and palm (reds). DBT cells were pre-
treated with different concentrations of 5-AZC for 30 min. Treatment was removed and cells were 
infected with indicated viruses at an MOI of 0.01. Media containing 5-AZC was replaced 30 min p.i. 
Virus samples were taken at 32 h.p.i and titer was determined by plaque assay. Data represents 5 
independent experiments, each with 2 replicates. Error bars represent SEM (*P < 0.05 by ratio paired t 
test relative to nsp14-ExoN(-) virus).	
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Figure 14. The nsp12-V553I mutation confers decreased accumulation of mutations in the 
nsp14-ExoN(-) background with no bias toward the exclusion of specific nucleotides  
DBTs were infected with an MOI of 0.01 and total RNA collected. Deep sequencing was performed 
on these samples. The statistically significant mutations present as greater than or equal to 1% of the 
total population are shown for wild type, nsp14-ExoN and nsp12-V553I or nsp12-M611F in both 
backgrounds. These were graphed (A-F) according to their distribution across the genome with 
intentionally introduced mutations (B-F) shown with circles colored blue (nsp12-V553I), red (nsp12-
M611F) or green (nsp14-ExoN(-)), as (G) the total number of mutations present in the population and 
as (H) the percent of specific mutations present. 
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frequency of mutations compared to nsp14-ExoN(-) alone (Figure 14g), again with no change in 
the distribution of mutations across the genome (Figure 14c, d). These results are consistent with 
both the 5-FU and 5-AZC data in suggesting increased fidelity. Results from the nsp12-M611F 
mutant viruses were more complicated. To our surprise, the nsp12-M611F/nsp14-ExoN(-) virus 
fully reverted at both engineered nsp12-M611F nucleotides during the low MOI infection, 
resulting in a viral population that was nsp14-ExoN(-) alone (Figure 14f). This reversion made 
the results for the nsp12-M611F/nsp14-ExoN(-) virus interpretable. However, since 
accumulation of mutations to over 1% of the population is a combination of all replication cycles 
from initial recovery to the final sample (roughly 11 total for nsp12-M611F/nsp14-ExoN(-)) I 
included this data in Figure 14g and 14h. In the WT background the nsp12-M611F mutations 
were still present as 100% of the population and resulted in a 1.93 fold increase in the total 
number of accumulated mutations. I observed only a slight increase in the number of mutations 
accumulated in the nsp12-M611F/nsp14-ExoN(-) sample over those of nsp14-ExoN(-), which 
was not surprising seeing as the M611F mutation was no longer present. Neither sample 
appeared to have mutations concentrated in specific locations across the genome suggesting the 
accumulation of mutations was due to random generation of mutations rather than strong 
selection in particular locations or proteins (Figure 14e and f). Of note, one mutation in nsp3 of 
the nsp14-ExoN(-) sample and a mutation in nsp3, nsp13 and the E proteins of nsp12-
V553I/nsp14-ExoN(-) reached nearly 100% of the sample population. None of these mutations 
were present in the fragments used for recovery and the nsp3 mutation, which arose in the nsp14-
ExoN(-) population, was not present prior to the final low MOI infection. It is possible that these 
mutations provide some benefit to these viruses since they were fixed so rapidly in the 
population.  
I next determined whether either of the mutations resulted in a change in the types of mutations 
occurring during replication (Figure 14h). Consistent with our previous studies, there were 
differences in the types of mutations incorporated when comparing WT and nsp14-ExoN(-) 
backgrounds (Smith et al., 2013). However, the addition of nsp12-V553I or nsp12-M611F did 
not alter these patterns in either WT or nsp14-ExoN(-) backgrounds. Thus, nsp12-V553I results 
in an overall decrease in the accumulation of mutations over passage while nsp12-M611F seems 
to increase the number of mutations accumulated. These results confirm by sequence analysis the 
results from the 5-FU and 5-AZC resistance experiments for nsp12-V553I, specifically that the 
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effects of nsp12-V553I are dependent on inactivation of nsp14-ExoN for their detection and that 
nsp12-V553I likely confers broad resistance to the incorporation of incorrect nucleotides. In 
contrast, these results further increase the complexity of the nsp12-M611F mutation in relation to 
incorporation of nucleotides and their analogs. I conclude that nsp12-M611F confers resistance 
to 5-FU but that this resistance is not likely to be due to a broad resistance to the incorporation of 
alternate nucleotides.  
Discussion 
RdRp structures of divergent RNA viruses are structurally conserved and likely have common 
determinants of activity in the finger, palm and thumb domains. Positive strand RNA virus 
polymerases appear to utilize a common palm domain-based mechanism for active site closure 
(Gong and Peersen, 2010), and associated molecular determinants of fidelity in different RdRp 
domains have been proposed based on biochemical and mutagenesis studies (Campagnola et al., 
2015). To date there are no solved crystal structures of any CoV RdRp and thus direct 
comparison with other virus RdRp structures has not been possible. Further, regulation of CoV 
fidelity is likely dependent on multiple proteins, including the RdRp and proofreading nsp14-
ExoN. Thus it was not clear that a CoV would phenotypically exhibit effects from mutating 
fidelity-determining residues located in the RdRp itself. In this chapter I sought to determine 
whether I could use structure and mutagenesis data from distantly related RNA viruses to 
identify determinants of CoV nsp12-RdRp fidelity. Our results suggest that CoV RdRps do in 
fact participate in fidelity regulation, at residues orthologous to those in the picornaviruses, and 
likely in other RNA virus RdRps. The results also define, for the first time, a CoV RdRp 
determinant that increases resistance to multiple mutagens, decreases the accumulation of 
mutations over time and so, likely increases overall fidelity. Additionally, the data in this paper 
suggest that CoV RdRp-mediated increased fidelity is only detectable when nsp14-ExoN is 
inactive, and is only partially compensating for the loss of nsp14-ExoN high fidelity. Finally, 
both the nsp12-V553I and M611F mutations confer a replication cost in the WT background but 
only nsp12-M611F confers a fitness disadvantage in the nsp14-ExoN(-) background. Together 
the results suggest that nsp14-ExoN proofreading activity is epistatic to nsp12-RdRp fidelity but 
that in contrast the replication defects of an inactive nsp14-ExoN are epistatic to replication 
defects in nsp12-RdRp.  
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Determinants of nucleotide selectivity and fidelity in CoVs may be conserved with other 
RNA viruses 
Picornavirus functional RdRps contain only RdRp domains (Campagnola et al., 2008; Hansen et 
al., 1997). This is not the case for many viral RdRps, CoVs included (Lehmann et al., 2015; 
Velthuis, 2014). In addition to the predicted RdRp core domain, all CoV nsp12 proteins contain a 
“CoV-specific” domain of over 350 amino acids at the N terminus of the protein. A 
nucleotidyltransferase activity was identified in this CoV-specific domain and has been shown to 
be important in SARS-CoV replication, but the specific function in replication remains to be 
determined (Lehmann et al., 2015). The N-terminal CoV-specific domain could not be modeled 
due to lack of evolutionary homologues of known structure but, the predicted RdRp core domain 
could be modeled with high confidence using bioinformatics approaches. The structures that 
provided the best models for the CoV RdRp were from picornaviruses, including enterovirus 71, 
foot and mouth disease virus and coxsackievirus B3. This allowed for direct alignment and 
comparison of the known fidelity determinants in CVB3 with the MHV nsp12 core domain, 
across both fingers and palm domains. The recovery of mutations in these structurally conserved 
residues and their participation in CoV nucleotide selectivity supports the hypothesis that there 
are determinants of base specificity conserved between CoVs and distantly related RNA viruses, 
specifically the picornaviruses. This supports the idea that all RdRps function similarly due to 
their structural conservation and despite the low level of sequence similarity and attached 
domains (Yang et al., 2012). It also suggests that the CoV RdRp domain folds in a manner 
similar to other RdRps, likely separate from the CoV-specific domain. 
RdRp fidelity and nucleotide selectivity has been investigated extensively in picornaviruses, 
especially poliovirus (Hobdey et al., 2010; Korneeva and Cameron, 2007; Pfeiffer and 
Kirkegaard, 2003; Verdaguer and Ferrer-Orta, 2012; Vignuzzi et al., 2005a). However, even 
between picornaviruses, the impact on fidelity of changes at identical or similar residues can 
vary dramatically (Campagnola et al., 2015). Mutations at the same residues in the RdRp of 
poliovirus and CVB3 affect fidelity differently; poliovirus mutations generally result in increased 
fidelity and CVB3 mutations in decreased fidelity (11). Specifically, the structurally orthologous 
residue to nsp12-M611 in poliovirus is F230 and in CVB3 it is I230; when F230 is mutated to an 
Ile in poliovirus it results in an increase in fidelity, but when I230 in CVB3 is mutated to a Phe, 
Trp or Val it results in a decrease in fidelity (Campagnola et al., 2015). Similarly, the 
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orthologous residue to nsp12-V553 in CVB3 is I176; when I176 is mutated to a Val in CVB3 it 
results in a decrease in fidelity (Campagnola et al., 2015; Gnädig et al., 2012). Although the 
specific substitutions differ, when nsp12-V553I and nsp12-M611F are introduced into the MHV 
genome the resulting 5-FU resistance, and for nsp12-V553I a likely increase in fidelity, mimics 
results seen in poliovirus rather than CVB3. However, nsp12-M611F seems to accumulate more 
mutations over time than controls, and many of the predicted mutations were only recoverable in 
the WT background. Therefore, changes in nucleotide selectivity and fidelity were not tested, so 
it remains possible that the mutations that were non-viable in the nsp14-ExoN(-) background had 
decreased fidelity and that nsp14-ExoN(-) treated with 5-FU defines the error threshold for 
CoVs.  
Coronavirus nsp12-RdRp and nsp14-ExoN cooperate to optimize both fidelity and 
replication kinetics  
In addition to nsp12-RdRp, CoVs encode nsp14-ExoN, which functions as a proofreading 
enzyme (Bouvet et al., 2012; Eckerle et al., 2007; 2010; Smith et al., 2013). Beyond nsp14-
ExoN, there are additional CoV-encoded nsps that potentially contribute to overall fidelity, such 
as: the small molecule modulator of nsp14-ExoN encoded in nsp10 (Bouvet et al., 2012; Chen et 
al., 2011), nsp7 and nsp8 that together function as an elongation factor (Velthuis et al., 2012) and 
a primase (Imbert et al., 2006; Xiao et al., 2012), and nsp13 that functions as a helicase (Adedeji 
et al., 2012). These proteins interact with each other and likely function as a multi-protein 
replication/fidelity complex (Smith and Denison, 2013; Subissi et al., 2014). The results of this 
study show that while determinants in nsp12-RdRp are likely capable of increasing fidelity, those 
changes are only detectable in the setting of loss of nsp14-ExoN proofreading, and do not 
completely compensate for the impaired fidelity associated with nsp14-ExoN(-). If altering 
nucleotide selectivity determinants within nsp12-RdRp no longer significantly affect the overall 
nucleotide selectivity of the WT virus, then the evolutionary pressure on nsp12-RdRp may be 
more heavily weighted toward other aspects of replication, such as speed. Recent evidence 
suggests that RdRp fidelity and speed have an inverse relationship (Campagnola et al., 2015; 
Regoes et al., 2012). So, if fidelity regulation by nsp14-ExoN occurs more rapidly than correct 
nucleotide selectivity by the RdRp then CoV nsp12-RdRp may have been selected specifically 
for replication speed. Our data may support this hypothesis, as in the WT background both 
nsp12-V553I and nsp12-M611F resulted in increased replication lag phases (Figure 9a and e), 
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though early RNA synthesis was not observably different in our system (Figure 9c). However, 
this was not seen in the nsp14-ExoN(-) background, which could be explained by our data 
indicating that replication is already slowed when nsp14-ExoN is inactivated. One possible 
mechanism for this could be that the nsp14-ExoN(-) protein is trying to remove incorrect 
nucleotides and stalling replication due to its inability to do so. In this case nsp14-ExoN(-) would 
be epistatic to nsp12-RdRp in relation to speed, thereby obscuring decreases in replication speed 
caused by mutations in nsp12-RdRp itself.  
Conclusion 
My results support the hypothesis that determinants of nucleotide selectivity are conserved 
across viral orders, identify the first likely increased fidelity determinant for CoV nsp12-RdRp, 
and demonstrate that nsp14-ExoN proofreading activity is epistatic to nsp12-RdRp nucleotide 
selectivity. Knowing that some fidelity determinants may be conserved across viral orders is an 
exciting discovery, as many fidelity determinants identified so far have resulted in attenuation 
(Coffey et al., 2011; Gnädig et al., 2012; Lauring et al., 2010; Pfeiffer and Kirkegaard, 2005; 
Vignuzzi et al., 2008; Yang et al., 2012). It would be interesting to determine whether nsp12-
V553I is also attenuated. I would predict that it would be, based on the fitness cost in vitro. 
However, there is also no clear increase in nucleotide selectivity or fidelity in the WT 
background. This may be due to a very minimal change that is just not measureable even with 
the deep sequencing technology used in this study. Alternatively, it could be that any change is 
simply overwhelmed by the high fidelity of intact nsp14-ExoN proofreading. In any case, these 
mutations or other changes at these residues may allow for selection of viruses that replicate with 
normal kinetics in vitro and in vivo, yet confer attenuation in an animal setting. We know that the 
nsp14-ExoN(-) mutations confer genotypically and phenotypically stable attenuation in vivo 
(Graham et al., 2012). However, the concept of a high level mutator as a mechanism for 
attenuation in live viruses may be problematic. The identification of increased fidelity mutations 
in the RdRp that can partially, or potentially completely, compensate for the fidelity impairment 
of nsp14-ExoN(-) viruses, may allow for development of approaches that can benefit from the 
stability of the nsp14-ExoN(-) mutator phenotype while allowing more stability to the input 
genomes. Finally, these results combined with those from previous work (Bouvet et al., 2012; 
Smith et al., 2015) suggest that CoVs encode at least three proteins involved in fidelity (nsp12-
RdRp, nsp14-ExoN and nsp10) supporting the assembly of a multi-protein replicase / fidelity 
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complex as described previously (Subissi et al., 2014). This increases the importance of 
establishing a biochemical model of the multi-protein complex to directly test the interactions of 
fidelity determinants as well as potential inhibitors of each or all of these functions. 
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CHAPTER III  
 
IDENTIFICATION OF COMPENSATORY MUTATIONS IN CORONAVIRUS NSP12 
AND NSP14 AFTER PASSAGE IN THE PRESENCE OF MUTAGEN 
 
Introduction 
In the previous chapter, I identified residues involved in nucleotide selectivity by structural 
analysis and homology modeling of the murine hepatitis virus (MHV) RNA-dependent RNA 
polymerase (RdRp) encoded in nonstructural protein 12 (nsp12). However, the classically used 
method for identifying fidelity determinants is selection for resistance to mutagens. Additionally, 
at the start of this dissertation research, there were solved structures for neither any CoV nsp12 
nor nsp14, which encodes for the proofreading 3′-5′ exoribonuclease (ExoN), thus limiting the 
domains I could investigate by homology to the highly conserved nsp12-RdRp domain. In 
contrast, allowing the virus to select for mutations in the presence of mutagen provides an 
opportunity to investigate all domains including those with no known structure or function. 
Many mutagens are available to select for resistance mutations. Ribavirin is one of the most 
commonly used mutagens; however, it is known to have additional antiviral effects (Graci and 
Cameron, 2006; Parker, 2005). Another common mutagen is 5-FU, used in RNA viral studies 
and currently not known to have additional roles affecting RNA virus replication (Longley et al., 
2003). Additional nucleoside analogs are available that provide strong selection against CoVs, 
such as the non-obligate chain terminator 2′-C-methyladenosine (2′-C-MeA). However, 2′-C-
MeA is a sugar analog instead of a base analog and so is less likely to identify mutations that 
would confer altered base-pairing fidelity in a natural system (Carroll et al., 2003).  
In this chapter, I investigate the result of mutations in MHV-A59 nsp12 and nsp14 on nucleotide 
selectivity and replication. I demonstrate that minority variants present in 5-FU-treated virus 
populations are not likely candidates for increased fidelity variants, but variants that fix in 5-FU-
treated virus populations typically result in resistance to the nucleotide analog. For wild type 
(WT) viruses, resistance may be specific to 5-FU, whereas in nsp14-ExoN(-) viruses selection 
may be skewed towards a preference for increased overall fidelity and/or replication. Xiaotao Lu 
assisted in the preparation and sending of sequencing samples across nsp12 and nsp14 and the 
final recovery steps of some of the viruses used. Additionally, Dr. Everett Clinton Smith 
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performed the 5-FU replication kinetics experiments. I performed all other experiments reported 
in this chapter. 
Identification of minority variants in SARS-CoV populations after treatment with 5-FU 
In previously published work from our lab, SARS-CoV was treated with 400uM 5-FU over one 
0.01 MOI infection and total RNA was sent for deep sequencing (Smith et al., 2013). Analysis of 
the minority variants present in these populations identified a panel of mutations in SARS-CoV 
nsp12. From this data, I further identified mutations that were non-synonymous, present at 1.5% 
or more of the population, and where the original amino acid was conserved between SARS-
CoV and MHV-A59. This analysis resulted in a final panel of six nsp12 mutations: nsp12-
L364F, P374S, E519G, E519N, Q520L and S900C. These mutations made up 1.5, 4.8, 5.7, 25, 
6.8 and 2 percent of the population, respectively. The identified residues span all domains of 
nsp12 except the palm domain (Table 2). I next attempted to recover viruses with the identified 
mutations in isogenic backgrounds. Virus recovery was attempted a maximum of three times, 
resulting in recovery of five out of the six attempted mutant viruses in the WT background; only 
P374S was not recovered. All five engineered viruses had no additional mutations present across 
nsp12. Since results from the previous chapter demonstrated that proofreading by nsp14-ExoN is 
epistatic to nucleotide selectivity by the RdRp, I attempted recovery of the WT-background 
viable mutants in the setting of and inactivated nsp14-ExoN (nsp14-ExoN(-)). Only three of the 
five mutants recoverable in the WT background were also recoverable in the nsp14-ExoN(-) 
background: nsp12-E519N/nsp14-ExoN(-), nsp12-Q520L/nsp14-ExoN(-), and nsp12-
S900C/nsp14-ExoN(-) (Table 2). 
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Engineered viruses result in no change in selectivity for the nucleotide analogs 5-
fluorouracil or 2′-C-methyladenosine 
I next wanted to test whether engineered viruses resulted in altered nucleotide selectivity for the 
RNA mutagen 5-FU. 5-FU is routinely utilized as a screen to identify altered fidelity. WT CoVs 
(MHV, SARS-CoV) are resistant to 5-FU, while nsp14-ExoN(-) mutants are profoundly 
sensitive to 5-FU inhibition, consistent with nsp14-ExoN-mediated removal of misincorporated 
5-FU (Sexton et al., 2016; Smith et al., 2013). Likely oweing to efficient removal of 5-FU by 
nsp14-ExoN, nsp12-RdRp mutations often have no effect on overall viral sensitivity or 
resistance to 5-FU when present in the WT background (Figure 8a). Therefore, I compared WT 
viruses with nsp12 mutant viruses in both the WT-nsp14 and nsp14-ExoN(-) backgrounds. 
Similar to what was observed for mutations identified by homology modeling, there was no 
significant change in selectivity for 5-FU for any of the nsp12-RdRp mutant viruses in the WT 
background at up to 300uM 5-FU when compared to WT viruses (Figure 15a). However, the 
same was observed for nsp12 variant viruses in the nsp14-ExoN(-) background, for which all 
were non-recoverable at 120uM 5-FU (Figure 15b). These data demonstrate that 5-FU-treated 
minority variants do not confer resistance across CoVs to the mutagen 5-FU and suggest that 
they are not fidelity determinants. However, it is possible that these variants confer resistance to 
5-FU in SARS-CoV. As mutations in nsp12-RdRp can result in differential selectivity between 
nucleotide analogs (Sexton et al., 2016), I next tested engineered viruses for altered selectivity 
for the non-obligate chain terminator 2′-C-methyladenosine (2′-C-MeA). Again, no change in 
selectivity for 2′-C-MeA was observed for any of the viruses tested (Figure 15c, d). One 
mutation, nsp12-E519G, resulted in a virus that was more sensitive to 2′-C-MeA in the WT-
nsp14 background, however this mutation was not recoverable in the nsp14-ExoN(-) background 
and therefore was not pursued further (Figure 15c). Of note, almost all viruses engineered after 
identification by homology modeling displayed altered selectivity for 2′-C-MeA, even in the 
WT-nsp14 background (Figure 16). Together, these data suggest that the minority variants 
present in mutagen-treated populations are not good candidates for residues involved in the 
regulation of fidelity but are instead beneficial in another way or are an accident of a 
bottlenecking event.  
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Figure 15. Selectivity for 5-FU or 2′-C-MeA of MHV engineered 5-fluorouracil-treated CoV 
minority variant viruses  
Domain location of mutations is indicated by: CoV-specific domain (yellow), fingers (blues) and 
thumb (green). DBT cells were pre-treated with different concentrations of 5-FU (A and B) or 2′-C-
MeA (C and D) for 30 min. Treatment was removed and cells were infected with indicated viruses in 
the WT background (A and C) or nsp14-ExoN(-) background (B and D) at an MOI of 0.01. Media 
containing 5-FU or 2′-C-MeA was replaced 30 min p.i. Virus samples were taken at 24 (WT) or 32 
(nsp14-ExoN(-)) h.p.i and titer was determined by plaque assay. Data represents 2 independent 
experiments, each with 2 replicates, except panel A, which represents 1 independent experiment with 2 
replicates. Error bars represent SEM.	
	 49	
 
Figure 16. Selectivity for 2′-C-MeA of MHV nsp12-RdRp mutant viruses identified by homology 
modeling  
Domain location of mutations is indicated by: fingers (blues) and palm (reds). DBT cells were pre-
treated with indicated concentrations of 2′-C-MeA for 30 min. Treatment was removed and cells were 
infected with indicated viruses in A. the WT background or B. nsp14-ExoN(-) background at an MOI 
of 0.01. Media containing 2′-C-MeA was replaced 30 min p.i. Virus samples were taken at 24 (WT) or 
32 (nsp14-ExoN(-)) h.p.i and titer was determined by plaque assay. Data represents 2 independent 
experiments, each with 2 replicates. Error bars represent SEM.	
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Replication kinetics of nsp12-E519N, nsp12-Q520L and nsp12-S900C mutant viruses in the 
WT and nsp14-ExoN(-) backgrounds 
Although mutations identified in 5-FU-treated nsp14-ExoN(-) CoV populations didn’t confer 
observable changes in nucleotide selectivity, alternative replicative advantages could have 
allowed for selection of these minority variants. To address this, I next sought to determine if 
nsp12-E519N, nsp12-Q520L or nsp12-S900C viruses resulted in altered replication kinetics. In 
the WT-nsp14 background, nsp12-E519N replicated with kinetics mimicking that of the WT 
virus alone, whereas both nsp12-Q520L and nsp12-S900C resulted in a delay in replication and 
never reached peak titers. Strikingly, nsp12-Q520L resulted in a lag phase of at least eight hours, 
similar to that seen for the nsp14-ExoN(-) virus. However, at eight hours, titers increased to 2-
logs more than nsp14-ExoN(-) viruses (Figure 17a). Similar to what was observed with mutant 
viruses identified by homology modeling (Chapter II), replication of both nsp12-E519N and 
nsp12-Q520L viruses in the nsp14-ExoN(-) background displayed similar replication kinetics to 
nsp14-ExoN(-) (Figure 17b). However, nsp12-Q520L/nsp14-ExoN(-) resulted in a longer lag 
phase from which it did not recover, but instead maintained the delay throughout the exponential 
replication phase (Figure 17c). Overall, these data do not support the hypothesis that these 
mutations are present in the mutagenized population to help increase replication kinetics of the 
virus. In the case of nsp12-Q520L, these data also demonstrate that this variant delays replication 
kinetics beyond that of nsp14-ExoN(-).  
Next, I assessed RNA synthesis for nsp12-E519N and nsp12-S900C by RT-qPCR. Similar to 
previous data, virus replication kinetics and genomic RNA levels of nsp12 mutant viruses were 
consistent within the WT-nsp14 background. I observed no difference in genomic RNA 
accumulation for nsp12-E519N but delayed and decreased genome RNA accumulation for 
nsp12-S900C in the WT-nsp14 background after multiple rounds of replication (Figure 18a). In 
contrast, in the nsp14-ExoN(-) background, RNA synthesis levels for nsp12-E519N/nsp14-
ExoN(-) surpassed those of nsp14-ExoN(-) and the opposite was true for nsp12-S900C/nsp14-
ExoN(-) (Figure 18b). These data suggest that the increase in the percentage of nsp12-E519N in 
the 5-FU-treated population may be partially attributable to an increase in the accumulation of 
RNA by this virus.  
 
	 51	
 
 
Figure 17. Replication kinetics of 5-fluorouracil-treated, minority-variant engineered MHV 
nsp12-RdRp mutant viruses  
Mutation location is indicated by: fingers (blues) and thumb (green). DBT cells were infected with the 
viruses indicated in the A. WT background at an MOI of 0.1 PFU/cell or B and C. Nsp14-ExoN(-) 
background at an MOI of 0.01 PFU/cell. Supernatant aliquots were taken at indicated times p.i. and 
titer determined by plaque assay. Data represents 3 independent experiments. Error bars represent 
SEM.	
	 52	
 
 
 
Figure 18. RNA accumulation by MHV nsp12-RdRp mutant viruses  
Mutation location is indicated by: fingers (blues) and thumb (green). DBT cells were infected with the 
viruses indicated in the A. WT background or B. nsp14-ExoN(-) background at an MOI of 0.01 
PFU/cell. Total RNA was taken at indicated times p.i. and RT-qPCR was performed. Data represents 2 
independent experiments. Error bars represent SEM.		
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The effect on fitness of nsp12-E519N and nsp12-S900C in the nsp14-ExoN(-) background 
Although there was no change in replication kinetics for nsp12-E519N/nsp14-ExoN(-) or nsp12-
S900C/nsp14-ExoN(-), my previous results demonstrated that subtle changes in fitness were not 
detected in the replication data. Therefore, I sought to determine if nsp12-E519N/nsp14-ExoN(-) 
or nsp12-S900C/nsp14-ExoN(-) would result in any change in fitness compared to nsp14-ExoN(-
) alone. Here, fitness is defined as the ability of one virus to outgrow another in co-infections. 
Supporting the finding that the presence of nsp12-E519N/nsp14-ExoN(-) is 25% of the originally 
sequenced population, when co-infected with nsp14-ExoN(-) at ratios from 1:9 to 9:1, nsp12-
E519N/nsp14-ExoN(-) was present at a larger than input percentage of the population at every 
ratio. Additionally, when infected in the presence of 60uM 5-FU, the ratio further increased in 
the favor of nsp12-E519N/nsp14-ExoN(-). Specifically, when infected at identical initial MOIs 
nsp12-E519N/nsp14-ExoN(-) was present at approximately 80% of the resulting population 
untreated and 90% treated (Figure 19a). A similar result was observed for nsp12-S900C/nsp14-
ExoN(-) in the presence of 60uM 5-FU, trending toward an increase in the ratio of nsp12-
S900C/nsp14-ExoN(-) rather than nsp14-ExoN(-) alone. However, in the case of nsp12-
S900C/nsp14-ExoN(-), the virus was less fit than nsp14-ExoN(-) when 5-FU was not present, 
and fitness only matched that of nsp14-ExoN(-) when 5-FU was present (Figure 19b). These data 
suggest that both nsp12-E519N and nsp12-S900C result in a minor fitness advantage for nsp14-
ExoN(-) viruses when replicating in the presence of the mutagen 5-FU and that their greater 
abundance as minority variants of the population may be a result of this selective advantage. 
Additionally, the fitness advantage observed for each of the variants correlates with the percent 
of the deep sequenced population they comprised (Figure 19 and table 2).  
Identification of consensus sequence mutations in MHV nsp12 and nsp14 after passage in 
the presence of the mutagen 5-FU 
Although co-infection results suggested that in the nsp14-ExoN(-) background two of the 
variants identified may confer subtle effects on viral fitness in the presence of 5-FU, 
investigating these variants further will require a robust biochemical system. In the absence of a 
robust biochemical system, I next sought to identify residues resulting from selection for 
resistance to 5-FU by passaging. WT and nsp14-ExoN(-) viruses were blind passaged in media 
alone or in sub-lethal doses of 5-FU for seven total passages (Figure 20a). Nsp14-ExoN(-) 
viruses were not able to replicate beyond the seventh passage even when cells were infected in
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Figure 19. Competitive fitness analysis of MHV nsp12-RdRp mutant viruses in the nsp14-
ExoN(-) background   
DBT cells were pre-treated with media alone or containing 60uM 5-FU for 30 min. Treatment was 
removed and cells were co-infected, at total MOI of 0.01, with nsp14-ExoN(-) and A. nsp12-
V553I/nsp14-ExoN(-) or B. nsp12-M611F/nsp14-ExoN(-) at a ratio of 9:1, 1:1 or 1:9. Media alone or 
containing 60uM or 300uM 5-FU was replaced 30 min p.i. Total RNA was taken at 24 h.p.i 
Sequencing was performed across a 1.7kb region of nsp12-RdRp that included both mutations. Data 
represents 2 independent experiments.		
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the absence of 5-FU, suggestive of lethal mutagenesis. The inability to continue passage suggests 
that any mutations that arose were not enough to compensate for the population damage, which 
occurred during extended treatment with 5-FU. In contrast, cells infected with WT virus in the 
presence of 5-FU became fully involved in syncytia progressively more quickly with less 
transferred volume as passaging continued. This suggested that mutations arose within the 
mutagenized WT population that confer resistance to 5-FU. Both WT and nsp14-ExoN(-) viruses 
passaged in the absence of 5-FU maintained relatively consistent passaging conditions, and 
nsp14-ExoN(-) remained viable at the end of the passage series. Total RNA was taken from the 
final passage of all lineages and subjected to Sanger sequencing across all of nsp12 and nsp14.  
Sequencing results from passaged populations across nsp12 and nsp14 were analyzed for non-
synonymous mutations present at 50% or greater of the total population. No mutations were 
observed in nsp12 or nsp14 for any of the three lineages of WT virus passaged in the absence of 
5-FU. Similarly, nsp14-ExoN(-) populations resulted in no observed non-synonymous mutations 
in nsp14 and only one in nsp12 (M814K). Nsp12-M814K was found in one of the three untreated 
populations and is a residue of the nsp12-RdRp thumb domain. At least one mutation was 
observed in nsp12 for every lineage of WT virus passaged in the presence of 5-FU, and lineages 
one and three also selected for individual mutations within nsp14-ExoN. Finally, every lineage 
of nsp14-ExoN(-) virus passaged in the presence of 5-FU selected for non-synonymous 
mutations in both nsp12 and nsp14. All mutations identified were unique to their lineage, except 
nsp12-M814K, which was observed in one untreated nsp14-ExoN lineage and two treated nsp14-
ExoN(-) lineages. In total, 11 unique mutations were identified across nsp12. Of these, four 
mutations were in the nsp12-CoV-specific domain: nsp12-P180H, A193S, V223I and A379T; 
and seven were in the nsp12-RdRp domain: nsp12-N548S, H644Y, T645A, A695T, P735S, 
S768F and M814K. There were six unique mutations identified across nsp14. The residues were 
also divided between the nsp14-ExoN(-) domain: nsp14-A93V, D175G, F216L and P258S; and 
the nsp14-N7-methyltransferase (N7-MT) domain: nsp14-V327A and A338T (Figure 20b). The 
residues identified were variably conserved across CoVs with 100% nsp12-A695 conservation 
across 13 CoVs and no nsp14-P258 conservation to the proline of MHV-A59.  
I next sought to compare the location of mutations identified by selection with the structural 
locations of known catalytic residues, as well as the residues previously predicted by homology
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Figure 20. Identification of mutations in nsp12 and nsp14 selected for in the presence of 5-FU  
A. DBT cells were infected with at an initial MOI of 0.01 PFU/cell with either WT or nsp14-ExoN(-) 
viruses in triplicate lineages. Infections were performed in media alone or containing 5-FU (60uM for 
nsp14-ExoN(-) and 800uM for WT). Populations were then blind passaged for 6 additional passages. 
Total RNA was taken and prepared for Sanger sequencing. Sequencing was performed across all of 
nsp12 and nsp14. B. Domains of nsp12 are indicated by: CoV specific domain (black), fingers (blues), 
palm (red) and thumb (green). Domains of nsp14 are indicated by: ExoN (blue), N7-MT (black) and 
zinc fingers within ExoN (gray). Non-synonymous majority mutations were identified across nsp12 
and nsp14.		
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Figure 21. Conservation of selection-identified residues across CoVs  
Amino acid alignments of nsp12 and nsp14 for a representative set of CoVs. Residues where 
mutations occurred are highlighted with colors indicating the degree of conservation across CoVs as 
high (green), medium (yellow), and low (red). Conservation ranged from completely conserved 
(nsp12-A695) to no residues matching that of MHV-A59 (nsp14-P258).		
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modeling. Mutations that arose by passage in nsp12-RdRp were mapped onto the modeled 
structure from Chapter II (Sexton et al., 2016). All of the mutations identified by selection are 
distinct from those previously identified by homology, although nsp12-T645A and nsp12-
H644Y (in the fingers domain) are adjacent to nsp12-Y649H. One additional mutation, nsp12-
N548S, was identified in the fingers domain. Three mutations: nsp12-A695T, S768F and P735S 
were found in the palm domain but all were distant from the SDD active site. Finally, the only 
mutation present in multiple lineages, nsp12-M814K, is within the thumb domain. However, 
modeling suggests that nsp12-M814K folds into a pocket behind the active site where many of 
the residues identified by homology modeling also reside (Figure 22a). In order to investigate the 
structural layout of mutations that arose in nsp14, a model of nsp14 needed to be generated. The 
SARS-CoV nsp14 structure was solved and published during this dissertation research, providing 
the opportunity to model MHV nsp14 using Phyre2 software as described for nsp12-RdRp core 
domain in Chapter II (Kelley et al., 2015). Residues identified by selection were mapped onto 
the modeled structure. One of the mutations, nsp14-A93V, was located just behind the DEED 
catalytic residues. Two of the mutations were in zinc fingers of nsp14-ExoN: nsp14-F216L and 
P258S. Another, nsp14-D175G, resides at the interface between nsp14-ExoN and nsp14-N7-MT. 
Finally, nsp14-V327S and nsp14-A338T were identified in the nsp14-N7-MT domain (Figure 
22b). Overall, most mutations were predictably identified in the RdRp domain of nsp12 and in 
the ExoN domain of nsp14. However, a few mutations were identified in the nsp12 CoV-specific 
domain and in the nsp14-N7-MT domain. Furthermore, of the mutations identified in the nsp12-
RdRp domain, most were in either the fingers or the palm, and the only mutation identified in the 
thumb domain appears to be structurally within the predicted fidelity-modulating pocket behind 
the SDD motif.  
Resistance of 5-FU-treated virus populations to the mutagens 5-FU and 5-azacitidine 
The goal of passaging WT and nsp14-ExoN(-) viruses in the presence of 5-FU was to identify 
residues that confer increased fidelity; therefore, I next sought to determine if the treated and 
passaged virus populations displayed increased resistance to mutagens. I compared resistance to 
either 5-FU or the mutagen 5-azacytidine (5-AZC) between WT and nsp14-ExoN(-) stock 
viruses and 5-FU-passaged virus populations. When treated with 5-FU, all WT lineages result in 
increased resistance to 5-FU at 200 and 400uM 5-FU when compared to the original virus stock 
(Figure 23a). In contrast, no difference in resistance to 5-AZC was observed for any WT lineage
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Figure 22. Location of identified residues on modeled MHV-A59 structures on nsp12-RdRp and 
nsp14  
Phyre2 software was used to model A. the core RdRp domain of nsp12 and B. nsp14. Mutations that 
arose within these structures were mapped and compared with previously identified mutations, known 
domains and catalytic residues. The RdRp domain contains fingers (blue), palm (red) and thumb 
(green) domains.			
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Figure 23. Resistance of 5-fluorouracil (5-FU) treated population to 5-FU or 5-azacytidine (5-
AZC) 
DBT cells were pre-treated with indicated concentrations of 5-FU (A and C) or 5-AZC (C and D) for 
30 min. Treatment was removed and cells were infected with stock viruses used for initiating passages 
or passage 7 5-FU-treated populations in the WT background (A and B) or passage 6 5-FU-treated 
populations nsp14-ExoN(-) background (C and D) at an MOI of 0.01. Passaged populations were 
from the final passage 7 supernatants except for Media containing 5-FU or 5-AZC was replaced 30 
min p.i. Virus samples were taken at 24 (WT) or 32 (nsp14-ExoN(-)) h.p.i and titer was determined by 
plaque assay. Data represents 2 independent experiments, each with 2 replicates. Error bars represent 
SEM.		
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(Figure 23b). I also tested nsp14-ExoN(-) populations passaged in the presence of 5-FU for 
resistance to 5-FU and 5-AZC. However, as the final passage seven populations were no longer 
capable of replicating they could not be used for these studies. Therefore, I tested the passage six 
populations instead. Nsp14-ExoN(-) lineages two and three resulted in increased resistance to 5-
FU or 5-AZC (Figure 23c and d). However, the magnitude of increased resistance to 5-FU 
observed was smaller than for WT lineages (Figure 23a and c). Interestingly, nsp14-ExoN(-) 
lineage one did not demonstrate any increase in resistance to 5-FU or 5-AZC (Figure 23c and d). 
This suggests that the mutations selected for in this lineage benefited the virus by a mechanism 
unrelated to nucleotide selectivity. This idea is further supported by the fact that all of the 
mutations selected for in lineage one are found outside of the nsp12-RdRp and nsp14-ExoN 
domains (Figure 20b). Replication assays demonstrated that nsp14-ExoN(-) viruses are delayed 
in replication (Figure 17). Therefore, passaging nsp14-ExoN(-) viruses may result in 
compensatory mutations not directly related to the proofreading function of nsp14-ExoN.  
Replication kinetics of nsp14-ExoN(-) viruses treated with 5-FU result in an increased lag 
phase as well as decreased titers 
Since MHV 5-FU passaged populations resulted in differential resistance to mutagens between 
WT and nsp14-ExoN(-) lineages as well as within nsp14-ExoN(-) lineages, I wanted to 
determine the effect of 5-FU treatment on replication kinetics. Clint Smith infected DBT cells 
with WT or nsp14-ExoN(-) viruses (at an MOI of 1) in the presence of 0, 100 or 200uM 5-FU. 
Supernatant samples were collected at 4, 6, 8, 10, 12, 16 and 24 hours post infection and titered 
by plaque assay. Replication kinetics for WT viruses were similar for treated and untreated 
samples with a similar lag phase, exponential phase, and peak titers. The only difference 
observed between treated and untreated replication curves were half-log decreases in titers 
observed at 24 hours post infection. These decreased titers were identical for WT viruses treated 
with 100uM 5-FU or 200uM 5-FU (Figure 24). Nsp14-ExoN(-) viruses result in an increased lag 
phase over WT-nsp14 viruses and never reached peak titers. This phenotype was exaggerated in 
a dose dependent manner when nsp14-ExoN(-) viruses were treated with 5-FU. When treated 
with 100uM 5-FU, the lag phase increased from six hours to eight hours and peak titers were 2-
logs lower than replication without 5-FU. The lag phase extended to 10 hours and titers dropped 
an additional 1.5-logs when nsp14-ExoN(-) viruses were treated with 200uM 5-FU (Figure 24). 
These data support the hypothesis that WT viruses are highly resistant to 5-FU due to the
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Figure 24. Replication kinetics of WT and ExoN(-) viruses in the presence of 5-FU 
DBT cells were infected with the viruses indicated at an MOI of 1 PFU/cell. Supernatant aliquots were 
taken at indicated times p.i. and titer determined by plaque assay. Data represents 3 independent 
experiments. Error bars represent SEM.	
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presence of nsp14-ExoN proofreading activity. In addition they demonstrate how mutations that 
alter phenotypes other than fidelity could compensate for the effects of 5-FU treatment.  
Engineering and recovery of a subset of mutant viruses identified by selection in the WT 
and nsp14-ExoN(-) background 
Having investigated the involvement of residues in the nsp12-RdRp fingers and palm domains 
on fidelity (Chapter II), I next wanted to determine if residues outside of these regions regulate 
fidelity. Therefore, I engineered and attempted recovery of mutant viruses for a sub-set of the 
mutations identified by selection. Mutant viruses with the following mutations were engineered: 
nsp12-P180H/A193S/V223I (nsp12-PH-AS-VI) of the CoV-specific domain, nsp12-N548S of 
the fingers domain, nsp12-M814K of the thumb domain, nsp14-A93V located just outside of the 
DEED catalytic site, nsp14-D175G found at the interface between nsp14-ExoN and the nsp14-
N7-MT, and nsp14-P258S in the second zinc finger of nsp14-ExoN. Recovery of mutant viruses 
was attempted in the WT and nsp14-ExoN(-) backgrounds a maximum of three times. In contrast 
to residue identification by homology modeling or 5-FU population minority variants, all 
engineered viruses were recoverable in both the WT and nsp14-ExoN(-) background, with only 
one exception, nsp14-D175G, which was only recovered in the WT background (Table 3).  
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This is consistent with identification by selection, which should result in highly fit viruses. In the 
case of nsp14-D175G it is likely that this mutation is dependent on one of the other mutations 
selected for in this passage series. Further supporting this hypothesis, nsp14-D175G was present 
as only 60% of the population, while the other mutation in nsp12 and nsp14 for lineage 3 were 
already fixed in the population. Nsp14-D175G may have arisen later during passaging once a 
complementary mutation was fixed. No additional mutations were identified in nsp14 but three 
were identified in nsp12-RdRp (Figure 20).  
Discussion 
At the start of this dissertation research, no mutations in CoV nsp12 had been identified that 
altered nucleotide selectivity and only the DEED active site of nsp14 had been altered resulting 
in decreased fidelity (Eckerle et al., 2007; 2010; Graham et al., 2012; Smith et al., 2013). 
Additionally, interactions between nsp12 and nsp14 activities had not been investigated. Chapter 
II of this dissertation identified residues involved in nucleotide selectivity within the nsp12-
RdRp by homology (Sexton et al., 2016). However, nsp12 also encodes a CoV-specific domain 
and nsp14 influences fidelity. Further, as regulation of CoV fidelity is dependent on multiple 
proteins, disrupting or strengthening interactions between these proteins could alter CoV fidelity 
(Eckerle et al., 2007; Sexton et al., 2016; Smith et al., 2015). Chapter III of this dissertation built 
upon the data presented in Chapter II, with the goal of identifying mutations across nsp12 or 
nsp14, which alter nucleotide selectivity and fidelity. In this work, I sought to determine whether 
the residues identified by selection would be unique or would mimic those identified by 
homology modeling. Additionally, I sought to determine if minority variants (defined as present 
at greater than 1% of the population) of nsp14-ExoN(-) populations treated with 5-FU confer 
increased resistance to 5-FU or demonstrate other measureable benefits to the virus. Finally, I 
sought to investigate the interaction between the phenotypic effects of mutations in nsp12 and 
nsp14.  
Some minority variants of mutagen-treated CoVs require the presence of alternative 
residues for viability 
RNA viruses are known to replicate with high mutation rates resulting in mutant swarms: 
populations with a common consensus sequence where most individuals vary from the consensus 
(Domingo et al., 1996; Lauring and Andino, 2010; Vignuzzi et al., 2005b). Mutant swarms 
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influence the overall phenotype of viral populations (Vignuzzi et al., 2005b). However, 
individual minority-variant mutations from CoV populations had not been previously 
investigated. In this study, I identified minority variants present in nsp12 and recovered viruses 
containing identified mutations in an isogenic MHV background. Considering that these 
mutations were identified from nsp14-ExoN(-) populations that arose in the presence of 5-FU, it 
was possible that these variants would result in increased resistance to 5-FU. Additionally, since 
these mutations were present at a frequency of 1% of the population or more, it seemed likely 
that they would be recoverable as variant viruses in an isogenic background. As expected, the 
majority of mutations identified were recoverable in the WT background. Only nsp12-P374S 
was non-recoverable. However, in the nsp14-ExoN(-) background two additional mutations were 
non-recoverable (Table 2). Since the mutations arose originally in the nsp14-ExoN(-) 
background, this was particularly surprising. There are many possible explanations for the non-
recovery of these variant viruses. In the case of nsp12-P374S, it may be that this virus would be 
viable in the nsp14-ExoN(-) background. This could be the case if the mutation is beneficial in 
the context of an inactivated nsp14-ExoN but detrimental in the WT-nsp14 background this 
could be the case. One way this could occur is if the mutation results in an increase in the fidelity 
of nsp12-RdRp. For variants non-recoverable in the nsp14-ExoN(-) background (nsp12-L364F, 
nsp12-E519G and potentially nsp12-P374S), several possibilities exist to explain these data. The 
simplest explanation is that MHV and SARS-CoV are different viruses and these variants may 
affect replication differently between the two. However, in most cases attempted, conserved 
mutations between MHV and SARS-CoV have resulted in similar phenotypes (Sexton et al., 
2016; Smith et al., 2013). It is also possible that the observed minority variant viruses require co-
infection with WT viruses or the presence of additional mutations within the viral clone in order 
to persist in a population. 
Minority variants result in subtle to no alternations of replication phenotypes  
The minority variants present in a population could represent mutations that are likely to be fixed 
in subsequent rounds of replication under similar conditions or could be present only when 
complemented by the mutant swarm. None of the mutations investigated in this study resulted in 
a significant change in resistance to the nucleotide analogs 5-FU or 2′-C-MeA (Figure 15). 
Similarly, none resulted in any increase in replication kinetics or peak titers, and some even 
resulted in decreases in both (Figure 17). Therefore, it is unlikely that the majority of 5-FU-
	 66	
treated population minority variants are present in the mutant swarms resist incorporation of 5-
FU into viral RNA or increase replication kinetics. However, in co-infection experiments, nsp12-
S900C/nsp14-ExoN(-) resulted in equal fitness to nsp14-ExoN(-) in the presence of 5-FU, 
despite replication and RNA accumulation defects in the absence of 5-FU (Figures 17a, 18 and 
19b). Therefore, some of the minority variants present in mutant swarms may represent viruses 
that are neutral compared with WT viruses in the specific selective environment. These viruses 
are likely ones which benefit from minor to major bottlenecking events and so are able to persist 
in the population under specific conditions. Additionally, a threshold may exist, dependent on the 
specific conditions, which defines what fraction of the population is likely to consist of these 
types of minority variants. Above the bottlenecking threshold may be where mutations with 
measurable outcomes for virus replication can be identified. In this set of variants, nsp12-E519N 
was present as 25% of the original population (Table 2). This is also the only variant that resulted 
in a measurable beneficial phenotype, specifically in the nsp14-ExoN(-) background, RNA 
accumulation was increased over np14-ExoN(-) alone and in co-infection experiments nsp12-
E519N/nsp14-ExoN(-) increased in the population over input (Figures 18b and 19a). However, 
even in the case of nsp12-E519N the phenotypes were relatively subtle. Together, these data 
suggest that minority variants arising in the presence of a selective pressure are not strong targets 
for overcoming the specific applied selective pressure.  
Selection for mutations that result in resistance to 5-FU identifies residues involved in 
nucleotide selectivity, but also increases titers by an alternate mechanism 
In contrast to identifying minority variants of 5-FU treated populations, selection for resistance 
to a mutagen followed by the identification of majority variants by Sanger sequencing is a 
reliable source of residues involved in fidelity regulation (Arias et al., 2008; Beaucourt et al., 
2011; Coffey et al., 2011; Levi et al., 2010; Zeng et al., 2014). In 5-FU treated populations, 
mutations arose within the expected domains of nsp12 and nsp14, as expected, the nsp12-RdRp 
finger and palm domains and the nsp14-ExoN domain (Campagnola et al., 2015; Korneeva and 
Cameron, 2007). Yet, mutations were also identified in all other domains (nsp12-RdRp thumb, 
nsp12-CoV-specific and nsp14-N7-MT). None of the mutations identified were the same as 
those identified by homology modeling and only nsp12-M814K was identified in multiple 
lineages (Figures 20, 22). In fact, nsp12-M814K was also the first mutation to arise in a separate 
nsp14-ExoN(-) passaging experiment performed by Xiaotao Lu in our lab (unpublished). This 
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separate passaging experiment was performed in the absence of any intentional, external 
selective pressures. The repeated selection for the variant nsp12-M814K in the nsp14-ExoN(-) 
background (whether treated or untreated) suggests that this variant provides significant 
compensation for the replication defects conferred by the inactivation of nsp14-ExoN. Yet the 
facts that none of the mutations flagged by selection were identified by homology modeling, and 
only nsp12-M814K was identified in multiple lineages and in alternative passaging experiments, 
suggests that CoVs exist in a robust mutational landscape, where many viable mutations are 
generated and available for selection and can compensate for treatment with 5-FU and likely 
other mutagens. To determine the breath of mutations available to overcome challenge with 5-
FU, it would be interesting to see how many lineages it would take before repetitive mutations 
were identified.  
The 5-FU-treated WT populations resulted in increased resistance specifically to 5-FU rather 
than broadly to mutagens; whereas, the 5-FU-treated nsp14-ExoN(-) populations resulted in 
increased resistance to multiple mutagens or had no change in resistance (Figure 23). These data 
suggest that there are different pressures being applied to WT vs. nsp14-ExoN(-) viruses when 
treated with 5-FU. Replication kinetics experiments for WT and nsp14-ExoN(-) viruses further 
support this observation, WT viruses exhibited no change in replication kinetics when treated 
with 5-FU, but nsp14-ExoN(-) viruses had longer lag phases and reached decreased peak titers in 
the presence of increasing concentrations of 5-FU (Figure 24). It is important to remember that 
nsp14-ExoN(-) viruses encode a full nsp14 protein, which is inactivated by substituting two of 
the active site residues. Therefore, it is possible that 5-FU effects on nsp14-ExoN(-) replication 
kinetics can be explained if the mutant nsp14-ExoN still recognizes and attempts to remove 5-FU 
nucleotides incorporated by nsp12-RdRp. If this is the case, nsp14-ExoN may stall the 
replication-transcription complex (RTC) each time 5-FU is incorporated and ultimately result in 
an increased lag phase. If this hypothesis is correct, then in the context of an inactivated nsp14-
ExoN, reducing or eliminating the interaction between nsp12-RdRp and nsp14-ExoN may be 
beneficial and thus selected for. Generally, any mutations that increase the speed of replication 
would be selected for, unless it is otherwise deleterious to fitness. It will be interesting to 
determine if nsp12-PH-AS-VI, nap12-M814K, nsp14-D175G or nsp14-F216L result in increased 
replication speed in the context of an nsp14-ExoN(-) virus.  
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Conclusion 
The results described in this chapter demonstrate that (1) minority variants found in 5-FU treated 
populations provide subtle to no ability to resist 5-FU; (2) that selection identifies a diverse panel 
of mutations most of which are likely involved in nucleotide selectivity; and (3) that nsp14-
ExoN(-) viruses may be compensated for by mutations involved in increasing replication 
kinetics. The increased lag phase for MHV nsp14-ExoN(-) viruses is a consistently observed 
phenotype (Eckerle et al., 2007; Sexton et al., 2016; Smith et al., 2013). Defects in viral 
replication are generally attributed exclusively, and specifically, to the loss of proofreading. 
However, a recent paper demonstrated that mutating one of the nsp14-ExoN zinc fingers results 
in an altered innate immune response (Becares et al., 2016). The results of that study suggest that 
nsp14-ExoN may have additional functions. They also suggest it may be possible to unlink the 
proofreading defect from that of the larger replication lag phase. This could greatly simplify 
fidelity studies in the future and provide a mechanism for further understanding the interactions 
between nsp14 and other CoV proteins involved in fidelity, particularly nsp12. Finally, the 
results of this chapter again highlight the need for a robust and reproducible biochemical assay 
for the CoV RTC. 
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CHAPTER IV  
 
DEVELOPMENT OF A ROBUST AND QUANTATATIVE MEASURE OF FIDELITY 
FOR CORONAVIRUSES 
 
Introduction 
Fidelity of viral replication has been studied most extensively for the picornaviruses 
(Campagnola et al., 2015; Gnädig et al., 2012; Gohara et al., 2004; Korneeva and Cameron, 
2007; Moustafa et al., 2011; Pfeiffer and Kirkegaard, 2003; 2005; Vignuzzi et al., 2005a). Many 
tools have been developed for the picornavirus field to investigate the incorporation of incorrect 
nucleotides and the rate of misincorporations. The RNA-dependent RNA polymerase (RdRp) of 
coronaviruses (CoVs) modeled closely to the RdRps of picornaviruses (Sexton et al., 2016). 
However, CoV genomes are roughly three times the length of picornavirus genomes and encode 
many proteins, which interact to form the CoV replication-transcription complex (RTC). 
Therefore, many of the methods used to investigate fidelity in picornaviruses may not be 
effective for CoVs. For instance, there are no robust biochemical systems available for CoV 
replication. The RdRp of CoVs, located in non-structural protein 12 (nsp12), is often unstable 
when expressed alone (Velthuis et al., 2009). In fact, nsp12-RdRp requires the presence of (at 
minimum) nsp7 and nsp8 for stable and processive polymerization (Subissi et al., 2014).  
Testing for changes in selectivity to one or more mutagens is a regularly used screening strategy 
for identifying RdRp variant viruses that alter replication fidelity. To determine if RdRp variant 
viruses that exhibit altered selectivity for mutagens have altered fidelity, a fraction of RdRp 
variant virus genomes are cloned and Sanger sequenced to determine any change in the 
accumulation of mutations (Gnädig et al., 2012; Rozen-Gagnon et al., 2014; Zeng et al., 2014). 
In the case of poliovirus a specific fidelity assay was developed. The poliovirus 2C protein (an 
ATPase) is sensitive to guanidine hydrochloride (GUA-HCl), and resistance is conferred by 
specific mutations. Therefore, plaque reduction in the presence of GUA-HCl was assayed to 
quantify escape mutants in a population (Pfeiffer and Kirkegaard, 2003). Orthoreoviruses are 
also sensitive to GUA-HCl, demonstrating that sensitivity is not picornavirus specific (Murray 
and Nibert, 2007). After identifying RdRp fidelity determinants, deep sequencing of RdRp-
variant virus populations was performed to further describe the types and number of mutations 
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arising compared to WT populations. However, current deep sequencing platforms result in a 
relatively high number of errors. These errors arise during each step of sample preparation and 
can confound data interpretation. New techniques have recently been developed to limit the 
influence of such processing errors such as circle resequencing and duplex sequencing (Acevedo 
and Andino, 2014; Kennedy et al., 2014; Lou et al., 2013; Schmitt et al., 2012). Circle 
resequencing and duplex sequencing require a large amount of RNA, which can be a limiting 
factor for some virus variants. In particular, CoV nsp12-RdRp variants in the nsp14-ExoN(-) 
background result in greatly reduced total RNA and RNA genomes (Figure 9d, f and 18b). 
Additionally, determining changes in fidelity by deep sequencing is difficult because of 
selection. Beneficial viral mutations are selected for and those that are detrimental are selected 
against, providing a bias in mutation frequencies. A bioinformatics approach was developed to 
determine changes in fidelity by deep sequencing. This method only counts stop codons and 
known lethal mutations introduced in viral genomes (Xiao et al., 2016); therefore, it requires an 
extensive knowledge of the genome, which is not always available.  
A novel method for investigating RNA virus fidelity was introduced by Marco Vignuzzi et al. 
Briefly, a microRNA target was cloned into poliovirus genomes encoding WT or fidelity-altered 
RdRps. Viruses were grown in cell lines known to produce complementary microRNA thus, 
virus replication was restricted except when mutations were present in the microRNA target that 
could evade detection (Vignuzzi et al., 2008). MicroRNA targeting as a fidelity assay could be 
applied to many viruses and isn’t affected by genome size or RNA quantity. However, it requires 
a reverse genetics system and knowledge of microRNAs produced by cell lines permissive for 
infection. In the case of CoVs, a reverse genetics system is available for MHV, SARS-CoV and 
MERS-CoV but viral recovery is cumbersome and time intensive. Additionally, the cell line 
typically used for MHV studies, murine delayed brain tumor (DBT), is not well characterized 
(Chen and Baric, 1996). Finally, CoVs are known for high rates of recombination and rapid 
deletion of nonfunctional genes (Makino et al., 1986), which may prevent observation of fidelity 
data when applying this system to CoVs. In this chapter, I present a strategy for the development 
of a broadly applicable assay for investigating fidelity in CoVs. The CRISPR/Cas based assay I 
propose utilizes similar principles to that of the above microRNA method but doesn’t require 
engineering microRNA targets into viruses.  
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CRISPR/CAS is a prokaryotic system for acquiring immunity to foreign nucleic acids. There are 
many CRISPR (clustered regularly interspaced short palindromic repeats) associated system 
(CAS) proteins encoded for in prokaryotic systems, discussed here is the Cas9 endonuclease. 
The targeting of foreign DNA using CRISPR/Cas9 has been well elucidated. Briefly, fragments 
of invading DNA are inserted between CRISPR elements and are expressed as small non-coding 
RNAs, called CRISPR RNAs (crRNAs). When bound to adapter RNAs called transactivating 
CRISPR RNAs (tracrRNA), crRNAs function to target Cas9 endonucleases to cleave 
reintroduced foreign DNA (Mohanraju et al., 2016). The CRISPR/Cas9 system was developed as 
a general DNA editing tool. In these editing systems, crRNAs and tracrRNAs are expressed in a 
single RNA construct and called sgRNAs (single guide RNAs) (Le Cong et al., 2013; Mali et al., 
2013). Recently, it was discovered that CRISPR/CAS type systems could target mRNAs. One 
mechanism for targeting mRNA is through expression of an alternate Cas9-like protein, such as 
C2c2, which cleaves RNA instead of DNA. Once activated C2c2 cleaves RNAs nonspecifically 
and is toxic to the bacterial cell in which it is expressed (Abudayyeh et al., 2016; East-Seletsky 
et al., 2016). Alternatively, Cas9 itself can be targeted to RNA instead of DNA. RNA targeting 
occurs through an alternative RNA, the small CRISPR/CAS-associate RNA (scaRNA). 
Interestingly, when Cas9 interacts with mRNA it likely doesn’t cleave the RNA, as all of the 
known catalytic domains of Cas9 can be mutated without consequence to mRNA down 
regulation. However, mutating the RNA interacting arginine-rich motif (ARM) of Cas9 resulted 
in the restoration of WT levels of targeted mRNAs (Sampson et al., 2013). RNA-targeted Cas9 
was adapted to inhibit the RNA virus HCV. The tracrRNA and scaRNA were combined into a 
single construct, coined RNA-targeting guide RNA (rgRNA), with a 20bp region complementary 
to HCV (Price et al., 2015). In both the endogenous bacterial system and the bioengineered 
system, RNA with secondary structure was targeted. Unexpectedly, only the 2 nucleotides at the 
3′ end of the HCV genome target needed to be a perfect match in the rgRNA for effective 
inhibition of viral translation (Price et al., 2015). Considering the specificity of targeting by this 
system, RNA targeted Cas9 may be adaptable as a quantitative fidelity assay for CoVs. 
In this chapter, I describe a strategy to develop an rgRNA/Cas9-based system for investigating 
fidelity in CoVs and report preliminary studies toward this goal. I first demonstrate that methods 
used in picornaviruses aren’t effective screens or measures for CoVs. I then provide evidence 
that MHV translation and replication can be targeted by rgRNA/Cas9. I show that transfection of 
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the Cas9 vector into HEK293T cells unexpectedly increases translation of MHV but doesn’t 
increase viral titer. Further, I present preliminary data demonstrating that rgRNAs targeted to 
MHV alone may inhibit translation of MHV. Finally, I present additional preliminary data 
suggesting that small differences in escape may be observable between WT and nsp12-RdRp 
mutant viruses. I performed all of the work described in this chapter. 
TOPO TA cloning, combined with Sanger sequencing of a 1kb region of the genome results 
in a small dynamic range  
Cloning subsets of viral genomes and counting mutations present in individual bacterial clones 
has been routinely used to determine changes in fidelity between viruses (Chung et al., 2007; 
Gnädig et al., 2012; Rozen-Gagnon et al., 2014). Moreover, in a paper from the Denison lab, full 
genomes of individual clones were sequenced for WT and nsp14-ExoN(-) MHV viruses and 
mutations present were identified by Sanger sequencing. This resulted in a 15-fold change in 
mutations present between WT and nsp14-ExoN(-) viruses (Eckerle et al., 2007). Therefore, I 
first attempted to assess fidelity for CoVs by TOPO TA cloning a 1kb region across nsp2. The 
nsp2 protein was chosen because nsp2 is dispensable for replication in cell culture and has no 
known role in the regulation of fidelity (Freeman et al., 2014). Since nsp2 is dispensable for 
replication, it is one of the proteins most likely to experience neutral selection and thus would be 
capable of carrying mutations but would not artificially enhance the number of mutations 
observed due to positive selection. Additionally, nsp2 is likely to maintain neutral selection in 
the context of an altered fidelity virus or the introduction of a nucleoside analog. WT, nsp12-
M611F (from homology modeling, Chapter II), nsp14-ExoN(-), and nsp12-M611F/nsp14-
ExoN(-) viruses were cultured in triplicate for 5 passages. The nsp2 region was cloned into the 
TOPO TA vector and 75 to 100 transformed bacterial clones were Sanger sequenced. Four 
mutations per 104 nucleotides were recorded for WT MHV (Figure 25). This is much higher than 
the number of mutations recorded by full genome sequencing, 0.29 (Eckerle et al., 2007). 
However, the full genome sequencing only measured fixed mutations where as TOPO cloning 
allowed for observation of minority variants. Additionally, initial infections were performed with 
MOIs of 0.1 and 0.01, respectively. Therefore, differential results were not unexpected. The 
nsp14-ExoN(-) virus resulted in just over 7 mutations per 104 nucleotides (Figure 25), again 
more than the 4.4 mutations per observed for full genome sequencing (Eckerle et al., 2007). The 
mutation frequency for nsp12-M611F viruses was similar to those of WT and nsp14-ExoN(-)
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Figure 25. Mutation frequency determined by TOPO TA cloning  
DBTs were infected with an initial MOI of 0.01 then blind passaged in triplicate for 5 passages. Total 
RNA was collected and cloned into TOPO TA vector. A 1kb region in nsp2 was sequenced for 
between 75 and 100 clones for each virus. Average mutation accumulation per 104 nucleotides is 
shown. (Error bars represent SEM; ns, not significant; *P < 0.05; **P < 0.01 by Mann Whitney test). 
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alone, with 3.2 and 6 mutations observed, respectively (Figure 25). The fold change in mutations 
observed, when nsp14-ExoN was inactivated, was 1.8 for the TOPO TA experiment and 15.2 for 
the full genome sequencing. A two-fold change in mutations observed between WT and nsp14-
ExoN(-) mutations is uncharacteristic for CoVs, which have an average reported fold change of 
14 (Eckerle et al., 2007; 2010; Graham et al., 2012; Sexton et al., 2016; Smith et al., 2013). No 
statistically significant difference between WT and nsp12-M611F viruses was observed, which 
was not surprising considering the relatively minor difference observed between WT and nsp14-
ExoN(-) viruses. Additionally, reversion data demonstrated that nsp12-M611F/nsp14-ExoN(-) 
had nearly completely reverted to WT-nsp12 by passage 5, so little to no difference between 
these samples would be expected (Figure 12b). Together these data suggest that TOPO TA 
cloning is not an effective way to measure changes in mutation frequency conferred by mutations 
in either the nsp12-RdRp or nsp14-ExoN of CoVs. However, utilizing a different region of the 
genome could result in frequencies with enough resolution to observe fidelity changes for nsp12-
RdRp mutant viruses and that are consistent with previously observed differences between WT 
and nsp14-ExoN(-) viruses. 
Selectivity for nucleotide analogs varies between mutant viruses and nucleoside analogs  
When my dissertation research began, all published reports of fidelity-altered RNA viruses 
(except one) demonstrated that resistance to nucleoside analogs, specifically mutagens, 
correlated with changes in fidelity. An exception was a foot and mouth disease RdRp variant 
virus, selected in the presence of ribavirin, which exhibited in decreased fidelity for natural 
nucleotides while specifically excluding ribavirin incorporation (Arias et al., 2008). However, 
since the majority of reported variants demonstrated consistency between fidelity and nucleotide 
analog selectivity, I tested nsp12-RdRp mutant viruses for altered sensitivity to a panel of 
nucleoside analogs. I included in this panel the mutagens 5-FU, a uracil analog; 5-AZC, a 
cytidine analog; and ribavirin, a guanosine analog. I additionally tested for altered sensitivity to 
the non-obligate chain terminator: 2′-C-MeA, a cytidine analog with an altered sugar. WT, 
nsp14-ExoN(-), nsp12-M611F/nsp14-ExoN(-) or nsp12-V553I/nsp14-ExoN(-) viruses were 
assessed for altered selectivity for any of the nucleoside analogs described. As presented in 
Chapter II, nsp12-V553I/nsp14-ExoN(-) viruses were resistant to both 5-FU and 5-AZC (Figure 
26a, b). However, nsp12-V553I/nsp14-ExoN(-) was more sensitive to 2′-C-MeA and didn’t 
demonstrate any change in sensitivity to ribavirin (Figure 26c, d). The nsp12-M611F/nsp14-
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ExoN(-) mutant virus demonstrated similarly inconsistent results, demonstrating resistance to 5-
FU and 2′-C-MeA but no change in selectivity for either 5-AZC or ribavirin (Figure 26). The 
only virus that resulted in predictable sensitivity to nucleoside analogs was nsp14-ExoN(-) when 
compared to WT viruses; in all cases observed nsp14-ExoN(-) viruses are more sensitive to 
nucleoside analogs – consistent with their known proofreading defect (Figure 26a-c). This result 
was observed for ribavirin as well (data not shown). Together this suggests that mutating nsp12-
RdRp may result in complex changes to nucleotide selectivity, where each specific nucleotide is 
differentially incorporated. Therefore, mutagen treatment assays do not define the overall fidelity 
of a virus.  
Coronaviruses are not sensitive to guanidine hydrochloride at concentrations that inhibit 
picornaviruses  
Since CoV proteins show homology with picornavirus proteins such as the RdRp, and 3C 
protease, I next sought to determine if CoVs were sensitive to guanidine hydrochloride (GUA 
HCl) similar to picornaviruses, and if I could utilize this sensitivity to develop a fidelity assay 
similar to that used in picornaviral systems. In picornaviruses, GUA HCl specifically inhibits the 
2C protein and mutations in 2C that result in escape from GUA HCl inhibition have been 
characterized. To test for inhibition in CoVs, cultures were inoculated with 200 plaque forming 
units (PFU) of either WT or nsp14-ExoN(-) viruses. Next, cells were overlaid with agar 
containing up to 2mM GUA HCl. For all conditions tested approximately 200 PFU were 
observed, and GUA HCl-treated WT virus plaques appeared to be homogeneous and of a similar 
size to the untreated ones. Similarly, plaques formed by nsp14-ExoN(-) viruses treated with 
GUA HCl were similar to plaques formed in its absense (Figure 27). Together this shows that 
MHV is not sensitive to GUA HCl at the concentrations tested, and treatment with GUA HCl 
will not serve as a CoV fidelity assay.  
Developing an rgRNA/FnCas9 assay for investigating fidelity in CoVs 
Identification of targets in the MHV genome  
In order to investigate the contributions of CoV fidelity regulating proteins beyond ExoN, and 
particularly nsp12, a sensitive and rapid assay is required. Therefore, I attempted to assess the 
ability of RNA-targeted Cas9 endonuclease to inhibit MHV. Cas9 from Francisella novicida 
(FnCas9) was used for this study as it is currently the best characterized RNA-targeted 
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Figure 26. Selectivity of mutant viruses in the nsp14-ExoN(-) background for a panel of 
nucleotide analogs  
Domain location of mutations is indicated by: fingers (blues) and palm (reds). DBT cells were pre-
treated with indicated concentrations of 5-FU, 5-AZC, 2′-C-MeA or Ribavirin for 30 min. Treatment 
was removed and cells were infected with indicated viruses in A. the WT background or B. nsp14-
ExoN(-) background at an MOI of 0.01. Media containing 5-FU, 5-AZC, 2′-C-MeA or Ribavirin was 
replaced 30 min p.i. Virus samples were taken at 32 h.p.i and titer was determined by plaque assay. 
Data represents 3 independent experiments, each with 2 replicates (except ribavirin, which is only one 
experiment with two replicates). Error bars represent SEM.	
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Figure 27. Treatment of WT and nsp14-ExoN(-) viruses with GUA-HCl  
DBT-9 cells were infected with 200 PFU per well of WT or nsp14-ExoN(-) viruses in 6-well plates. 
Overlays were placed with indicated concentrations of GUA-HCl (0mM – 2mM left to right) and 
allowed to incubate overnight. Plates were fixed and imaged. 
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Cas9, and the only Cas9 with a demonstrated ability to specifically require the two 3′ most 
nucleotides for inhibition (Price et al., 2015). The pFnCas9 and pU6rgRNA plasmids used in    
(Price et al., 2015) were acquired from David Weiss’s lab. The acquired pU6rgRNA plasmid   
targets the E2 protein of murine herpes virus 68 (MHV68) – a DNA virus – and is used in this 
study as a control rgRNA, which doesn’t target the CoV MHV genome. I next identified three 
structured RNA regions of the MHV genome to target rgRNA/FnCas9 to (Figure 28). I selected 
20 base pair regions of the 5′-UTR, the Orf1a/Orf1b -1 ribosomal frame shift and the 3′-UTR. 
The 5′-UTR site, 5′-AGUUUAUAAACGGCACUUCC-3′ (TRS-SL4), starts with the last four 
nucleotides of the transcription-regulating sequence (TRS) and ends in an open loop of stem-
loop 4 (SL4) (Kang et al., 2006). The Orf1a/Orf1b -1 ribosomal frame shift site, 5′-
CCCGUCUUGUACCCUGUGCC-3′ (Frame Shift) begins four nucleotides after the stop codon 
of Orf1a and continues through the stem-loop of the pseudoknot (Bredenbeek et al., 1990). The 
final 3′-CC nucleotides are not involved in nucleotide binding to form the pseudoknot but are the 
final cytosines of a GCC codon, which encodes for an alanine in the CoV-specific domain of 
nsp12. All changes to the final C retain an alanine, whereas substitutions at the second positions 
result in a valine, aspartic acid or glycine. This suggests that the virus should tolerate mutations 
in at least the final cytosine. Finally, the 3′-UTR site, 5′-AGGCGCCCCCUGGGAAGAGC-3′ 
(HVR-Oct), exists entirely with in the hypervariable region (HVR) of the 3′-UTR and the final 
GC are located in the conserved octanucleotide (Oct), which makes up and open loop. All 
mutations are tolerated at all positions of the Oct (Goebel et al., 2007). pU6rgRNA plasmids 
were engineered to target each of the described regions of the MHV genome.  
HEK293T cells transiently transfected with CEACAM1 are permissive for MHV 
replication  
Having identified targets, I next needed to develop a system for transient transfection of cells 
followed by MHV infection. The commonly used cell line for MHV studies is the murine 
delayed brain tumor (DBT) cell line; however, data in our lab suggest that DBT cells are rarely 
permissive to infection after transfection (unpublished). Therefore, I chose to use HEK293T 
cells, well described for efficient transfection. However, HEK293T cells do not express the 
MHV receptor, murine CEACAM1. I first determined if HEK293T cells transiently transfected 
with CEACAM1 were permissive for MHV replication. WT or nsp14-ExoN(-) viruses with the 
firefly luciferase (FFL) gene inserted at the 5′ end of nsp2 were used to infect HEK293T cells 
	 79	
 
 
 
Figure 28. Structured regions of the MHV genome identified for targeting of FnCas9 by rgRNAs   
Three structured RNA regions of the MHV genome A) the 5′-UTR, B) the Orf1a/Orf1b -1 ribosomal 
frame shift and C) the 3′-UTR. The 3′-UTR site (HVR-Oct) exists entirely with in the hypervariable 
region (HVR) of the 3′-UTR and the final GC are located in the conserved octanucleotide (Oct) 
(Goebel et al., 2007). The Orf1a/Orf1b -1 ribosomal frame shift site (Frame Shift) begins four 
nucleotides after the stop codon of Orf1a and continues through the stem-loop of the pseudoknot 
(Bredenbeek et al., 1990). The 5′-UTR site (TRS-SL4) starts with the last four nucleotides of the 
transcription-regulating sequence (TRS) and ends in an open loop of stem-loop 4 (SL4) (Kang et al., 
2006).	
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(Freeman et al., 2014), which were mock transfected or transfected with CEACAM1 or FnCas9. 
No FFL expression was measured for mock transfected or FnCas9 transfected cells, however, 
cells transfected with CEACAM1 resulted in high FFL expression for both WT and nsp14-
ExoN(-) viruses (Figure 29).  
Translation of MHV is inhibited in the presence of MHV targeted rgRNAs and FnCas9  
Having demonstrated that HEK293T cells support MHV translation, I next wanted to determine 
if rgRNA/FnCas9 targeted to the MHV genome could inhibit translation of MHV. To test this, I 
transiently transfected cells with CEACAM1 and either rgRNAs alone or with FnCas9. 24 hours 
after transfection, I infected cells with WT-FFL or nsp14-ExoN(-)-FFL viruses at an MOI of 0.1 
PFU/cell. Cell lysates were measured for the expression of FFL. WT or nsp14-ExoN(-) viral 
translation was inhibited when FnCas9 was expressed in combination with any of the three MHV 
targeted rgRNAs (rgRNAHVR-Oct, rgRNATRS-SL4 and rgRNAFrame Shift) (Figure 30). The efficiency 
of translation of WT viruses, as measured by relative FFL expression, for rgRNAHVR-Oct and 
rgRNATRS-SL4 co-transfected with FnCas9 (rgRNAHVR-Oct/FnCas9 and rgRNATRS-SL4/FnCas9) 
was 54 and 49% of no-rgRNA/FnCas9, respectively. Whereas, rgRNAFrame Shift/FnCas9 resulted 
in almost complete abolishment of FFL expression from WT viruses (Figure 29b). Nsp14-
ExoN(-) viruses were similarly inhibited (Figure 30d). Surprisingly, rgRNAMHV68 E2 increased 
translation compared with both the no-rgRNA and rgRNAHVR-Oct controls, in the absence of 
FnCas9. However, it didn’t increase translation over no-rgRNA/FnCas9. Similarly, cells 
transfected with FnCas9 resulted in increased translation compared to CEACAM1 alone (Figure 
30a, c). Together, these data suggest that rgRNA targeting of FnCas9 to the MHV genome can 
specifically inhibit translation. However, it also suggests that FnCas9 alone and rgRNAMHV68 E2 
enhance translation of MHV proteins by an unknown mechanism.  
MHV viral replication is inhibited in the presence of MHV frame shift targeted rgRNAs 
and FnCas9  
Having shown that translation can be inhibited by rgRNA/FnCas9 targeted to the MHV genome, 
I next wanted to investigate whether viral replication was also inhibited. Similar to the 
previously described experiments, cells were transiently transfected with CEACAM1 and 
rgRNAs with or without FnCas9. 24-hours later cells were infected with WT-FFL or nsp14-
ExoN(-)-FFL viruses and supernatants were titered. HEK293Ts form weak attachment to plates 
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Figure 29. MHV viruses are able to infect HEK293T cells when CEACAM1 is transiently 
expressed  
HEK293T cells were transfected with the MHV receptor: CEACAM1, FnCas9, or mock transfected. 
24 hours after transfection cells were infected with WT or ExoN(-) MHV viruses encoding firefly 
luciferase (FFL) at the end of nsp2 at an MOI of 1. Infection was allowed to proceed for 16 hours at 
which time monolayers were lysed and assessed for expression of luciferase. Data represents 3 
replicates. Error bars represent SEM.	
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Figure 30. Translation of WT and ExoN(-) MHV-FFL viruses is reduced when rgRNA targets 
structured regions and FnCas9 is expressed 
HEK293T cells were mock transfected or transiently transfected with the MHV receptor: CEACAM1, 
FnCas9, and/or rgRNAs targeted to either the hyper-variable region (HVR) of the 3′-UTR, the 
translational regulatory sequence (TRS) of the 5′-UTR, or the -1 ribosomal frame shift at the 
Orf1a/Orf1b junction in the nsp12-RdRp coding region at equal molar concentrations of each plasmid. 
24 hours after transfection cells were infected with WT or ExoN(-) MHV viruses encoding firefly 
luciferase (FFL) at the end of nsp2 at an MOI of 0.1 PFU/cell. Infection was allowed to proceed for 24 
hours at which time monolayers were lysed and assessed for expression of luciferase. Data represents 
three independent experiments, with three replicates. Error bars represent SEM.  
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and so were not washed after virus infections but WT viruses resulted in no detectable virus 
when CEACAM1 was not present in HEK293Ts cells demonstrating that infectious virus was 
not present in the supernatant (Figure 31a). In contrast to the translation data, titers were not 
lower in rgRNAHVR-Oct/FnCas9 or rgRNATRS-SL4/FnCas9 samples (Figure 31a and b). However, 
rgRNAFrame Shift/FnCas9 resulted in decreased titers similar to the decreased in translation (Figure 
31b). Nsp14-ExoN(-) virus titers did not decrease in cells expressing rgRNAHVR-Oct/FnCas9, 
rgRNATRS-SL4/FnCas9, or rgRNAFrame Shift/FnCas9 (Figure 31c and d). However, nsp14-ExoN(-) 
viruses were not assessed for viruses persisting in the supernatant; so, it is possible that the 
measured viruses were those remaining from initial inoculation. Interestingly, FnCas9 did not 
increase WT titers; yet, rgRNAMHV68 E2 did (Figure31a). Finally, although introduction of 
rgRNAHVR-Oct/FnCas9 didn’t result in decreased WT titers, rgRNAHVR-Oct alone did reduce titers. 
RgRNAHVR-Oct reduced WT titers by 50% compared to rgRNA and close to 75% compared to 
rgRNAMHV68 E2 (Figure 31a and c). Importantly, rgRNAFrame Shift/FnCas9 remains a promising 
target to continue studies.  
FnCas9 transfection increases MHV translation in a concentration dependent manner, and 
MHV targeted rgRNAs decrease translation without FnCas9 
The discovery that FnCas9 increases translation was unexpected; therefore, I next sought to 
determine if this was a concentration dependent increase in translation. Serial dilutions of the 
FnCas9 plasmid were performed starting with equimolar concentrations to that of the 
CEACAM1 plasmid. Transfected HEK293T cells were infected with WT-FFL viruses and 
samples were then assessed for expression of FFL in cell lysates and viral titer in supernatants. 
Confirming the data for the single concentration experiment, expression of FFL increased with 
increasing concentration of plasmid, yet titer doesn’t significantly change with increasing 
concentration of FnCas9 plasmid (Figure 32). Next, I sought to determine if rgRNAHVR-Oct alone 
truly resulted in decreased FFL expression and viral titers compared with rgRNA controls 
(Figure 30a and 31a). Therefore, I infected HEK293T cells with WT-FFL after transfected with 
either rgRNAMHV68 E2, rgRNAHVR-Oct, rgRNATRS-SL4 or rgRNAFrame Shift plasmids. Cell lysates 
were collected and FFL expression measured. Expression of FFL decreased by a similar 
proportion to that observed when FnCas9 was present (Figure 30a and 33). This suggests that   
restriction of MHV translation may be dependent solely on the introduction of MHV targeted 
rgRNA constructs. However, in contrast to previous data the no target control resulted in higher 
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Figure 31. Viral propagation of WT MHV-FFL viruses is reduced when rgRNA targets to the 
frame shift and FnCas9 is expressed  
HEK293T cells were mock transfected or transiently transfected with the MHV receptor: CEACAM1, 
FnCas9, and/or rgRNAs targeted to either the hyper-variable region (HVR) of the 3′-UTR, the 
translational regulatory sequence (TRS) of the 5′-UTR, or the -1 ribosomal frame shift (Frame Shift) at 
the Orf1a/Orf1b junction in the nsp12-RdRp coding region at equal molar concentrations of each 
plasmid. 24 hours after transfection cells were infected with WT or ExoN(-) MHV viruses encoding 
firefly luciferase (FFL) at the end of nsp2 at an MOI of 0.1 PFU/cell. Infection was allowed to proceed 
for 24 hours at which time supernatants were collected and tittered by plaque assay. Data represents 
three independent experiments, with three replicates. Error bars represent SEM.  
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Figure 32. WT	 MHV-FFL	 translation	 increases	 with	 increasing	 transfection	 of	 FnCas9	
plasmid,	however	this	does	not	result	in	increased	titer HEK293T	cells	were	transiently	transfected	with	the	MHV	receptor:	CEACAM1	and	FnCas9.	The	FnCas9	 plasmid	 was	 serially	 diluted	 2-fold	 from	 equimolar	 with	 CEACAM.	 24	 hours	 after	transfection	cells	were	infected	with	WT	MHV	viruses	encoding	firefly	luciferase	(FFL)	at	the	end	of	 nsp2	 at	 an	 MOI	 of	 0.1.	 Infection	 was	 allowed	 to	 proceed	 for	 24	 hours	 at	 which	 time	supernatants	 were	 collected	 and	 tittered	 by	 plaque	 assay	 and	 monolayers	 were	 lysed	 and	assessed	 for	 expression	 of	 luciferase.	 Data represents 3 independent experiments, with three 
replicates. Error bars represent SEM.		
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Figure 33. WT MHV-FFL translation is inhibited by rgRNAs targeted to structured regions of 
the genome even in the absence of FnCas9  
HEK293T cells were mock transfected or transiently transfected with the MHV receptor: CEACAM1 
and rgRNAs targeted to the HVR, TRS or the frame shift at equal molar concentrations of each 
plasmid. 24 hours after transfection cells were infected with WT MHV viruses encoding firefly 
luciferase (FFL) at the end of nsp2 at an MOI of 0.1 PFU/cell. Infection was allowed to proceed for 24 
hours at which time monolayers were lysed and assessed for expression of luciferase. Data represents 
three replicates. Error bars represent SEM. 
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expression of FFL than rgRNAMHV68 E2. Additionally, this experiment is only preliminary, and it 
is therefore uncertain whether inhibition of translation results in inhibition of viral replication.  
Changes to WT MHV translation resulting from the presence of rgRNAs and FnCas9 in 
DBT cells are similar to those in HEK293T cells 
Having identified an unexpected increase in WT MHV translation when HEK293T cells 
transfected with FnCas9 or the control rgRNA, rgRNAMHV68 E2, were infected with MHV, I next 
wanted to determine if this outcome was cell type dependent. I attempted the same translation 
experiment described previously for HEK293T cells in DBT cells. In DBT cells transfected with 
rgRNAHVR-Oct/FnCas9, rgRNATRS-SL4/FnCas9, and rgRNAFrame Shift/FnCas9 WT translation 
decreased, resulting in decreased FFL expression (Figure 34). Similar to data in HEK293Ts, 
rgRNAHVR-Oct/FnCas9 or rgRNATRS-SL4/FnCas9 resulted in a 60 and 54% decrease in FFL 
expression, respectively, when compared to rgRNAMHV68 E2/FnCas9. However, in contrast to the 
97% decrease in translation observed in infections performed in HEK293T cells transfected with 
rgRNAFrame Shift/FnCas9, in DBT cells rgRNAFrame Shift/FnCas9 resulted in a 21% decrease in WT 
MHV translation (Figure 34b). Additionally, in DBT cells, there was no apparent effect on 
translation conferred by rgRNAHVR-Oct, rgRNATRS-SL4 or rgRNAFrame Shift when compared to no 
rgRNA. Finally, an increase in FFL expression was observed in DBT cells transfected with 
rgRNAMHV68 E2, with or without FnCas9, similar to what was observed in HEK293T cells (Figure 
34a). Together, these data demonstrate that rgRNAMHV68 E2 enhances CoV translation and suggest 
that rgRNAs targeted to CoV genomes result in restriction of translation when in the presence of 
FnCas9. However, translation was increased in all cases where an rgRNA and FnCas9 were 
transfected in cells together over that of no rgRNA. These results are preliminary and require 
repeating.  
I next sought to determine if differences between nsp12-RdRp variant viruses could be measured 
using transiently transfected FnCas9 and rgRNAs. Therefore, I next tested for changes in FFL 
expression between WT MHV and an MHV virus with two mutations in the nsp12-RdRp. Erica 
Andres, a research assistant in the Denison lab, identified two mutations during passage in the 
presence of GS5734, an uncharacterized nucleoside analog from Gilead Sciences, which resulted 
in a dramatically less sensitive virus:  nsp12-V553L and nsp12-F476L. A variant virus 
containing these two mutations and the FFL protein at the beginning of nsp2 was engineered and 
	 88	
 
 
Figure 34. Translation	 in	 DBT	 cells	 and	 comparison	 between	WT	 and	 an	 nsp12-RdRp-
double	mutant  DBT-9	 cells	 were	 mock	 transfected	 or	 transiently	 transfected	 with	 FnCas9,	 and/or	 rgRNAs	targeted	 to	 either	 a	 control	 rgRNA,	 the	 hypervariable	 region	 (HVR)	 of	 the	 3′-UTR,	 the	translational	 regulatory	 sequence	 (TRS)	 of	 the	 5′-UTR,	 or	 the	 -1	 ribosomal	 frame	 shift	 at	 the	Orf1a/Orf1b	 junction	 in	 the	 nsp12-RdRp	 coding	 region	 at	 equal	molar	 concentrations	 of	 each	plasmid.	24	hours	after	transfection	cells	were	infected	with	WT	or	nsp12-RdRp-double	mutant	MHV	viruses	encoding	firefly	luciferase	(FFL)	at	the	end	of	nsp2	at	an	MOI	of	0.1.	Infection	was	allowed	 to	 proceed	 for	 24	 hours	 at	 which	 time	 monolayers	 were	 lysed	 and	 assessed	 for	expression	of	luciferase.	Data represent three replicates. Error bars represent SEM.		
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recovered (nsp12-double-FFL). It is likely that this virus is altered in fidelity, although this has 
not yet been determined. DBT cells transfected with rgRNAMHV68 E2/FnCas9, rgRNAHVR-
Oct/FnCas9, rgRNATRS-SL4/FnCas9, or rgRNAFrame Shift/FnCas9 were infected with WT-FFL or 
nsp12-double-FFL viruses. When compared to WT,  the nsp12-double-FFL virus resulted in less 
inhibition of translation in cells expressing rgRNAHVR-Oct/FnCas9, rgRNATRS-SL4/FnCas9, or 
rgRNAFrame Shift/FnCas9 (Figure 34c). There was no difference in FFL expression between WT 
and nsp12-double-FFL viruses in cells transfected with rgRNAMHV68 E2/FnCas9 (data not shown). 
In total these data support the feasibility of an rgRNA/FnCas9-based system to investigate 
changes in fidelity.  
Generation of a dual expression plasmid for stable expression of FnCas9 and rgRNAs in 
cell lines 
Having demonstrated that FnCas9 targeted to the MHV genome by rgRNAs results in decreased 
translation and that rgRNAFrame Shift/FnCas9 results in decreased viral titers, I moved forward 
with development of a fidelity assay using the rgRNA/FnCas9 system. In order to measure small 
changes in fidelity FnCas9 and rgRNAs will need to be present in every cell available for 
infection. Therefore, I next sought to generate a stable cell line expressing both rgRNA and 
FnCas9 constructs. As screening with CRISPR/Cas9 is common, plasmids are commercially 
available for dual expression. However, targeting of RNA with Cas9 was only recently 
discovered, thus reagents are limited. In order to generate stable cell lines with rgRNA/FnCas9, I 
started with a plasmid for lentiviral transduction of CRISPR/Cas9 (Sanjana et al., 2014). I 
replaced the Cas9 present in the original plasmid (and removed the nuclear localization signal) 
with the FnCas9 from the transient transfection plasmid described, including the flexible linker 
and HA tag (Price et al., 2015). Similarly, I need to replace the DNA-targeting chimeric RNA 
tail present in the commercially available dual expression plasmid with the rgRNA tail from the 
pU6rgRNA plasmid used for transient transfection (Figure 35). CoV genome targets will be 
rapidly introduced using annealed primers with over hanging ends that match those of the vector 
after digestion with BsmBI. The plasmid includes a puromycin resistance gene that will be 
expressed as one protein with FnCas9 separated by P2A, a self-cleaving peptide (Sanjana et al., 
2014). Stable cell lines will be selected for resistance to puromycin.  
 DBT cells will be used for the generation of cell lines expression rgRNA/FnCas9 as they are 
naturally permissive for MHV. Therefore, I next sought to determine the lethal dose of 
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Figure 35. Plasmid for the generation of stable cell lines  Plasmid	 to	 be	 used	 for	 the	 generation	 of	 stable	 cell	 lines	 containing	 FnCas9	 with	 an	 HA	 tag	adjacent	 to	 the	 self-cleaving	 peptide	 P2A,	 adjacent	 to	 the	 puromycin	 resistance	 gene.	Additionally,	 the	 rgRNA	 tail	 is	 adjacent	 to	 a	 BsmBI	 cut	 site	 where	 targeting	 primers	 with	matching	overhangs	can	be	inserted	after	digestion	to	generate	full-length	rgRNAs.	
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puromycin for DBT cells. In duplicate, DBT cells were grown in 0, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 
or 9ug/mL puromycin for 7 days. Media containing puromycin was replaced every second day. 
On the 7th day media without puromycin was provided and cells were allowed to replicate for 
two more days. Toxicity resulting from the presence of puromycin was observed on day one post 
treatment at concentrations as low as 1ug/mL. On day seven, cell numbers were reduced at all 
concentrations, and 1ug/mL was the lowest concentration that appeared to have no viable cells 
present. To confirm that all cells were non-viable at 1ug/mL cells were observed at day 9. At 
1ug/mL no viable cells were present, whereas in the wells previously treated with 0.25 or 
0.5ug/mL puromycin cells had begun to re-populate. These data suggest that 1ug/mL puromycin 
is an appropriate concentration for selection of cell transduced with the FnLentirgRNAv2 
plasmid once generated.  
Discussion  
CoVs provide a unique RNA virus system to investigate fidelity because they encode a multi-
protein replication-transcription complex (RTC) where many of the involved proteins may 
influence fidelity. Among RNA viruses, only the large Nidoviruses are known to encode a 
proofreading enzyme. Understanding the relationship between the proteins of the RTC, and 
identifying fidelity determinants throughout it, may provide future targets for attenuation of 
current and future HCoVs. To date, rapid and reliable measures of fidelity are not available for 
CoV systems. Some assays used for other viruses may not work because of the size of CoV 
genomes and potential differential evolution across the large genome (this may be the case for 
TOPO cloning). Others may not work well for any virus system, such as sensitivity to nucleoside 
analogs for RdRp variant viruses. Finally, in the case of the GUA-HCl sensitivity assay used for 
picornaviruses, CoVs may simply not share any proteins similar enough for inhibition to occur. 
In this chapter, I present work towards the development of a potential assay for the assessment of 
CoV fidelity. I demonstrate that CoV replication can be restricted by rgRNA/FnCas9 targeted to 
structured regions of the genome and that small difference in the magnitude of restriction may be 
observable between nsp12 variant viruses. However, much of this data is preliminary and will 
need to be further investigated.  
The results of the combined CEACAM1/rgRNAFrameshift/FnCas9 transient transfection 
experiments in HEK293T cells result in reduced translation and titers, suggesting feasibility for a 
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plaque reduction assays in stably expression cells (Figures 30 and 31). However, a few 
unexpected results occurred with experimental controls. One such result was the observation that 
both translation and viral propagation increased when cells were transfected with rgRNAMHV68 
E2. One way this result might occur is if the viral target matched that of RNA native to the cell. 
Increased translation was observed in both HEK293T and DBT cells. It would be interesting to 
determine if either or both cell types contain an RNA sequence with high similarity to the viral 
target DNA. Another way increased CoV translation could occur is if nonspecific rgRNAs 
somehow divert the cellular immune response toward the rgRNAs and away from CoV 
replication. More experimentation is needed to address this finding. Similarly, transfection of 
FnCas9 resulted in increased translation in HEK293T cells in a plasmid concentration-dependent 
fashion. However, in this case increased translation didn’t correlate with increased titers. The 
introduced FnCas9 does not include a nuclear localization signal, so it is unlikely that it is 
targeting cellular DNA. It is possible that FnCas9 is able to bind to cellular RNA or proteins 
(Walsh et al., 2013). Transcription of MHV viral genomes and translation are mutually exclusive 
processes (Andino et al., 1999). So, one could imagine that FnCas9 may stabilize translational 
complexes, thus preventing transcription and decreasing titers. However, how binding a cellular 
RNA or protein would result in increased translation of viral genomes without altering titers is 
more difficult to explain. It would be interesting to pursue what effects FnCas9 has on cells when 
introduced in the absence of rgRNAs with or without virus and if any cellular protein or RNA 
could be pulled down.  
The surprising results of transfection controls observed should be considered when moving 
forward with the development of an FnCas9/rgRNA based assay for the assessment of fidelity in 
CoV systems. However, the data supporting CoV-specific inhibition is promising. Further study 
is warranted to determine if escape occurs similarly to HCV, by changing individual nucleotides 
at the 3′ end of the viral target. Additionally, stable cells lines need to be developed and assessed 
for stable expression of constructs and quantitative plaque reduction between cells containing 
FnCas9/rgRNA targeted to CoVs or a non-CoV target. Even in the event that restriction is not 
complete with this method, if viruses with intact targets result in small plaques, it will still be 
possible to quantify escape mutations. If successful, a fidelity assay based on FnCas9/rgRNA 
targeting of CoV genomes will be particularly beneficial as it could be edited to target any RNA 
virus, thus potentially providing a mechanism to compare changes in fidelity across viruses. 
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Additionally, if the mechanism of escape is consistent across viruses (specifically between HCV 
and CoVs) then it will provide a mechanism to quantitatively determine fidelity for specific 
natural nucleotides during viral replication (Price et al., 2015). CoVs provide a unique system to 
study the influence of altered fidelity on viral biology, yet established methods for investigating 
viral fidelity have not been effective. This FnCas9/rgRNA assay may provide the opportunity to 
effectively probe into CoV determinants of fidelity across the proteins of the RTC. 
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CHAPTER V  
 
MATERIALS AND METHODS 
 
Virus and cell culture 
Murine delayed brain tumor (DBT) cells (Chen and Baric, 1996), baby hamster kidney 21 cells 
expressing the murine hepatitis virus (MHV) receptor (BHK-R) (Yount et al., 2002) and HEK-
293T cells were maintained at 37°C in Dulbecco’s modified Eagle medium (DMEM; Gibco) 
supplemented with 10% FBS (Invitrogen), penicillin, streptomycin (Gibco) and amphotericin B 
(Corning). BHK-R cells were further supplemented with 0.8mg/mL of G418 (Mediatech). All 
virus work was performed using recombinant WT-MHV strain MHV-A59 (GenBank accession 
number AY910861 (Yount et al., 2002)).  
Sequence analysis and homology modeling of CoV MHV nsp12-RdRp and nsp14 
The MHV RdRp domain structure was generated using Phyre2 online program (Kelley et al., 
2015) using nsp12 residues 385-887 that correspond to the reported SARS-CoV nsp12-RdRp 
model (Xu et al., 2003). Briefly, the Phyre2 online available bioinformatics software uses 
multiple alignments to identify publicly available solved structural domains similar to . First 
secondary structures are identified (alpha helices and beta sheets). These are then used to create a 
likely structural backbone, next loops are added based off loop structures available and finally, 
side chains are incorporated into the modeled structure. The structural model was compared to 
the X-ray crystal structures of coxsackievirus B3 (CVB3) and poliovirus (PDB accession 
numbers 3DDK and 1RA7 respectively) using the Pymol Molecular Graphics System 
(Schrödinger, LLC). The MHV nsp14 structure was also generated using Phyre2; the whole 
sequence was used. ClustalX multiple-sequence alignments were generated using the program 
MacVector.  
Cloning, recovery and verification of mutant viruses 
Quick-change mutagenesis was used to generate point mutations in individual MHV genome 
cDNA fragment plasmids using the previously described MHV infectious clone reverse genetics 
system (Yount et al., 2002). Mutant viruses were recovered in co-cultured BHK-R and DBT 
cells (or in BHK-R cells alone) following electroporation of in vitro transcribed genome RNA in 
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BHK-R cells. All viruses that included nsp14-ExoN(-) mutations were generated using the F 
fragment previously described (Eckerle et al., 2007). Before use in viral recovery all 
mutagenized plasmids were fully sequenced (GenHunter Corporation, Nashville, TN) to assure 
no additional mutations were introduced. We also sequence verified engineered mutations in 
recovered viruses. Viruses in the nsp14-ExoN(-) background took between 84 and 96 hours to 
reach around 80 percent involvement in syncytia for a P0 stock in contrast to viruses in the WT 
background, which were frozen at 24-48 h.p.i P1 working stocks were made by infecting D9s at 
an MOI 0.01 and freezing when 80 percent involved in syncytia, approximately 24 h p.i for WT 
viruses and 36 h p.i for nsp14-ExoN(-) viruses (2-3 rounds of replication).  
Compounds and drug sensitivity studies 
5-fluorouracil (5-FU), 5-azacytidine (5-AZC) and Ribavirin were obtained from Sigma. 5-FU 
and ribavirin were prepared as 200mM stock solution in DMSO. 5-azacytidine (5-AZC) was 
prepared as a 50mM stocks solution in water. 2′-C-MeA was a kind gift from Gilead Sciences 
and was prepared as 20mM stocks in DMSO. Sub-confluent DBT cells were pre-treated for 
30min with DMEM with the indicated concentrations of 5-FU, ribavirin, 2′-C-MeA or DMSO, 5-
AZC or media alone. Treatment was removed, and inocula added and allowed to adsorb for 1hr 
at 37°C. Inocula was then removed and media with or without drug or DMSO was returned. 
Infection proceeded for 24hrs for WT or 32hrs for nsp14-ExoN(-) viruses, when supernatants 
were acquired, frozen and titered by plaque assay as previously described (Eckerle et al., 2007).  
Virus replication and RNA synthesis assays 
Sub-confluent DBT cell monolayers in triplicate were infected at an MOI of 0.01 PFU/cell. Virus 
was allowed to adsorb for 30min when inocula were removed and the cells were washed 2X with 
PBS, followed by addition of pre-warmed media. For replication kinetics assays samples were 
taken at various time points post infection and an equal volume of media replaced. For 
replication kinetics in the presence of 5-FU, 5-FU was added 30min prior to time zero and media 
containing 100 or 200uM 5-FU was restored after PBS washes. Titering was performed by 
plaque assay as previously described (Eckerle et al., 2007). For analysis of RNA synthesis, total 
infected-cell RNA was obtained by extraction using TRIzol reagent (Invitrogen) at various times 
post infection and two-step RT-qPCR was performed as previously described (Smith et al., 
2015).  
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Determination of specific infectivity 
Sub-confluent DBT cells were pre-treated for 30min with DMEM with indicated concentrations 
of 5-FU or DMSO alone. Treatment was removed, and inocula added and allowed to adsorb for 
1hr at 37°C. Inocula was then removed and media with drug or DMSO was returned. Infection 
proceeded for 20hrs for WT or 24hrs for nsp14-ExoN(-) viruses then supernatants were acquired, 
frozen and titered by plaque assay as previously described (Eckerle et al., 2007). Supernatants 
were also used for RNA genome isolation by adding 100uL supernatant to 900uL TRIzol reagent 
(Invitrogen), chloroform extracting by phase separation and using the aqueous layer in the 
PureLink Mini RNA kit (Ambion) as per the manufacturers protocol. One-step RT-qPCR was 
performed as below and the ratio of PFU to genomes of the supernatant was determined.  
One-step RT-qPCR for determining supernatant genome copies for specific infectivity 
assay 
An RNA standard was generated using MHV A fragment (Yount et al., 2002) to generate a 931 
nucleotide RNA. First cDNA was generated by PCR using the primers: forward 5′-
TAATACGACTCACTATAGGGGGCTATGTGGATTGTTGTGG-3′ which begins with a T7 
promoter and reverse 5′-AATTCTTGACAAGCTCAGGC-3′. RNA for the standard curve was 
then generated using mMessage mMachine T7 kit (Ambion). An agarose gel with 1% bleach was 
run and a ~900nt band was observed. RNA was purified using RNeasy Mini kit (Qiagen). 
Dilutions of the standard curve were made from 103 to 108 genome equivalents for use in assay 
as needed. Primers and probes for one-step RT-qPCR were purchased from BioSearch Tech. 
Probe is 5′-FAM labeled and 3′ BHQ-1 labeled with the sequence 5′-
TTCTGACAACGGCTACACCCAACG-3′ and made up to 5uM in nuclease free water. The 
primers used were forward 5′-AGAAGGTTACTGGCAACTG-3′ and reverse 5′-
TGTCCACGGCTAAATCAAAC-3′. Reactions were set-up on ice with enzyme added last. Final 
volume for reactions was 20uL with 150nM probe, 900nM each primer, 2uL sample RNA and 
10uL 2X ToughMix, one-step, low ROX enzyme mix (Quantas) used per reaction. Samples were 
plated in duplicate and run on the Applied Biosciences 7500 Real-Time PCR System with the 
conditions 55C for 10min, 95C for 5min, 95C for 30sec and 60C for 1min with the last two steps 
repeated 40X. The standard curve was graphed and genomes per mL determined.  
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Competitive fitness of mutant viruses 
Sub-confluent DBT monolayers were co-infected at a total MOI of 0.01 PFU/mL with RdRp 
mutant viruses in the nsp14-ExoN(-) background and nsp14-ExoN(-) at either a 1:1, 1:9 or 9:1 
ratio. When 50-70% of the monolayer was involved in syncytia, total RNA was harvested. RNA 
was then reverse transcribed using SuperScriptIII (Invitrogen) per the manufactures protocol and 
amplicons were generated using Comp12_F and Comp12_R primers covering the region of 
nsp12 including the codons for both the V553 and M611 residues. Amplicons were sent for 
sequencing with Comp12_F and electropherograms were analyzed using MacVector.  
Passage reversion analysis 
Triplicate monolayers of sub-confluent DBT cells were infected with an initial MOI of 0.01 
PFU/mL of nsp12-V553I and nsp12-M611F viruses in both the WT and nsp14-ExoN(-) 
background. Viruses were then blind passaged in triplicate for 5 passages. Total RNA was 
sequenced across a 1.7kb region of nsp12-RdRp, using Comp12_F and Comp12_R primers, 
which included both nsp12-RdRp mutations. Electropherograms were analyzed using 
MacVector.  
Preparation of amplicons for deep sequencing of full viral genomes 
Sub-confluent DBT cells were infected at an MOI of 0.01 PFU/mL with nsp12-V553I or nsp12-
M611F in either the WT or nsp14-ExoN(-) background, nsp14-ExoN(-) alone or WT alone. 
Infections were allowed to progress for 20 hours then RNA was isolated. RNA was reverse 
transcribed using SuperScriptIII (Invitrogen) per the manufactures protocol, and 12 amplicons 
were generated to cover the whole genome and processed as described previously (Smith et al., 
2015).  
Deep sequencing sample preparation and analysis 
Amplicons were subsequently purified via a nucleospin PCR purification kit (Macherey-Nagel), 
quantified by picogreen, fragmented (Fragmentase) and prepared using the Illumina NextSeq500 
Mid Output 150 cycle kits following the standard protocols. Sequences were obtained with an 
Illumina NextSeq500 machine. Sequencing runs were analyzed using the previously published 
ViVan bioinformatics pipeline (Isakov et al., 2015). Briefly, the pipeline performs quality 
filtering and adaptor cleaning was done using fastq-clipper 
(http://hannonlab.cshl.edu/fastx_toolkit/index.html). The 150-nt reads were aligned to the 
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reference sequence with a maximum 2 mismatches per read, using BWA (Li and Durbin, 2010) 
and processed using SAMTOOLS (Li et al., 2009) to obtain the nucleotide/base calling at each 
position. The ViVan pipeline then identifies statistically significant variants above the 
background noise due to sequencing error, calculated for each nucleotide site: for each position 
throughout the viral genome, base identity and their quality scores are gathered. Each variant 
allele's rate is initially modified according to its covering read qualities based on maximum 
likelihood estimation, and tested for significance using a generalized likelihood-ratio test. 
Additionally, an allele confidence interval is calculated for each allele. In order to correct for 
multiple testing, Benjamini-Hochberg false-discovery rate of 5% was set. In all experiments, a 
minimum coverage of 3000X reads was obtained and the background error frequency at every 
nucleotide site was always below 0.0001. For analysis we use a conservative frequency cut off of 
0.01 consistent with previous studies (Bordería et al., 2015; Pauly and Lauring, 2015; Van Slyke 
et al., 2015).  
Passaging in the presence and absence of 5-FU 
Triplicate monolayers of sub-confluent DBT cells were infected with an initial MOI of 0.01 
PFU/cell with either WT or nsp14-ExoN(-) viruses. Infections were performed in media alone or 
containing sub-lethal concentrations of 5-FU (60uM for nsp14-ExoN(-) and 800uM for WT). 
Populations were then blind passaged in triplicate for 6 additional passages. Total RNA was 
taken from cell monolayers and prepared for Sanger sequencing. Sequencing was performed 
across all of nsp12 and nsp14 as described previously (Smith et al., 2015).  
Mutation frequency by TOPO TA cloning 
Triplicate monolayers of sub-confluent DBT cells were infected with an initial MOI of 0.01 
PFU/mL of nsp12-M611F viruses in both the WT and nsp14-ExoN(-) background and WT and 
nps14-ExoN(-) viruses. Viruses were then blind passaged in triplicate for 5 passages. Total RNA 
was extracted and RT-PCR amplified using the primers sets Freq2_F and Freq2_R covering a 
~1kb part of nsp2. PCR products were TOPO TA-cloned (Invitrogen), sequenced, and analyzed 
using MacVector software. Mutation frequency was calculated as the number of mutations 
identified per virus over the total number of nucleotides sequenced multiplied by 104, as 
described previously (Gnädig et al., 2012).  
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Guanidine hydrochloride sensitivity assay 
Guanidine hydrochloride, GUA-HCl (Sigma) was prepared as a 1M stock solution in water. 
Monolayers of sub-confluent DBT cells were infected with 200PFU of WT or nsp14-ExoN(-) 
viruses. Inocula were allowed to incubate for 45min then plaque assay overlays (prepared as 
previously described (Eckerle et al., 2007)) containing 0, 0.25, 0.5, 1, 1.5 or 2mM GUA HCl 
were placed. Infection was allowed to continue for 24 hours then plates were fixed as previously 
described (Eckerle et al., 2007). Images were captured using a 12-megapixel camera (Apple).  
Transient-transfection followed by infection of HEK293T and DBT cells 
The pcDNA3.3 FnCas9-hu (ampr) and control FnrgRNA (kanr) plasmids used in this dissertation 
research for transfection experiments were acquired as kind gifts from David Weiss’s lab and 
were previously described in (Price et al., 2015). The pcineo-mCEACAM1 plasmid was 
acquired from Brett Case. Finally, the LentiCRISPRv2 plasmid was acquired as a gift from Chris 
Aiken’s lab (Addgene) and is described in (Sanjana et al., 2014). The 20bp control target or the 
FnrgRNA plasmid was replaced using around-the-horn or exponential-megapriming PCR (Ulrich 
et al., 2012). MHVrgRNA_HVROCT8_F, MHVrgRNA_TRS_F, or MHVrgRNA_Frameshift_F 
and MHVrgRNA_R primers were treated with T4 PNK (NEB), using T4 DNA ligase buffer. 
PCR was set up with Q5 Hot Start High-Fidelity 2X Master Mix (NEB) was run with the 
conditions 98°C for 30sec, 98°C for 10sec, 57°C for 30sec and 72°C for 2min with the last three 
steps repeated 30X then 72°C for 2min and hold at 4°C. PCR product was treated with 1uL DpnI 
(NEB) to digest template, followed by ligation with T4 ligase (NEB) as per manufacturers 
protocol. Plasmids were sequenced using U6_F primer.  
HEK293T or DBT cells were plated at 1X104 cells per well of 96-well plates. 24hrs after plating 
transfected cells using FuGene 6 Transfection Reagent (Promega). A 4:1 FuGene to DNA ratio 
was used and an equimolar ratio of plasmids was transfected resulting in a total of 150ng total 
DNA/well in samples with all three plasmids (mCEACAM1, FnCas9 and an rgRNA). Plasmids 
were prepared in OptiMEM (Gibco) and allowed to sit for 5min after reagents were mixed before 
adding 5uL/well. Transfected cells were incubated for an additional 24 hours. Half the media 
was removed (50uL) so as not to disrupt the cell monolayer. Cells were then infected with 50uL 
WT, nsp14-ExoN(-) or nsp12-double viruses at an MOI of 0.1. After a final 24-hours 
supernatants were removed and titered by plaque assay as described previously (Eckerle et al., 
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2007), and cells were lysed with 80uL/well of PBS+/+ (Gibco) containing 0.5% Triton-X100 
(INC Biomedicals Inc.) while rocking for 30 min. 40uL lysate was transferred to opaque plates 
and assayed using 40uL luciferase assay reagent (Promega) on a Veritas microplate luminometer 
as described previously (Freeman et al., 2014).  
Puromycin treatment of DBT cells 
Puromycin (Sigma) was prepared as a 20ug/uL stock solution in water. Duplicate monolayers of 
sub-confluent DBT cells were grown in DMEM (Gibco) alone or containing 50-1000ug/mL 
puromycin (changed every other day) for seven days. After seven days cells were bathed in 
media alone for two days.  
Plasmid cloning for the generation of stable cell lines 
LentiCRISPRv2 plasmid was digested with XbaI and BamHI to remove SpCas9. The FnCas9, 
flexible liner and HA tag from the pcDNA3.3 FnCas9-hu (ampr) plasmid were amplified using 
the primers: FnCas9InsXbaI_F and FnCas9InsBamHI_R. 7.5nmol cut vector and 20nmol insert 
were incubated with Gibson Assembly Master Mix (Gibson) at 50C for 1 hour. Resulting 
plasmid was sequenced using primers LntCRSPRCasSeq_F and LntCRSPRCasSeq_R. Plasmid 
was amplified in chemically competent Stbl3 E. Coli (Invitrogen).  
Statistical analysis 
Statistics were applied as described in figure legends using GraphPad Prism 6 software (La Jolla, 
CA). The number of replicates performed for each experiment is similarly listed in each 
respective figure legend. Finally, some of the data was normalized to controls; GraphPad Prism 6 
software also performed this analysis. Ratio paired t-tests were used to determine if mutant 
viruses treated with paired groups of increasing concentrations of mutagens differed from each 
other, unless values were included in the data set where no virus was observed at which point 
Wilcoxon tests were applied. Two-way ANOVA was used to determine if 5-FU concentration or 
mutant virus used in specific infectivity assays resulted in differences between the condition 
applied and WT viruses without 5-FU. Bonferroni method of correcting for multiple 
comparisons was used to compare the set of 5-FU-treated WT viruses with the sets of mutant 5-
FU-treated viruses. The Mann-Whitney test was applied to TOPO cloned amplicons to determine 
if differences existed between the mean mutations accumulated for the unpaired viruses tested, 
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which were larger than expected by random sampling. SEM was used to indicated the probability 
that the mean of the data presented is representative of the true mean for all data with 
representative error bars.  
Primers generated for this dissertation research 
Table 4: Primers generated for this dissertation research (IDT) 
Primer Name Sequence 5′-3′ 
Quick-change primers for generation of homology mutant viruses 
V553Afor GGGCCCGCACCGCTGCTGGTGTCTC 
V553Arev GAGACACCAGCAGCGGTGCGGGCCC 
V553Ifor TAGGGCCCGCACCATTGCTGGTGTCTC 
V553Irev GAGACACCAGCAATGGTGCGGGCCCTA 
M611Ffor ATGTTGATAGTCCTGTACTCTTCGGTTGGGACTATCCTAAATG 
M611Frev CATTTAGGATAGTCCCAACCGAAGAGTACAGGACTATCAACAT 
W613Yfor GATAGTCCTGTACTCATGGGTTATGACTATCCTAAATGTGATCGT 
W613Yrev ACGATCACATTTAGGATAGTCATAACCCATGAGTACAGGACTATC 
A621Gfor ATCCTAAATGTGATCGTGGTATGCCAAACATACTGCG 
A621Grev CGCAGTATGTTTGGCATACCACGATCACATTTAGGAT 
K794Rfor GTGTTTATGTCTGAGGCCAGATGTTGGGTAGAAACAGAC 
Y649Hfor CGCATACGGATAGATTCCATCGTCTTGCGAACGAG 
Y649Wfor TGCTGTTCGCATACGGATAGATTCTGGCGTCTTGCGAACG 
Y649Wrev CGTTCGCAAGACGCCAGAATCTATCCGTATGCGAACAGCA 
Y649Hrev CTCGTTCGCAAGACGATGGAATCTATCCGTATGCG 
K794Rrev GTCTGTTTCTACCCAACATCTGGCCTCAGACATAAACAC 
    
Quick-change primers for generation of minority variant mutant viruses 
L364Ffor ACACATCGTTATCGCTTGTCTTTTAAGGACTTGCTTTTGTATG 
L364Frev CATACAAAAGCAAGTCCTTAAAAGACAAGCGATAACGATGTGT 
P374Sfor CTTTTGTATGCTGCAGACAGTGCCCTTCATGTGGCGTC 
P374Srev GACGCCACATGAAGGGCACTGTCTGCAGCATACAAAAG 
E519Gfor GAGGCATTATCATTTGAGGGGCAGGATGAAATTTATGCG 
E519Grev CGCATAAATTTCATCCTGCCCCTCAAATGATAATGCCTC 
E519Nfor CTATTATGAGGCATTATCATTTGAGAATCAGGATGAAATTTATGCGTATACCA 
E519Nrev TGGTATACGCATAAATTTCATCCTGATTCTCAAATGATAATGCCTCATAATAG 
Q520Lfor AGGCATTATCATTTGAGGAGCTGGATGAAATTTATGCGTATAC 
Q520Lrev GTATACGCATAAATTTCATCCAGCTCCTCAAATGATAATGCCT 
S900Cfor ATCAGATCCTGGACAGCTACTGTGTTATTTTAAGTACTTGTG 
S900Crev CACAAGTACTTAAAATAACACAGTAGCTGTCCAGGATCTGAT 
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Quick-change primers for generation of drug passage mutant viruses 
XSP180HF ATTAATGTGTATAAAAAGCTTGGTCACATATTTAATAGAGCCCTGCTTAAC 
XSP180HR GTTAAGCAGGGCTCTATTAAATATGTGACCAAGCTTTTTATACACATTAAT 
XSA193SF CCTGCTTAACACTGCCAAGTTTTGTGACGCATTAGT 
XSA193SR ACTAATGCGTCACAAAACTTGGCAGTGTTAAGCAGG 
XSV223IF GGTCAATGGTATGACTTTGGAGATTTTATTAAGACAGTACCT 
XSV223IR AGGTACTGTCTTTATAAAATCTCCAAAGTCATACCATTGACC 
A379TF CCTGCCCTTCATGTGACCTCTGCTAGTGCAC 
A379TR GTGCACTAGCAGAGGTCACATGAAGGGCAGG 
N548SF ATATGCTATTAGTGCTAAGAGCAGGGCCCGCACC 
N548SR GGTGCGGGCCCTGCTCTTAGCACTAATAGCATAT 
HT644YAF AAACATGATTCGTGCTGTTCGTACGCCGATAGATTCTATCGTCTTG 
HT644YAF CAAGACGATAGAATCTATCGGCGTACGAACAGCACGAATCATGTTT 
A695TF TGCTAATTCTGTGTTTAACATTTGTCAAACAGTTTCCGCCAATG 
A695TR CATTGGCGGAAACTGTTTGACAAATGTTAAACACAGAATTAGCA 
P735SF TACTCACTAACAAATGCGCTGTCAACATGGTCCGCACG 
P735SR CGTGCGGACCATGTTGACAGCGCATTTGTTAGTGAGTA 
S768FF TGTGTTATAATTCAGAGTTTGCGTTTAAGGGTTATATTGCTAATATAAG 
S768FR CTTATATTAGCAATATAACCCTTAAACGCAAACTCTGAATTATAACACA 
XM814KF TGAATTTTGTTCTCAACATACAAAACTAGTCAAGATGGATGGTG 
XM814KR CACCATCCATCTTGACTAGTTTTGTATGTTGAGAACAAAATTCA 
14A93VF CTTCGATGCAGAAGGTGTGCATGCGATACGTGATA 
14A93VR TATCACGTATCGCATGCACACCTTCTGCATCGAAG 
14A93VXF CTGGGTTGGCTTCGCAGCAGCAGGTGTGCATGCGATACGTG 
14A93VXR CACGTATCGCATGCACACCAGCTGCTGCGAAGCCAACCCAG 
14F216LF CCAAGCGTGCGACATGTCTAAATTCTAGAACTGGATACT 
14F216LR AGTATCCAGTTCTAGAATTTAGACATGTCGCACGCTTGG 
14D175GF CAGACCACCTAGCGGGATTGGCAGACAGTGT 
14D175GR ACACTGTCTGCCAATCCCGCTAGGTGGTCTG 
14P258SF GATCTTTAACTAGCAATCATGATAGTATTTGCAGCGTGCATAAGGGTG 
14P258SR CACCCTTATGCACGCTGCAAATACTATCATGATTGCTAGTTAAAGATC 
    
Primers for competition assay and reversion analysis 
Comp12_F AGGGGAGCTCCGTTGATTTG 
Comp12_R AACTACAGACAACGCAGGCA 
    
TOPO-TA cloning primers 
FREQ2_F ACGCAGTTTGGCTATGTGGA 
FREQ2_R GCCAGCAAGACACACCCTAT 
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FnCas9/rgRNA cloning and sequencing primers 
MHVrgRNA_HVROCT8_F GCTCTTCCCAGGGGGCGCCTCTCGTAATTAATAAACCATGAAAG 
MHVrgRNA_TRS_F GGAAGTGCCGTTTATAAAGTCTCGTAATTAATAAACCATGAAAG 
MHVrgRNA_Frameshift_F GGCACAGGGTACAAGACGGGCTCGTAATTAATAAACCATGAAAG 
MHVrgRNA_R CGGTGTTTCGTCCTTTC 
U6_F CGATACAAGGCTGTTAGAGAG 
FnCas9InsXbaI_F 
GCCAGAACACAGGACCGGTTCTAGAGCGCTGCCACCATGAACTTTAAGATCCT
CCCTATTG 
FnCas9InsBamHI_R GCAGAGAGAAGTTTGTTGCGCCGGATCCCGGCGTAGTCAGGCACATC 
LntCRSPRCasSeq_F GTTCTTTTTCGCAACGGG 
LntCRSPRCasSeq_R CAGAGAGAAGTTTGTTGC 
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CHAPTER VI  
 
SUMMARY AND FUTURE DIRECTIONS 
 
Introduction 
Coronaviruses (CoVs) are the cause of mild to severe disease in humans, as well as economically 
important infections in livestock and pets (Weiss and Navas-Martin, 2005). CoVs have been 
emerging as novel infections in human populations for centuries and the two most recent human 
CoVs (SARS-CoV and MERS-CoV) result in severe disease (Graham et al., 2013). Currently, 
there are no approved treatments or vaccines for any human CoV. Effective treatments are 
available for many other RNA viruses utilizing nucleoside analogs (Crotty et al., 2002; Jacobson 
et al., 2013); however, ribavirin treatment of patients infected with SARS-CoV suggested that 
the virus was at best resistant, and at worst resulted in enhanced pathogenesis in the presence of 
the mutagen (Stockman et al., 2006). CoV resistance to ribavirin may be due to increased fidelity 
as a result of the proofreading activity encoded in the 3′-5′ exoribonuclease found in non-
structural protein 14 (nsp14-ExoN) (Smith et al., 2013). Fidelity of viral replication has evolved 
to assure sufficient mutational diversity is available for positive selection during shifts in 
selective pressures, while concurrently preserving the core sequence essential to virus viability 
and fitness. This is a critically fine balance, since for RNA viruses studied to date, most 
mutations resulting in changes to fidelity are attenuating in vivo (Smith et al., 2014). Finally, 
CoVs encode for a large replication-transcription complex (RTC) (Sevajol et al., 2014; Smith 
and Denison, 2013; Snijder et al., 2016). Thus, CoVs provide a compelling system to investigate 
determinants of replication fidelity and the interactions between them.  
At the start of this dissertation research, the fidelity of CoVs had only been investigated in 
relation to the inactivation of nsp14-ExoN, by substituting residues of the active site motifs 
(nsp14-ExoN(-)) (Bouvet et al., 2012; Chen et al., 2007; Eckerle et al., 2007; 2010). The nsp14-
ExoN(-) mutant viruses demonstrate an average 14-fold decrease in replication fidelity, impaired 
replication, increased sensitivity to RNA mutagens, and attenuation in vivo. In contrast, for all 
other RNA viruses outside of the order Nidovirales, the RNA-dependent RNA polymerase 
(RdRp) is the key enzyme regulating replication fidelity. The overall goal of this dissertation 
research was to test whether determinants in the CoV nonstructural protein 12 (nsp12), including 
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those in the RdRp (nsp12-RdRp), or in nsp14-ExoN outside of the active site regulate overall 
CoV replication fidelity. The main objectives of the research design were to test whether nsp12 
encodes specific determinants of fidelity, whether nsp12 or nsp14-ExoN are capable of 
adaptation for increased fidelity, and how nsp12 interacts with nsp14-ExoN to regulate fidelity. 
In this dissertation research, I investigated three separate methods (homology modeling, analysis 
of mutagen-treated minority variants and selection for consensus mutations after treatment with 
mutagen) for identifying determinants of nucleotide selectivity and fidelity in nsp12, 
emphasizing nsp12-RdRp, and nsp14-ExoN.  
The results from this dissertation research demonstrate complex phenotypic interactions between 
nsp12 and nsp14-ExoN during virus replication, and they support the hypothesis that nsp14-
ExoN is epistatic (defined as one protein masking the phenotypic effect of another) to nsp12-
RdRp with respect to fidelity. Contrarily, any change to nsp12-RdRp resulted in a decrease in 
replication capacity in the WT background, but had a variety of effects in the nsp14-ExoN(-) 
background. This dissertation research also suggests that nsp12-RdRp can be readily selected for 
alterations in nucleotide pools by natural or experimental approaches. This research also 
demonstrates that, both dependent and independent of fidelity changes, fitness defects conferred 
by inactivation of nsp14-ExoN can be partially compensated for by mutations in nsp12-RdRp. 
Finally, I introduce a potential approach for rapidly assessing the fidelity of CoVs. 
CoVs may be capable of selecting for nsp12-RdRps specialized for local nucleotide pools  
Viruses often have specific nucleotide biases (van Hemert et al., 2016). For CoVs there is a 
preference for uracil and against cytosine (Berkhout and van Hemert, 2015). In natural systems it 
is possible that cells respond to viral infections by altering nucleotide pools (Löffler et al., 2016; 
Papadopoulou et al., 2015; Wang et al., 2016). In response, viruses may select for RdRps that 
optimize replication in the new environment. Ultimately, this may lead to altered nucleotide 
compositions and different codon usage by viral genomes (Berkhout and van Hemert, 2015; 
Lauring et al., 2012; van Hemert and Berkhout, 2016; van Hemert et al., 2016). One theme that 
emerged during my dissertation work was that mutations in the CoV nsp12-RdRp result in 
variable selectivity for nucleotide analogs. These data support the hypothesis that viruses are 
capable of selection for RdRps that exclude specific nucleotides while preserving the inclusion 
of others. Interestingly, ribavirin alters nucleotide pools in addition to acting as a mutagen, which 
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could explain why mutations identified by passaging in ribavirin have typically been reported to 
result in increased fidelity, rather than only excluding ribavirin specifically (Coffey et al., 2011; 
Crotty et al., 2000; Graci and Cameron, 2006; Pfeiffer and Kirkegaard, 2003; Zeng et al., 2014). 
However, passaging in the presence of other nucleoside analogs (generally mutagens) may not 
result in increased fidelity for natural nucleotides. This is an important consideration since 
passaging in the presence of mutagens is regularly used when attempting to identify fidelity 
determinants.  
The large Nidoviruses, including CoVs, are unique among (+)RNA viruses in that they encode a 
proofreading enzyme. So far nsp14-ExoN and nsp10 fidelity-altered viruses have demonstrated 
consistent changes in sensitivity to nucleoside analogs (Sexton et al., 2016; Smith et al., 2013; 
2015). This is likely representative of the different mechanisms used by these proteins to regulate 
fidelity. Currently, the structural and biochemical mechanisms of nsp14-ExoN proofreading are 
poorly understood; whereas for nsp12-RdRp, nucleotides must fit properly into the nucleotide 
binding pocket for efficient catalysis (Gong et al., 2009; Kortus et al., 2012; Moustafa et al., 
2011). It is possible that mismatched nucleotides are identified by nsp14-ExoN as larger-scale 
structural aberrations resulting in a less selective nsp14-ExoN compared with nsp12-RdRp. 
However, the deep sequencing results presented in Chapter II and (Smith et al., 2013) suggest 
that nsp14-ExoN may preferentially remove some specific misincorporations over others. In the 
case of nsp10, it functions in fidelity by enhancing the activity of nsp14-ExoN, therefore, it 
would likely alter fidelity in the same manner as nsp14-ExoN (Bouvet et al., 2014; Smith et al., 
2015).  
If CoV nsp12-RdRp, or nsp14-ExoN, can be selected to inhibit incorporation of specific 
nucleotides while retaining baseline fidelity for others, then the identification of fidelity 
determinants requires alternative methods to those typical in the RNA virus replication fidelity 
field. Specifically, passaging in the presence of altered nucleotide pools or multiple mutagens 
may be a more reliable method for the identification of broad fidelity determinants in the future. 
Similarly, testing mutant viruses for sensitivity or resistance to altered nucleotide pools, rather 
than nucleoside analogs, may provide a better screen for fidelity determinants. However, it is 
possible that selectivity for natural nucleotides is also specific for individual nucleotides. It 
would be interesting to determine if residues in nsp12-RdRp or nsp14-ExoN can specifically 
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alter the incorporation of individual natural purine or pyrimidine nucleotides. Questions of 
specific nucleotide preferences could be addressed with new reduced error deep sequencing 
technologies or with the development of a reproducible in vitro system. 
A WT nsp14-ExoN is required for the recovery of many mutant nsp12-RdRp viruses 
For the engineered mutations in nsp12-RdRp, many were recoverable only in the WT-MHV 
background, not the nsp14-ExoN(-) background (Tables 1-3). Additionally, none of the 
recovered viruses with mutations in nsp12-RdRp, in the nsp14-ExoN(-) background, resulted in 
increased sensitivity to any of the mutagens tested: 5-FU, 5-AZC, or ribavirin. It is possible that 
no mutations were identified that result in a decrease in fidelity; however, it is also possible that 
the nsp14-ExoN(-) virus results in decreased fidelity that is at or near the lowest level tolerated 
by the virus. Another result of the inactivation of nsp14-ExoN, beyond a change in replication 
fidelity, is an increase in the lag phase of replication. This lag phase was exacerbated by one of 
the mutations in nsp12, nsp12-Q520L, and also by growth in the presence of 5-FU. Similarly, 
only one mutation in nsp12, nsp12-S900C, resulted in an observed decrease in the accumulation 
of RNA. These data show that viruses are viable when replication is delayed or decreased 
beyond what results from the inactivation of nsp14-ExoN alone. However, the inability to 
recover viruses with mutation in nsp12, in the nsp14-ExoN(-) background, may have resulted 
from larger delays or decreases in RNA synthesis. Once an assay is developed to rapidly and 
quantitatively investigate changes in fidelity in the WT background it will be interesting to go 
back to the mutant viruses recovered in this dissertation research and determine whether they 
result in any changes to overall fidelity. 
Nsp12 and nsp14 have epistatic relationships 
Comparing the results of nsp12 mutations in the nsp14-WT and nsp14-ExoN(-) background 
revealed that specific phenotypes are masked depending on the presence or absence of nsp14-
ExoN activity. Proofreading by nsp14-ExoN seems to be epistatic to nucleotide selectivity by 
nsp12-RdRp (Sexton et al., 2016). When one considers that the fold-change in fidelity resulting 
from the inactivation of nsp14-ExoN is 14, yet RdRp mutations are rarely recoverable outside of 
a 5-fold change in fidelity, it is not entirely surprising that nsp14-ExoN proofreading might be 
epistatic to nsp12-RdRp fidelity (Eckerle et al., 2007; 2010; Graham et al., 2012; Sexton et al., 
2016; Smith et al., 2013; 2014). What was more surprising to observe was that in many cases 
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increased lag phases and decreased titers resulting from mutations introduced in nsp12 were only 
observable in the WT nsp14 background. Viruses with variant nsp12-RdRps in the nsp14-
ExoN(-) background generally replicated with identical kinetics to that of nsp14-ExoN(-) alone. 
While there are many possible explanations these results, I favor the hypothesis, that because 
nsp14-ExoN(-) viruses still encode the complete nsp14, albeit with a double alanine substitution 
in the active site, nsp14-ExoN is still able to recognize and attempt removal of incorrect 
nucleotides. If this is the case, then the RTC may be stalling every time an incorrect nucleotide in 
inserted and this stall may be more pronounced than any delay resulting from changes in the 
nsp12-RdRp. It would be interesting to determine if the fidelity and replication defects resulting 
from the inactivation of nsp14-ExoN can be separated. A knockout of nsp14 has been previously 
attempted but the virus was non-recoverable (unpublished). Nsp14 also encodes for an N7-
methyltransferase domain (N7-MT) (Chen et al., 2009). Additionally, the crystal structure of 
SARS-CoV nsp14 was solved and demonstrated that there is extensive interaction between 
nsp14-ExoN and nsp14-N7-MT (Ma et al., 2015). Thus, it would be difficult to remove nsp14-
ExoN without disrupting nsp14-N7-MT. In all passaging experiments to date nsp14-ExoN(-) 
viruses have not reverted (Graham et al., 2012; Sexton et al., 2016). Therefore, if nsp14-ExoN(-) 
is delaying replication by attempting to remove misincorporated nucleotides, then passaging 
nsp14-ExoN(-) viruses could result in the identification of mutations that alter or eliminate 
interactions between nsp12 and nsp14. During 5-FU virus passage, one set of mutations arose in 
the nsp12-CoV-specific domain that didn’t result in an increase in resistance to 5-FU but did 
increase virus titers. It is possible that this mutant virus, nsp12-PH-AS-VI, reduces the 
interaction between nsp12 and nsp14. Whether or not this is the case, identifying and weakening 
the site of interaction between nsp12 and nsp14 should be further pursued in order to fully 
understand the contributions and mechanisms of action of nsp14-ExoN proofreading in the 
context of viral infection. Finally, separating out the replication defect and the fidelity defect 
caused by nsp14-ExoN(-) could facilitate the investigation of other CoV proteins involved in 
fidelity. 
Multiple replicase proteins regulate CoV replication fidelity 
CoVs encode multiple proteins that together assemble in the replication-transcription complex 
(RTC). (Smith et al., 2014). At the start of this dissertation research, only nsp14-ExoN had been 
shown to regulate CoV fidelity during replication (Eckerle et al., 2007; 2010). In addition, nsp10 
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is now known to regulate fidelity through enhancement of nsp14-ExoN (Bouvet et al., 2012; 
Smith et al., 2015). In this dissertation research, I focused on the contributions of nsp12 and 
nsp14, emphasizing the nsp12-RdRp and nsp14-ExoN domains. The results presented suggest 
that mutations distant from the nsp12-RdRp active site and nucleotide-binding pocket may alter 
CoV replication fidelity. There are three main mechanisms with which mutations in the nsp12-
RdRp domain are likely to alter fidelity. The first is by altering the nucleotide-binding pocket. 
This could occur through mutations found directly in the pocket or by altering the overall 
structure on nsp12 in a way that also altered the pocket. A second way that mutations in nsp12-
RdRp could alter the mutation rate of the polymerase would be by altering the speed of catalysis. 
Evidence in picornaviruses suggest that when catalysis occurs more rapidly incorrect nucleotides 
are incorporated at a higher rate (Campagnola et al., 2015). The final mechanism for altering 
fidelity via mutations in nsp12-RdRp would be through interactions with other proteins of the 
RTC. For instance, biochemical data suggests that nsp7 and nsp8 act together as an essential 
processivity factor, which directly interacts with nsp12. It is conceivable that changes to 
processivity could alter viral fidelity and that altering the direct interaction between nsp8 and 
nsp12 could result in increased or decreased viral fidelity. Additionally, mutations that enhance 
or relax interactions with nsp14 could result in changes in fidelity. Modulation of fidelity could 
also occur through mutation in nsp12 that prevent nsp14-ExoN from accessing mispaired 
nucleotides. One way in which this could occur would be if nucleotide excision by the nsp14-
ExoN were occurring upon nsp12-RdRp backtracking after incorrect nucleotide addition similar 
to DNA replication (Dulin et al., 2015; Ren, 2016). If this is the case then mutations in nsp12-
RdRp that result in an inability to backtrack would result in decrease fidelity. Similarly, 
mutations in proteins that contact nsp14 may influence the overall fidelity of CoVs. Future 
research into which proteins are involved in regulating CoV fidelity is warranted. In most cases 
any change to fidelity for RNA viruses has resulted in attenuation where tested (Smith et al., 
2014). Similarly, when mice are infected with mouse-adapted SARS-CoV nsp14-ExoN(-) 
viruses, they survive and are protected from further challenge with WT SARS-CoV (Graham et 
al., 2012). Future research should determine if any of the nsp12 or nsp14 mutations identified in 
these studies result in attenuation. Similarly, it would be interesting to determine if fidelity 
changes in other proteins result in attenuation. Finally, it would be interesting to determine if 
CoV fidelity is set or if specific cellular conditions result in CoV driven increases or decreases in 
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fidelity. If instead only nsp12 and nsp14 are involved in fidelity, it will still be beneficial to 
understand the interface between proteins of the RTC. This knowledge could inform the 
development of small molecules that interfere with the assembly of CoV RTC, thus leading to 
novel drugs against CoVs.  
MHV replication is inhibited by targeted rgRNAs and FnCas9 
An assay to assess changes in CoV fidelity by absolute selection is needed. In this dissertation 
research, several methods were attempted to assess changes in mutation frequencies for CoVs. 
Overall, these data illustrate that replication by CoVs differs from that of other RNA viruses. 
Additionally, these data emphasize the need for a broadly applicable assay that functions to 
assess changes in fidelity in a wide range of RNA viruses. A broadly applicable assay will 
improve the overall understanding of the role of fidelity in RNA virus replication and evolution 
by facilitating comparisons between viruses; current methods are difficult to compare (Sanjuán et 
al., 2010). A novel approach was introduced in Chapter IV utilizing RNA targeted rgRNAs and 
FnCas9. There is much work left to determine if this approach will result in an effective, 
quantitative fidelity assay. However, so far, I was able to show that CoVs are inhibited through 
the introduction of an rgRNA targeted to the frame shift between Orf1a and Orf1b in the 
presence of FnCas9. Beyond a fidelity assay it is possible that these data could lead to a novel 
therapeutic for CoV infections. Since, RNA targeted FnCas9 is likely acting in a manor similar 
to siRNA (Sampson et al., 2013), which were recently shown to be effective treatments against 
Ebola when delivered to rhesus monkeys (Thi et al., 2015). Data presented in this dissertation 
suggest CoV targeted rgRNAs alone inhibit CoV replication. If these data are reproducible then 
development of a treatment using CoV targeted rgRNA may be more readily achievable. There is 
still concern that the introduction of Cas9 protein into cells in vivo could result in non-specific 
cleavage of DNA, and the same could be true for targeting non-specific RNAs in the system 
under development in this work (Abudayyeh et al., 2016). Clinical trials were recently approved 
for DNA editing in humans and will help to determine if in vivo therapeutics utilizing Cas9 
proteins will be possible in the future (‘First CRISPR clinical trial gets green light from US 
panel’, 2016). While developing the above rgRNA/FnCas9 fidelity assay some unexpected 
results arose in experimental controls, which may allow new areas of investigation in 
coronavirus biology. Specifically, an rgRNA targeting murine herpes virus 68 (MHV68) 
enhanced translation and replication of MHV-A59. It may be informative to determine by what 
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mechanism targeting of a non-CoV (and not present) DNA virus can enhance CoV replication. A 
new non-CoV control rgRNA should be developed, which hopefully results in no change in 
translation or replication in the presence or absence of FnCas9. 
One of the most important next steps in the development of an FnCas9 based fidelity assay is the 
generation of stable cells lines expressing FnCas9 and individual CoV targeted rgRNAs. Stable 
cell lines will be infected with predicted fidelity-altered viruses and agar overlays will be placed 
to allow counting on individual escape mutant viruses. WT MHV replication results in 5 X 10-5 
mutations per nucleotide per round of replication, and two different sites should result in escape 
from CoV targeted rgRNA restriction, I estimate that approximately 4.0 X104 PFU will be 
required to identify an escape mutation. A typical WT MHV virus titer is at least 107 PFU. So, 
titers should be high enough to result in a quantifiable assay. The results from the experimental 
controls for the transient transfection experiments highlight the importance of also generating a 
stable cell line expressing FnCas9 and a control rgRNA. Additionally, results from nucleotide 
selectivity experiments throughout this dissertation demonstrate that the key nucleotides at the 3′ 
end of the CoV genome target should be diverse to distinguish between selection for specific 
nucleotides. Finally, to verify that single mutations at the 3′ end of the genome target will allow 
for viral escape, mutant viruses should be developed containing these changes. Frame shift 
escape mutant viruses should be utilized to determine if they can restore translation and 
replication to the levels observed for untargeted FnCas9. Escape is essential to the success of an 
rgRNA/FnCas9 based fidelity assay. If this approach is successful, fidelity-altered mutant CoVs 
will be compared by identifying the number of escape mutants arising in a population after a 
controlled number of replication cycles. 
Conclusion 
Coronaviruses infect an impressive breath of species and continue to emerge in human 
populations (Woo et al., 2009). Even during the time this dissertation research, a new human 
CoV was identified, as were multiple non-human but potentially zoonotic CoVs (Crossley et al., 
2012; Shirato et al., 2012; Zaki et al., 2012). Our current understanding of what primes a virus to 
jump from one species to another and to be (or not to be) successful in that new species is 
lacking. Additionally, countermeasures against human, zoonotic, agricultural or domestic CoVs 
(antiviral – vaccines) are minimal, with none currently available against human CoVs. The 
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research in this dissertation is my contribution to the overall understanding of these much 
broader principles. I hope that the new knowledge provided by this research can be built upon in 
the future to provide an intricate picture of how CoVs and other pathogens interact with host 
species and emerge in new species. Finally, I hope that, as more knowledge is acquired regarding 
the detailed biology of CoVs, that new targetable mechanisms are illuminated, leading to 
treatments and preventions against current and future infections.  
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APPENDIX A: 
 
HOMOLOGY-BASED IDENTIFICATION OF A MUTATION IN THE CORONAVIRUS 
RNA-DEPENDENT RNA POLYMERASE THAT CONFERS RESISTANCE TO 
MULTIPLE MUTAGENS 
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Homology-Based Identification of a Mutation in the Coronavirus
RNA-Dependent RNA Polymerase That Confers Resistance to Multiple
Mutagens
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Molecular Biology, Colorado State University, Fort Collins, Colorado, USAe
ABSTRACT
Positive-sense RNA viruses encode RNA-dependent RNA polymerases (RdRps) essential for genomic replication. With the ex-
ception of the large nidoviruses, such as coronaviruses (CoVs), RNA viruses lack proofreading and thus are dependent on RdRps
to control nucleotide selectivity and fidelity. CoVs encode a proofreading exonuclease in nonstructural protein 14 (nsp14-ExoN),
which confers a greater-than-10-fold increase in fidelity compared to other RNA viruses. It is unknown to what extent the CoV
polymerase (nsp12-RdRp) participates in replication fidelity. We sought to determine whether homology modeling could iden-
tify putative determinants of nucleotide selectivity and fidelity in CoV RdRps. Wemodeled the CoVmurine hepatitis virus
(MHV) nsp12-RdRp structure and superimposed it on solved picornaviral RdRp structures. Fidelity-altering mutations previ-
ously identified in coxsackie virus B3 (CVB3) were mapped onto the nsp12-RdRpmodel structure and then engineered into the
MHV genome with [nsp14-ExoN(!)] or without [nsp14-ExoN(")] ExoN activity. Using this method, we identified twomuta-
tions conferring resistance to the mutagen 5-fluorouracil (5-FU): nsp12-M611F and nsp12-V553I. For nsp12-V553I, we also
demonstrate resistance to the mutagen 5-azacytidine (5-AZC) and decreased accumulation of mutations. Resistance to 5-FU, and
a decreased number of genomic mutations, was effectively masked by nsp14-ExoN proofreading activity. These results indicate
that nsp12-RdRp likely functions in fidelity regulation and that, despite low sequence conservation, some determinants of RdRp
nucleotide selectivity are conserved across RNA viruses. The results also indicate that, with regard to nucleotide selectivity,
nsp14-ExoN is epistatic to nsp12-RdRp, consistent with its proposed role in a multiprotein replicase-proofreading complex.
IMPORTANCE
RNA viruses have evolutionarily fine-tuned replication fidelity to balance requirements for genetic stability and diversity. Re-
sponsibility for replication fidelity in RNA viruses has been attributed to the RNA-dependent RNA polymerases, with mutations
in RdRps for multiple RNA viruses shown to alter fidelity and attenuate virus replication and virulence. Coronaviruses (CoVs)
are the only known RNA viruses to encode a proofreading exonuclease (nsp14-ExoN), as well as other replicase proteins involved
in regulation of fidelity. This report shows that the CoV RdRp (nsp12) likely functions in replication fidelity; that residue deter-
minants of CoV RdRp nucleotide selectivity map to similar structural regions of other, unrelated RNA viral polymerases; and
that for CoVs, the proofreading activity of the nsp14-ExoN is epistatic to the function of the RdRp in fidelity.
RNAvirus replication results in the incorporation of a relativelyhigh number of mutations, ranging from 10!4 to 10!6 muta-
tions per site per round of replication (1–5). It is thought that
low-fidelity replication is largely responsible for the capacity of
RNA viruses to evolve rapidly and adapt to new host species and
ever-changing environmental pressures (6–8). RNA-dependent
RNA polymerase (RdRp) is central to the replication of RNA vi-
ruses and is a key regulator of nucleotide selectivity and fidelity (9,
10). Recent studies of coxsackievirus virus B3 (CVB3), poliovirus,
HIV-1, and other viruses have demonstrated that viable viruses
are recoverable only within a 4-fold range of RdRp fidelity (11–
14). In most cases, altered RdRp fidelity decreases fitness relative
towild-type (WT) viruses; this has been demonstrated for changes
as small as a 1.2-fold difference in the accumulation of mutations
(12, 14–16). Despite having as little as no amino acid identity
outside conserved motifs (11–14, 17–19), all described polymer-
ase structures (including RdRps) resemble a “cupped right hand,”
with finger, palm, and thumb domains (20). The fingers form a
channel that allows entry of the template RNA and ribonucleotide
triphosphates (rNTPs) and assist in proper positioning of incom-
ing nucleotides in the active site (21). The palm contains the active
site, and the thumb functions in contacting exiting nascent RNA
(21–23). However, there is diversity in the viral genes that encode
RdRps; additional domains that perform a variety of functions,
such as methyltransferase, endonuclease, polyribonucleotidyl
transferase, guanylyltransferase, membrane targeting, protein-
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protein binding, or protein-RNA binding activities, are often
present (24–26).
Coronaviruses (CoVs) infect a wide array of species and have
emerged as highly pathogenic human pathogens twice in this cen-
tury, first with severe acute respiratory syndrome coronavirus
(SARS-CoV) in 2003 (27) and then with Middle East respiratory
syndrome coronavirus (MERS-CoV) in 2012 (28). CoVs, and
other large nidoviruses, replicate with higher fidelity than all other
known positive-sense RNA viruses (29, 30). CoVs also have the
largest known RNA virus genomes, ranging from 27 to 34 kb (31,
32), and increased fidelity in CoVs is likely required for the main-
tenance of these large genomes (14). CoV genomes encode 16
nonstructural proteins (nsp1 to nsp16), several of which are
known or predicted to function in fidelity regulation, including
nsp14-ExoN, a 3=-5= exoribonuclease, and nsp10, a modulator of
nsp14-ExoNactivity (33, 34).Mutating theDEof the nsp14-ExoN
active site to AA inactivates the exoribonuclease, yielding nsp14-
ExoN(!) viruses, and nsp14-ExoN(!) viruses exhibit a greater-
than-10-fold increase in mutation frequency (29, 35–37). Recent
evidence has demonstrated that nsp14 directly interacts with the
CoV RdRp encoded in nsp12 (nsp12-RdRp) (38), but the effect of
this interaction on nucleotide selectivity and overall fidelity regu-
lation is not known. There are no solved structures for any CoV
nsp12-RdRp, but the presence of conserved RdRp motifs and
modeling of theC-terminal half of nsp12 predict anRdRpdomain
that is structurally similar to those of other RNA viruses (39, 40).
The demonstrated function of nsp14-ExoN in high-fidelity
CoV replication raises the questions of whether and how nsp12-
RdRp participates in fidelity regulation. We sought to determine
whether nsp12-RdRp can modulate nucleotide selectivity inde-
pendently or in association with the proofreading nsp14 exonu-
clease.Wemodeled the RdRp domain of CoVnsp12 onCVB3 and
poliovirus polymerase structures and predicted the residues im-
portant for fidelity based onprior results from those virus systems.
Substitution mutations at these residues were introduced in the
isogenic recombinant genome of the "-CoV murine hepatitis vi-
rus (MHV-A59). We demonstrate that two of these mutations,
nsp12-V553I and nsp12-M611F, confer resistance to themutagen
5-fluorouracil (5-FU) and that one, nsp12-V553I, also results in
resistance to the mutagen 5-azacytidine (5-AZC) and demon-
strates decreased accumulation of mutations. Increased mutagen
resistance and decreased accumulation of mutations were ob-
served only in viruses with an inactivated ExoN, demonstrating
that nsp14-ExoN proofreading activity is epistatic to the nucleo-
tide selectivity of nsp12-RdRp. In this paper, we define epistasis as
a situationwhere the phenotype of one gene or viral proteinmasks
the phenotype of genetic variants of another viral protein. This
result is consistent with a primary role for nsp14-ExoN in error
recognition and removal. However, introduction of RdRp muta-
tions within the WT MHV background decreased fitness relative
toWT. Together, the results suggest that nsp12-RdRp shares com-
mon determinants of nucleotide selectivity with RdRps from
other RNA virus families. Further, the CoV RdRp has likely
evolved to function in cooperation with nsp14-ExoN rather than
independently.
MATERIALS AND METHODS
Virus and cell culture.Murine delayed brain tumor (DBT) cells (41) and
baby hamster kidney 21 cells expressing theMHV receptor (BHK-R) (42)
weremaintained at 37°C inDulbecco’s modified Eaglemedium (DMEM)
(Gibco) supplemented with 10% fetal bovine serum (FBS) (Invitrogen),
penicillin, streptomycin (Gibco), and amphotericin B (Corning). The
BHK-R cells were further supplemented with 0.8 mg/ml of G418 (Medi-
atech). All virus work was performed using the recombinant WT MHV
strain MHV-A59 (GenBank accession number AY910861 [42]).
Sequence analysis and homology modeling of CoV MHV nsp12-
RdRp. The MHV RdRp domain structure was generated with the Phyre2
online program (43) using nsp12 residues 385 to 887, which correspond
to the reported SARS-CoVnsp12-RdRpmodel (40). The structuralmodel
was compared to the X-ray crystal structures of CVB3 and poliovirus
(Protein Data Bank [PDB] accession numbers 3DDK and 1RA7, respec-
tively) using the Pymol Molecular Graphics System (Schrödinger, LLC).
ClustalX multiple-sequence alignments were generated using the pro-
gram MacVector.
Cloning, recovery, and verification ofmutant viruses.Quick-change
mutagenesis was used to generate point mutations in individual MHV
genome cDNA fragment plasmids using the previously described MHV
infectious clone reverse genetics system (42). Mutant viruses were recov-
ered in cocultured BHK-R and DBT cells following electroporation of in
vitro-transcribed genome RNA in BHK-R cells. All viruses that included
nsp14-ExoN(!) mutations were generated using the F fragment previ-
ously described (35). Before use in virus recovery, all mutagenized plas-
mids were fully sequenced (GenHunter Corporation, Nashville, TN) to
ensure no additional mutations were introduced. We also sequence veri-
fied engineered mutations in recovered viruses. Viruses in the nsp14-
ExoN(!) background took between 84 and 96 h to reach around 80%
involvement in syncytia for a passage zero (P0) stock, in contrast to viruses
in the WT background, which were frozen at 24 to 48 h postinfection
(p.i.). P1working stocksweremade by infectingDBT cells at amultiplicity
of infection (MOI) of 0.01 and freezing them when 80% were involved in
syncytia, approximately 24 h p.i. for WT viruses and 36 h p.i. for nsp14-
ExoN(!) viruses (2 or 3 rounds of replication).
Compounds and drug sensitivity studies. 5-FU was obtained from
Sigma, and prepared as 200 mM stock solutions in dimethyl sulfoxide
(DMSO). 5-AZC was also obtained from Sigma and prepared as 50 mM
stock solutions in water. Subconfluent DBT cells were pretreated for 30
min with DMEM with the indicated concentrations of 5-FU or with
DMSO, 5-AZC, or medium alone. The treatment was removed, and the
inoculumwas added and allowed to adsorb for 1 h at 37°C. The inoculum
was then removed, andmediumwith drug or DMSOwas returned. Infec-
tion proceeded for 24 h for WT or 32 h for nsp14-ExoN(!) viruses, after
which the supernatants were acquired and frozen and the titer was deter-
mined by plaque assay as previously described (35).
Virus replication and RNA synthesis assays. Subconfluent DBT cell
monolayers in triplicate were infected at an MOI of 0.01 PFU/cell. The
virus was allowed to adsorb for 30 min, after which the inocula were
removed and the cells were washed 2 times with phosphate-buffered sa-
line (PBS), followed by addition of prewarmed medium. For replication
kinetics assays, samples were taken at various time points postinfection.
Titering was performed by plaque assay, as previously described (35). For
analysis of RNA synthesis, total infected-cell RNA was obtained with
TRIzol reagent (Invitrogen) at various times postinfection, and two-step
reverse transcription-quantitative PCR (RT-qPCR) was performed as
previously described (44).
Determination of specific infectivity. Subconfluent DBT cells were
pretreated for 30 min with DMEM with the indicated concentration of
5-FU or with DMSO alone. The treatment was removed, and the inocu-
lum was added and allowed to adsorb for 1 h at 37°C. The inoculum was
then removed, and medium with drug or DMSO was returned. Infection
proceeded for 20 h forWTor 24 h for nsp14-ExoN(!) virus, and then the
supernatants were acquired and frozen, and the titer was determined by
plaque assay as previously described (35). The supernatantswere also used
for RNA genome isolation by adding 100#l supernatant to 900#l TRIzol
reagent (Invitrogen), chloroform extraction by phase separation, and us-
ing the aqueous layer in the PureLink Mini RNA kit (Ambion) according
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to the manufacturer’s protocol. One-step RT-qPCR was performed as
described below, and the ratio of PFU to genomes of the supernatant was
determined.
One-step RT-qPCR for determining supernatant genome copies for
specific infectivity assay. An RNA standard was generated using the
MHV A fragment (42) to generate a 931-nucleotide (nt) RNA. First,
cDNA was generated by PCR using the following primers: forward, 5=-TAA
TACGACTCACTATAGGGGGCTATGTGGATTGTTGTGG-3=, which
begins with a T7 promoter, and reverse, 5=-AATTCTTGACAAGCTC
AGGC-3=. RNA for the standard curve was then generated using an
mMessage mMachine T7 kit (Ambion). An agarose gel with 1% bleach
was run, and an!900-nt band was observed. RNA was purified using an
RNeasy minikit (Qiagen). Dilutions of the standard curve were made
from 103 to 108 genome equivalents for use in assays as needed. Primers
and probes for one-step RT-qPCR were purchased from BioSearch Tech.
The probe was 5= 6-carboxyfluorescein (FAM) labeled and 3= black hole
quencher 1 (BHQ-1) labeled with the sequence 5=-TTCTGACAACGGC
TACACCCAACG-3= and made up to 5 "M in nuclease-free water. The
primers usedwere forward, 5=-AGAAGGTTACTGGCAACTG-3=, and re-
verse, 5=-TGTCCACGGCTAAATCAAAC-3=. Reaction mixtures were set
up on ice, with enzyme added last. The final volume for reactionmixtures
was 20"l, with 150 nMprobe, 900 nMeach primer, 2"l sample RNA, and
10 "l 2# ToughMix one-step low ROX enzyme mix (Quantas) used per
reaction. Samples were plated in duplicate and run on the Applied Biosci-
ences 7500 real-time PCR system with the following conditions: 55°C for
10min, 95°C for 5min, 95°C for 30 s, and 60°C for 1min, with the last two
steps repeated 40 times. The standard curve was graphed, and the number
of genomes per milliliter was determined.
Competitive fitness of mutant viruses. Subconfluent DBTmonolay-
ers were coinfected at a total MOI of 0.01 PFU/ml with RdRp mutant
viruses in the nsp14-ExoN($) background and nsp14-ExoN($) at either
a 1:1, 1:9, or 9:1 ratio. When 50 to 70% of the monolayer was involved in
syncytia, total RNAwas harvested. The RNAwas then reverse transcribed
using SuperScriptIII (Invitrogen) according to the manufacturer’s proto-
col, and amplicons were generated using primers designed to cover the
region including the codons for both the V553 and M611 residues. Am-
plicons were sent for sequencing, and electopherograms were analyzed
using MacVector.
Passage reversion analysis. Triplicate monolayers of subconfluent
DBT cells were infected at an initial MOI of 0.01 PFU/ml of nsp12-V553I
and nsp12-M611F viruses in both the WT and nsp14-ExoN($) back-
grounds. The viruses were then blind passaged in triplicate for 5 passages.
Total RNA was sequenced across a 1.7-kb region of nsp12-RdRp that
included both nsp12-RdRpmutations. Electropherograms were analyzed
using MacVector.
Preparation of amplicons for deep sequencing of full viral genomes.
Subconfluent DBT cells were infected at an MOI of 0.01 PFU/ml with
nsp12-V553I or nsp12-M611F in either theWT or nsp14-ExoN($) back-
ground,with nsp14-ExoN($) alone, orwith theWTalone. The infections
were allowed to progress for 20 h, and then RNA was isolated. The RNA
was reverse transcribed using SuperScriptIII (Invitrogen) according to the
manufacturer’s protocol, and 12 amplicons were generated to cover the
whole genome and processed as described previously (44).
Deep-sequencing sample preparation and analysis.Amplicons were
subsequently purified with a nucleospin PCR purification kit (Macherey-
Nagel), quantified with PicoGreen, fragmented (Fragmentase), and pre-
pared using the Illumina NextSeq500Mid Output 150-cycle kit following
the standard protocols. Sequences were obtained with an Illumina
NextSeq500 machine. Sequencing runs were analyzed using the previ-
ously published ViVan bioinformatics pipeline (45). Briefly, the pipeline
performed quality filtering, and adaptor cleaning was done using fastq-
clipper (http://hannonlab.cshl.edu/fastx_toolkit/index.html). The 150-nt
reads were aligned with the reference sequence with a maximum of 2
mismatches per read using BWA (46) and processed using SAMtools (47)
to obtain the nucleotide/base calling at each position. The ViVan pipeline
then identified statistically significant variants above the background
noise due to sequencing error, calculated for each nucleotide site as fol-
lows. For each position throughout the viral genome, base identities and
their quality scores were gathered. Each variant allele’s rate was initially
modified according to its covering read qualities based on a maximum-
likelihood estimation and tested for significance using a generalized like-
lihood ratio test. Additionally, an allele confidence interval was calculated
for each allele. In order to correct formultiple testing, a Benjamini-Hoch-
berg false-discovery rate of 5% was set. In all experiments, a minimum
coverage of 3,000 readswas obtained, and the background error frequency
at every nucleotide site was always below 0.0001. For analysis, we use a
conservative frequency cutoff of 0.01, consistent with previous studies
(48–50).
Statistical analysis. Statistics were applied as described in the figure
legends using GraphPad (La Jolla, CA) Prism 6 software. The number of
replicates performed for each experiment is similarly provided in each
figure legend. Finally, some of the data were normalized to controls;
GraphPad Prism 6 software was also used to perform this analysis.
RESULTS
Homologymodeling ofMHVnsp12-RdRp polymerase core do-
main predicts putative fidelity determinants.Mutations that al-
ter nucleotide selectivity have been identified acrossmultiple RNA
virus RdRps (3, 11, 51–53); however, whether these residues are
conserved across virus families is unknown. We sought to deter-
mine whether residues within nsp12-RdRp that are structurally
homologous to known RNA virus fidelity determinants would
have similar effects on nucleotide selectivity when introduced into
the MHV background. To do this, we modeled the structure of
MHV nsp12-RdRp using Phyre2 software (43). A series of nsp12-
RdRp truncationswas assessed, and the highest-confidencemodel
was used for further study. This region corresponded to a pub-
lished model for the SARS nsp12-RdRp (40) and included resi-
dues 385 to 887 of theMHV nsp12 protein, referred to here as the
RdRp core domain (Fig. 1A and B). Deletion of the CoV-specific
domain (residues 1 to 384) and a small C-terminal portion of the
thumb domain (residues 888 to 928) was required to establish this
high-confidence model (Fig. 1A). The model was resolved by
highest-probability similarity to human rhinovirus serotype 14
(PDB ID 1XR5), rabbit hemorrhagic disease virus (PDB ID
1KHV), and enterovirus 71 (EV71) (PDB ID 3N6M). The Phyre2
confidence, i.e., the probability of true homology of the RdRp core
domain with these structures, was %99%, while the identity was
only 14 to 20%.Having generated a structuralmodel for theMHV
nsp12-RdRp core domain, we next sought to predict the residues
involved in nucleotide selectivity. The nsp12-RdRp core domain
model was aligned with the solved structure of CVB3 (PDB ID
3DDK) using PyMol (Fig. 1C). A series of CVB3 RdRp mutations
have been shown to result in decreased fidelity (10, 11, 54).
The CVB3 fidelity determinants were compared with the MHV
nsp12-RdRp core domain model. Those that aligned well struc-
turally and by amino acid similarity—MHV nsp12-V553, -M611,
-W613, -A621, -Y649, and -K794 (Fig. 1)—were further investi-
gated. Finally, the nsp12 amino acid sequences of 27 different &-,
'-, and (-CoVs were aligned, including SARS-CoV and MERS-
CoV. All six identified residues were conserved across these CoVs
(Fig. 1D). Analyses of similarity and the types of residues in the
picornaviruses were then used to determine the specific amino
acid changes that would be introduced at the identified MHV
residues. The resulting substitutionmutations were engineered in
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the isogenic cloned MHV genome: nsp12-V553A/I, -M611F,
-W613Y, -A621G, -Y694H/W, and -K794R (Table 1).
Recovery of mutant viruses in the MHV nsp14-ExoN(!)
(with ExoN activity) and nsp14-ExoN(") isogenic backgrounds.
We next tested whether viable viruses could be recovered with
substitutions at the identified residues. Virus recovery was at-
tempted a maximum of 3 times, resulting in recovery of 6 of the 8
mutant viruses in the WT background: nsp12-V553I, -M611F,
-W613Y, -A621G, -Y649H, and -K794R. The time required for
recovery ofmutant viruses in theWT background ranged from 24
to 48 h. No other mutations were identified across nsp12 se-
quences in recovered viruses. The A621G mutant was not further
studied, as it demonstrated rapid primary reversion even in the
recovery (P0) supernatant. Since our goal was to understand the
relationship of nsp12-RdRp and nsp14-ExoN in fidelity regula-
tion, we additionally attempted recovery of the WT background
viable mutants in the setting of inactivated nsp14-ExoN [nsp14-
ExoN(!)]. In contrast to mutant viruses recovered in the
WT background, we recovered only 2 of the 5 mutants in the
nsp14-ExoN(!) background: nsp12-V553I/nsp14-ExoN(!) and
FIG 1 Homology modeling of CoV nsp12-RdRp and identification of residues that potentially regulate fidelity based on CVB3 structure. (A) Phyre2 software
was used to model a subsection of the MHV nsp12-RdRp core domain (expanded from the nsp12-RdRp full schematic). (B and C) The modeled MHV RdRp
structure (B) was aligned with the solved CVB3 RdRp structure (C). (A and B) The residues chosen for site-directed mutagenesis were selected by comparing
previously determined fidelity-altering mutations of picornavirus RdRps. (D) Amino acid alignments across CoVs showing that all residues are almost com-
pletely conserved.
Sexton et al.
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nsp12-M611F/nsp14-ExoN(!) (Table 1). The time to recovery
for nsp12-V553I/nsp14-ExoN(!) was 84 h, and that for nsp12-
M611F/nsp14-ExoN(!) was 96 h. Working stocks of all the vi-
ruses were made by infecting DBT cells at an MOI of 0.01 and
recovering stocks at around 24 h p.i. forWT viruses or between 32
and 48 h p.i. for mutant viruses in the nsp14-ExoN(!) back-
ground. Therefore, 4 to 10 replication cycles were required to
generate stocks. Working stocks were sequenced to verify that the
introduced mutations were still present.
Resistance of recovered mutant viruses to the base analog
5-fluorouracil. We next tested our panel of recovered mutant
viruses for resistance to the RNA mutagen 5-FU. 5-FU has been
used with picornaviruses, influenza viruses, vesicular stomatitis
viruses, and others to reflect changes in fidelity based on increased
or decreased sensitivity to incorporation and virus inhibition (11,
30, 49, 55). WT CoVs (MHV and SARS-CoV) are resistant to
5-FU, while nsp14-ExoN(!) mutants are profoundly sensitive to
5-FU inhibition, consistent with nsp14-ExoN-mediated removal
of misincorporated 5-FU. The effect of 5-FU on DBT cell viability
was previously tested, with no effect observed up to 400 "M (30).
We compared WT-MHV with the nsp12 mutants in both the
WT and nsp14-ExoN(!) backgrounds. There was no significant
change in sensitivity to 5-FU compared to WT for any of the
nsp12-RdRp mutant viruses in the WT background at up to 120
"M 5-FU, although the mutation Y649H did appear to decrease
resistance slightly (Fig. 2A). In contrast, the nsp12-M611F/nsp14-
ExoN(!) and nsp12-V553I/nsp14-ExoN(!)mutant viruses were
both significantly less sensitive to 5-FU than nsp14-ExoN(!)
alone, with both populations persistingwhen treatedwith 120"M
5-FU, where nsp14-ExoN(!) was not detectable beyond 80 "M
5-FU (Fig. 2B). These data demonstrate that both nsp12-RdRp
mutations, V553I andM611F, confer resistance to 5-FU. This sug-
gests two possibilities: that it is not possible to increase the exclu-
sion of 5-FUbeyond the high level dictated by nsp14-ExoNor that
selectivity for native nucleotides over 5-FU is in fact increased
by nsp12 mutations, but at a low level that is not detectable as
changes in the virus titer.
Three of the mutations (nsp12-Y649H, -W613Y, and -K794R)
were viable in the nsp14-ExoN(#) background but failed to grow
in the absence of proofreading. The observation that they grew
only in an nsp14-ExoN(#) background indicated that the muta-
tions retained sufficient polymerase function to support virus rep-
lication but that it was critically dependent on having proofread-
ing functionality, suggesting these mutations may have given rise
to low-fidelity variants. Unfortunately, the low titer from the
nsp14-ExoN(!) background precluded direct-sequencing analy-
sis, and we therefore cannot definitively show this is the case.
Replication kinetics of nsp12-V553I and nsp12-M611F mu-
tant viruses in theWT and nsp14-ExoN(!) backgrounds. Since
we were interested in mutations that potentially confer altered
fidelity, we prioritized the nsp12-V553I and nsp12-M611F mu-
tant viruses for further analysis.We next sought to determine how
the nsp12-V553I and nsp12-M611F viruses replicated in compar-
ison to their isogenic backgrounds (Fig. 3). In the wild-type back-
ground, bothmutant viruses had slightly delayed exponential rep-
lication but eventually reached similar peak titers comparable to
FIG2 Resistance ofMHVnsp12-RdRpmutant viruses to 5-fluorouracil in the
WT and nsp14-ExoN(!) backgrounds. The domain locations of mutations
are indicated as follows: fingers, blues; palm, reds. DBT cells were pretreated
with different concentrations of 5-FU for 30min. The treatment was removed,
and the cells were infected with the indicated viruses in the WT background
(A) or the nsp14-ExoN(!) background (B) at an MOI of 0.01. The medium
containing 5-FUwas replaced 30min p.i. Virus samples were taken at 24 (WT)
or 32 [nsp14-ExoN(!)] h p.i., and the titer was determined by plaque assay.
The data represent the results of 3 independent experiments, each with 2 rep-
licates. The error bars represent standard errors of themean (SEM) *, P$ 0.05
by the Wilcoxon test.
TABLE 1 Recovery of mutant viruses using site-directed mutagenesis
nsp12-RdRp
region
Engineered
substitution
(nsp12) Recovery
CVB3a MHV
nsp14-ExoN(#)
(WT) nsp14-ExoN(!)
Fingers I176V V553A No Not attempted
V553I Yes Yes
Y268H Y649H Yes No
Y268W Y649W No Not attempted
Palm I230F M611F Yes Yes
F232Y W613Y Yes No
A239G A621G Revertant Not attempted
K360R K794R Yes No
a Reference 8.
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that of the WT. In contrast, in the nsp14-ExoN(!) background,
both nsp12-V553I and nsp12-M611F mutant viruses displayed
replication kinetics similar to those of the isogenic nsp14-
ExoN(!) background.We also assessed RNA synthesis for nsp12-
V553I and nsp12-M611F by RT-qPCR. The measured genomic-
RNA levels were consistent with the virus replication kinetics data,
and we observed delayed and decreased genome RNA synthesis in
theWT background aftermultiple rounds of replication (Fig. 3E).
FIG 3 Replication kinetics ofMHVnsp12-RdRpmutant viruses. Themutation location is indicated as follows: fingers, blues; palm, red. DBT cells were infected
with the viruses indicated in theWTbackground (A, C, and E) or the nsp14-ExoN(!) background (B,D, and F) at anMOI of 0.01 PFU/cell. Supernatant aliquots
were taken at the indicated times p.i., and titers were determined by plaque assay. Total RNAwas taken at the indicated times p.i., and RT-qPCRwas performed.
The data represent the results of 3 independent experiments. The error bars represent SEM.
Sexton et al.
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However, at early time points, there was no difference in RNA
accumulation, suggesting that decreased RNA is a result of post-
RNA synthesis steps (Fig. 3C). In the nsp14-ExoN(!) back-
ground, RNA synthesis levels were indistinguishable from the
nsp14-ExoN(!) background for both nsp12-V553I and nsp12-
M611F, with no additional RNA synthesis defects detectable (Fig.
3D and F). The results, along with the ability to recover several of
the nsp12-RdRp mutants only in the nsp14-ExoN(") back-
ground, support the hypothesis that nsp14-ExoN and nsp12-
RdRpmay have an epistatic relationship. However, for replication
kinetics, the effects of nsp12-V553I and nsp12-M611F were not
observable in the presence of inactive nsp14-ExoN, demonstrat-
ing that the replication phenotype of inactive nps14-ExoN is epi-
static to replication variants encoded in nsp12-RdRp.
Specific infectivity of nsp12-V553I and nsp12-M611F. Hav-
ing identified two mutant viruses with resistance to 5-FU, we
wanted to further test whether the resistance was due to decreased
incorporation of themutagen.Measurement of specific infectivity
has been useful for determining lethal mutagenesis for MHV and
other RNA viruses (30, 56). We tested the nsp12-M611F and
nsp12-V553I mutants in both theWT and nsp14-ExoN(!) back-
grounds for changes in specific infectivity when infected at an
MOI of 0.01 and treated with 5-FU (Fig. 4). Both nsp12-M611F
and nsp12-V553I resulted in an increased ratio of infectious par-
ticles (PFU per milliliter) to total particles (RNA genomes) in the
nsp14-ExoN(!) background (Fig. 4B). Similarly, in theWTback-
ground, nsp12-M611F demonstrated an increase in the ratio of
infectious particles to RNA genomes (Fig. 4A). Thus, specific in-
fectivitymay be amore sensitivemeasure of lower-level changes in
nucleotide selectivity in the setting of nsp14-ExoN(!).
Fitness costs of nsp12-V553I and nsp12-M611F in WT and
nsp14-ExoN(!) backgrounds. In multiple RNA viruses, includ-
ing CoVs, both increased and decreased fidelity have been re-
ported to have a fitness cost (14). We therefore sought to deter-
mine whether nsp12-V553I or nsp12-M611F conferred any cost
in fitness, defined as the ability to directly compete during coin-
fection. In the WT background, both nsp12-V553I and nsp12-
M611F demonstrated delays in replication and impaired RNA ac-
cumulation. However, since there were no observed additional
defects in replication or RNA synthesis for nsp12-V553I and
nsp12-M611F when introduced into the nsp14-ExoN(!) back-
ground (Fig. 3B,D, and F), we tested for any additional fitness cost
of nsp12-V553I/nsp14-ExoN(!) or nsp12-M611F/nsp14-
ExoN(!) virus compared with nsp14-ExoN(!) alone. When
coinfected with nsp14-ExoN(!) virus at ratios from 1:9 to 9:1,
nsp12-V553I/nsp14-ExoN(!)maintained the input ratio compared
with nsp14-ExoN(!) (Fig. 5A). A small advantage for nsp12-
V553I/nsp14-ExoN(!) was observed when the coinfected cul-
tures were treated with 60 #M 5-FU, consistent with a conferred
advantage for 5-FU resistance (Fig. 5A). Thus, there appeared to
be no additional fitness cost of nsp12-V553I/nsp14-ExoN(!)
compared to nsp14-ExoN(!) alone. In contrast, nsp12-M611F/
nsp14-ExoN(!) was not able to compete with nsp14-ExoN(!) at
any ratio (Fig. 5B). Treatment with 60 #M 5-FU again favored
nsp12-M611F/nsp14-ExoN(!); however, even then, the percent-
age of the population made up of nsp12-M611F/nsp14-ExoN(!)
virus remained at only around 30% when initially given a 9-fold
advantage (Fig. 5B).
We next tested whether the relative differences in fitness
cost resulted in selective pressure for reversion of nsp12-V553I
and nsp12-M611F (Fig. 6). DBT cells were infected with nsp12-
V553I, nsp12-V553I/nsp14-ExoN(!), nsp12-M611F, or nsp12-
M611F/nsp14-ExoN(!) virus at an initial MOI of 0.01. After 5
passages, the viruses were analyzed for retention of original mu-
tations using dideoxy (Sanger) sequencing. The nsp12-V553Imu-
tation was stable after passage in both WT and nsp14-ExoN(!)
backgrounds, maintaining the mutated AUU codon (Fig. 6A),
suggesting minimal selective pressure on that nucleotide, codon,
or amino acid. In contrast, the nsp12-M611F mutation demon-
strated significant change over passage in both the WT and the
nsp14-ExoN(!) backgrounds. The original mutation, UUC, was
no longer the majority codon in the nsp14-ExoN(!) background
and was less than 52% of the population in all WT background
lineages (Fig. 6B). The nsp12-M611F/nsp14-ExoN(!) popula-
tion resulted in a mixture of 2-nucleotide changes, resulting in
reversion to AUG (methionine) (!68% of the population); single
FIG 4 Specific infectivity is increased in both nsp12-V553I and nsp12-M611F
mutants. DBT cells were pretreatedwith increasing concentrations of 5-FU for
30 min. The treatment was removed, and the cells were infected with the
indicated viruses in the WT background (A) or the nsp14-ExoN(!) back-
ground (B) at an MOI of 0.01. The medium containing 5-FU was replaced 60
min p.i. Virus samples were taken at 20 and 24 h p.i. Titers were determined by
plaque assay, and the numbers of supernatant genomeswere determined using
one-step RT-qPCR. The data represent the results of 2 independent experi-
ments, each with 3 replicates. The error bars represent SEM (*, P $ 0.05 by
2-way analysis of variance [ANOVA] using the Bonferroni correction formul-
tiple comparisons).
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nucleotide changes that resulted inmutation to Leu (!55% of the
population), a somewhat smaller but still hydrophobic residue; or
retaining a Phe substitution (!27% of the population). Thus, the
fitness cost of nsp12-M611F results in significant selective pres-
sure for changes at that residue during passage in the absence of
5-FU.
Resistance of recovered mutant viruses to the base analog
5-azacytidine.Having shown that both nsp12-M611F and nsp12-
V553I mutations conferred resistance to 5-FU in the nsp14-
ExoN(!) background but that nsp12-M611F reverted quickly
and was at a fitness disadvantage in both the WT and nsp14-
ExoN(!) backgrounds, we next wanted to test whether the mu-
tations conferred resistance specifically to 5-FU or broadly to base
analogs and therefore were likely determinants of fidelity. A study
by Arias et al. demonstrated that for foot-and-mouth disease virus
(FMDV), resistance to a specific mutagen can result from a point
mutation while conferring the opposite overall fidelity (57). We
therefore tested for resistance to the additional mutagen 5-AZC.
Similar to the 5-FU results, the nsp12-V553I/nsp14-ExoN(!)
mutant virus was more resistant to 5-AZC than nsp14-ExoN(!)
alone, maintaining approximately 1-log-unit-higher titers from
20 to 50 "M 5-AZC (Fig. 7). However, the nsp12-M611F/nsp14-
ExoN(!) mutant virus showed no difference in resistance to
5-AZC compared with nsp14-ExoN(!) alone (Fig. 7). These data
suggest that nsp12-V553I is likely a fidelity determinant, whereas
nsp12-M611F confers specific resistance to 5-FU and has un-
known overall fidelity. This result is also consistent with the rapid
reversion observed for the nsp12-M611F mutation.
The nsp12-V533I mutation results in a decrease in the accu-
mulation of mutations.Having shown that the nsp12-V553I and
nsp12-M611F mutations resulted in resistance to 5-FU and that
nsp12-V553I additionally conferred resistance to 5-AZC, we
sought to directly determine whether either of the mutations re-
sulted in a change in the number of mutations accumulated in
viral RNA. DBT cells were infected with wild-type, nsp12-V553I,
nsp12-M611F, nsp14-ExoN(!), nsp12-V553I/nsp14-ExoN(!),
or nsp12-M611F/nsp14-ExoN(!) virus at an MOI of 0.01, and
RNAwas collected at 20 h p.i. The samples were then prepared for
Illumina next-generation sequencing (NGS) across the full ge-
nome and analyzed using the ViVan analysis pipeline (45). Muta-
tions present at 1% or more of the population were graphed by
frequency and position in the genome, with engineeredmutations
depicted with colored dots. Most nonengineered new mutations
were present at 10% or less of the population andwere distributed
across the genome with no detectable hot spots (Fig. 8A to F). For
nsp12-V553I in the WT background, no difference was observed
in the number of mutations accumulated to 1% or greater of the
population compared to the WT alone. In contrast, in the nsp14-
ExoN(!) background, nsp12-V553I was associated with a 1.7-
fold decrease in the frequency of mutations compared to nsp14-
ExoN(!) alone (Fig. 8G), againwith no change in the distribution
of mutations across the genome (Fig. 8C and D). These results are
consistent with both the 5-FU and 5-AZC data in suggesting in-
creased fidelity. The results from the nsp12-M611F mutant vi-
ruses were more complicated. To our surprise, the nsp12-M611F/
nsp14-ExoN(!) virus fully reverted at both engineered nsp12-
M611F nucleotides during the low-MOI infection, resulting in a
virus population that was nsp14-ExoN(!) alone (Fig. 8F). This
reversionmade the results for the nsp12-M611F/nsp14-ExoN(!)
virus uninterpretable. However, since accumulation of mutations
to over 1% of the population is a combination of all replication
cycles from initial recovery to the final sample [roughly 11 in total
for nsp12-M611F/nsp14-ExoN(!)], we included these data in
Fig. 8G and H. In the WT background, the nsp12-M611F muta-
tions were still present at 100% of the population and resulted in a
1.93-fold increase in the total number of accumulated mutations.
We observed only a slight increase in the number of mutations
accumulated in the nsp12-M611F/nsp14-ExoN(!) sample over
those of nsp14-ExoN(!), which was not surprising, as theM611F
mutation was no longer present. Neither sample appeared to have
mutations concentrated in specific locations across the genome,
suggesting the accumulation of mutations was due to random
generation of mutations rather than strong selection in particular
locations or proteins (Fig. 8E and F). Of note, one mutation in
nsp3 of the nsp14-ExoN(!) sample and a mutation in the nsp3,
nsp13, and E proteins of nsp12-V553I/nsp14-ExoN(!) reached
nearly 100% of the sample population. None of these mutations
were present in the fragments used for recovery, and the nsp3
FIG 5 Competitive fitness analysis in the nsp14-ExoN(!) background. DBT cells were pretreated with medium alone or medium containing 60 "M 5-FU for
30 min. The treatment was removed, and the cells were coinfected at a total MOI of 0.01 with nsp14-ExoN(!) and nsp12-V553I/nsp14-ExoN(!) (A) or
nsp12-M611F/nsp14-ExoN(!) (B) viruses at a ratio of 9:1, 1:1, or 1:9. Medium alone or containing 60 "M 5-FU was replaced 30 min p.i. Total RNA was taken
at 24 h p.i. Sequencing was performed across a 1.7-kb region of nsp12-RdRp that included both mutations. The data represent the results of 3 independent
experiments, each with 2 replicates. The error bars represent SEM.
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mutation that arose in the nsp14-ExoN(!) population was not
present prior to the final low-MOI infection. It is possible that
these mutations provided some benefit to the viruses, since they
were fixed so rapidly in the population. We next determined
whether either of themutations resulted in a change in the types of
mutations occurring during replication (Fig. 8H). Consistentwith
our previous studies, there were differences in the types of muta-
tions incorporated when WT and nsp14-ExoN(!) backgrounds
were compared (30). However, the addition of nsp12-V553I or
nsp12-M611F did not alter these patterns in either the WT or
nsp14-ExoN(!) background. Thus, nsp12-V553I results in an
overall decrease in the accumulation of mutations over passages
while nsp12-M611F seems to increase the number of mutations
accumulated. These results confirm by sequence analysis the re-
sults from the 5-FU and 5-AZC resistance experiments for nsp12-
V553I, specifically, showing that the effects of nsp12-V553I are
dependent on inactivation of nsp14-ExoN for their detection and
that nsp12-V553I likely confers broad resistance to the incorpo-
ration of incorrect nucleotides. In contrast, these results further
increase the complexity of the nsp12-M611F mutation in relation
to incorporation of nucleotides and their analogs. We conclude
that nsp12-M611F confers resistance to 5-FU but that this resis-
tance is not likely to be due to broad resistance to the incorpora-
tion of alternate nucleotides.
DISCUSSION
RdRp structures of divergent RNA viruses are structurally con-
served and likely have common determinants of activity in the
finger, palm, and thumb domains. Positive-strand RNA virus
polymerases appear to utilize a common palm domain-based
mechanism for active-site closure (23), and associated molecular
determinants of fidelity in different RdRpdomains have been pro-
posed based on biochemical and mutagenesis studies (10). To
date, there are no solved crystal structures of any CoV RdRp, and
thus, direct comparison with other virus RdRp structures has not
been possible. Further, regulation of CoV fidelity is likely depen-
dent on multiple proteins, including the RdRp and proofreading
ExoN. Thus, it was not clear that a CoV would phenotypically
exhibit effects from mutating fidelity-determining residues lo-
cated in the RdRp itself. In this study, we sought to determine
whether we could use structure and mutagenesis data from dis-
tantly related RNAviruses to identify determinants of CoVnsp12-
RdRp fidelity. Our results suggest that CoV RdRps do in fact par-
ticipate in fidelity regulation at residues orthologous to those in
the picornaviruses and likely in other RNA virus RdRps. The re-
sults also define, for the first time, a CoV RdRp determinant that
increases resistance to multiple mutagens, decreases the accumu-
lation of mutations over time, and so likely increases overall fidel-
FIG 6 The nsp12-V553I mutation is stable across passages; however, nsp12-
M611F is vulnerable to reversion. DBT cells were infected at an initial MOI of
0.01 and then blind passaged in triplicate for 5 passages. Total RNAwas taken,
and sequencing was performed across a 1.7-kb region of nsp12-RdRp that
included bothmutations. The percentage of each nucleotide present in each of
the triplicate lineages after 5 passages is shown. Mutant viruses in the WT and
nsp14-ExoN(!) backgrounds are shown. The original mutation for each of
the viruses is shown above the graph, and the likely majority, secondary and
tertiary codons present in the population are shown below the graph.
FIG 7 Resistance of MHV nsp12-RdRp V553I and M611F mutant viruses to
5-azacytidine in the nsp14-ExoN(!) background. The domain locations of
mutations are indicated as follows: fingers, blues; palm, reds. DBT cells were
pretreated with different concentrations of 5-AZC for 30 min. The treatment
was removed, and the cells were infected with the indicated viruses at an MOI
of 0.01. Themedium containing 5-AZCwas replaced 30min p.i. Virus samples
were taken at 32 h p.i., and the titer was determined by plaque assay. The data
represent the results of 5 independent experiments, each with 2 replicates. The
error bars represent SEM (*, P" 0.05 by ratio paired t test).
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FIG8 The nsp12-V553Imutation confers decreased accumulation ofmutations in the nsp14-ExoN(!) backgroundwith no bias toward the exclusion of specific
nucleotides. DBT cells were infected at anMOI of 0.01, and total RNAwas collected. Deep sequencing was performed on the samples. The statistically significant
mutations present at!1% of the total population are shown for the wild type, nsp14-ExoN, and nsp12-V553I or nsp12-M611F in both backgrounds. They are
graphed according to their distribution across the genome (A to F), with intentionally introducedmutations shownwith circles colored blue (nsp12-V553I), red
(nsp12-M611F), or green [nsp14-ExoN(!)] (B to F); as the total number ofmutations present in the population (G); and as the percentage of specificmutations
present (H).
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ity. Additionally, the data presented in this paper suggest that CoV
RdRp-mediated increased fidelity is detectable only when nsp14-
ExoN is inactive and only partially compensates for the loss of
nsp14-ExoN high fidelity. Finally, both the nsp12-V553I and
M611F mutations confer a replication cost in the WT back-
ground, but only nsp12-M611F confers a fitness disadvantage in
the nsp14-ExoN(!) background. Together, the results suggest
that nsp14-ExoN proofreading activity is epistatic to nsp12-RdRp
fidelity but that in contrast, the replication defects of an inactive
nsp14-ExoN are epistatic to replication defects in nsp12-RdRp.
Determinants of nucleotide selectivity and fidelity in CoVs
may be conserved with other RNA viruses. Picornavirus func-
tional RdRps contain only RdRp domains (58, 59). This is not the
case formany viral RdRps, including CoVs (26, 39). In addition to
the predicted RdRp core domain, all CoV nsp12 proteins contain
a “CoV-specific” domain of over 350 amino acids at the N termi-
nus of the protein. A nucleotidyltransferase activity was identified
in this CoV-specific domain and has been shown to be important
in SARS-CoV replication, but the specific function in replication
remains to be determined (39). The N-terminal CoV-specific do-
main could not be modeled due to a lack of evolutionary homo-
logues with known structures, but the predicted RdRp core do-
main could bemodeled with high confidence using bioinformatic
approaches. The structures that provided the best models for the
CoV RdRp were from picornaviruses, including enterovirus 71,
foot andmouth disease virus, and coxsackie virus B3. This allowed
direct alignment and comparison of the known fidelity determi-
nants in CVB3 with the MHV nsp12 core domain across both
finger and palm domains. The recovery of mutations in these
structurally conserved residues and their participation inCoVnu-
cleotide selectivity support the hypothesis that there are determi-
nants of base specificity conserved between CoVs and distantly
related RNA viruses, specifically the picornaviruses. This supports
the idea that all RdRps function similarly due to their structural
conservation and despite the low level of sequence similarity and
attached domains (54). It also suggests that theCoVRdRpdomain
folds in a manner similar to that of other RdRps, likely separate
from the CoV-specific domain.
RdRp fidelity and nucleotide selectivity have been investigated
extensively in picornaviruses, especially poliovirus (12, 15, 51, 53,
60, 61). However, even between picornaviruses, the impact on the
fidelity of changes at identical or similar residues can vary dramat-
ically (10). Mutations at the same residues in the RdRp of polio-
virus and CVB3 affect fidelity differently; poliovirus mutations
generally result in increased fidelity and CVB3 mutations in de-
creased fidelity (11). Specifically, the residue structurally ortholo-
gous to nsp12-M611 in poliovirus is F230, and in CVB3 it is I230;
when F230 is mutated to Ile in poliovirus, it results in an increase
in fidelity, but when I230 in CVB3 is mutated to Phe, Trp, or Val,
it results in a decrease in fidelity (10). Similarly, the residue or-
thologous to nsp12-V553 in CVB3 is I176; when I176 is mutated
toVal inCVB3, it results in a decrease in fidelity (10, 11). Although
the specific substitutions differ, when nsp12-V553I and nsp12-
M611F are introduced into the MHV genome, the resulting 5-FU
resistance, and for nsp12-V553I a likely increase in fidelity, mim-
ics results seen in poliovirus rather than CVB3. However, nsp12-
M611F seemed to accumulate more mutations over time than
controls, and many of the predicted mutations were recoverable
only in the WT background; therefore, changes in nucleotide se-
lectivity and fidelity were not tested, so it remains possible that the
mutations that were nonviable in the nsp14-ExoN(!) back-
ground had decreased fidelity and that nsp14-ExoN(!) treated
with 5-FU defines the error threshold for CoVs.
Coronavirus nsp12-RdRp and nsp14-ExoN cooperate to op-
timize both fidelity and replication kinetics. In addition to
nsp12-RdRp, CoVs encode nsp14-ExoN, which functions as a
proofreading enzyme (29, 30, 33, 35). Beyond nsp14-ExoN, there
are additional CoV-encoded nsps that potentially contribute to
overall fidelity, such as the small-molecule modulator of nsp14-
ExoN encoded in nsp10 (33, 62), nsp7, and nsp8, which together
function as an elongation factor (63) and a primase (64, 65), and
nsp13, which functions as a helicase (66). These proteins interact
with each other and likely function as a multiprotein replication-
fidelity complex (34, 38). The results of this study show that while
determinants in nsp12-RdRp are likely capable of increasing fidel-
ity, the changes are detectable only in the setting of loss of nsp14-
ExoN proofreading and do not completely compensate for the
impaired fidelity associated with nsp14-ExoN(!). If altering nu-
cleotide selectivity determinants within nsp12-RdRp no longer
significantly affects the overall nucleotide selectivity of the WT
virus, then the evolutionary pressure on nsp12-RdRp may be
more heavily weighted toward other aspects of replication, such as
speed. Recent evidence suggests that RdRp fidelity and speed have
an inverse relationship (10, 67). Therefore, if fidelity regulation by
nsp14-ExoNoccursmore rapidly than correct nucleotide selectiv-
ity by the RdRp, then CoV nsp12-RdRp may have been selected
specifically for replication speed. Our data may support this hy-
pothesis, as in theWT background, both nsp12-V553I and nsp12-
M611F resulted in increased replication lag phases (Fig. 3A andE),
though early RNA synthesis was not observably different in our
system (Fig. 3C). However, this was not seen in the nsp14-
ExoN(!) background, which could be explained by our data in-
dicating that replication is already slowed when nsp14-ExoN is
inactivated. One possible mechanism for this could be that the
nsp14-ExoN(!) protein is trying to remove incorrect nucleotides
and is stalling replication due to its inability to do so. In this case,
nsp14-ExoN(!) would be epistatic to nsp12-RdRp in relation to
speed, thereby obscuring decreases in replication speed caused by
mutations in nsp12-RdRp itself.
Conclusion. Our results support the hypothesis that determi-
nants of nucleotide selectivity are conserved across viral orders,
identify the first likely increased fidelity determinant for CoV
nsp12-RdRp, and demonstrate that nsp14-ExoNproofreading ac-
tivity is epistatic to nsp12-RdRp nucleotide selectivity. The possi-
bility that some fidelity determinants may be conserved across
viral orders is an exciting discovery, as many fidelity determinates
identified so far have resulted in attenuation (11, 15, 54, 68–70). It
would be interesting to determine whether nsp12-V553I is also
attenuated. We predict that it is, based on the fitness cost in vitro.
However, there is also no clear increase in nucleotide selectivity or
fidelity in theWT background. This may be due to a veryminimal
change that is not measureable even with the deep-sequencing
technology used in this study. Alternatively, it could be that any
change is simply overwhelmed by the high fidelity of intact ExoN
proofreading. In any case, these mutations or other changes at
these residues may allow selection of viruses that replicate with
normal kinetics in vitro and in vivo yet confer attenuation in an
animal setting.We know that the nsp14-ExoN(!)mutations con-
fer genotypically and phenotypically stable attenuation in vivo
(36). However, the concept of a high-level mutator as a mecha-
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nism for attenuation in live virusesmay be problematic. The iden-
tification of increased fidelity mutations in the RdRp that can
partially, or potentially completely, compensate for the fidelity
impairment of nsp14-ExoN(!) viruses, may allow the develop-
ment of approaches that can benefit from the stability of the
nsp14-ExoN(!) mutator phenotype while allowing more stabil-
ity to the input genomes. Finally, these results, combined with
those from previous work (33, 44), suggest that CoVs encode at
least three proteins involved in fidelity (nsp12-RdRp, nsp14-
ExoN, and nsp10), supporting the assembly of a multiprotein
replicase-fidelity complex, as described previously (38). This in-
creases the importance of establishing a biochemical model of the
multiprotein complex to directly test the interactions of fidelity
determinants, as well as potential inhibitors of each or all of these
functions.
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Abstract
When judged by ubiquity, adaptation, and emergence of new diseases, RNA
viruses are arguably the most successful biological organisms. This success
has been attributed to a defect of sorts: high mutation rates (low fidelity)
resulting in mutant swarms that allow rapid selection for fitness in new envi-
ronments. Studies of viruseswith small RNAgenomes have identified fidelity
determinants in viral RNA-dependent RNA polymerases and have shown
that RNA viruses likely replicate within a limited fidelity range to maintain
fitness. In this review we compare the fidelity of small RNA viruses with that
of the largest RNA viruses, the coronaviruses. Coronaviruses encode the
first known viral RNA proofreading exoribonuclease, a function that likely
allowed expansion of the coronavirus genome and that dramatically increases
replication fidelity and the range of tolerated variation. We propose models
for regulation of coronavirus fidelity and discuss the implications of altered
fidelity for RNA virus replication, pathogenesis, and evolution.
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SARS-CoV: severe
acute respiratory
syndrome coronavirus
MERS-CoV: Middle
East respiratory
syndrome coronavirus
Replication fidelity:
the accuracy with
which genetic
information, either
DNA or RNA, is
copied
CoV: coronavirus
Proofreading:
an error-correcting
process involving the
removal of a
mismatched nucleotide
during RNA or DNA
synthesis
Zoonotic: describes
an infectious agent
capable of
transmission between
animals and humans
INTRODUCTION
RNA viruses constitute some of the most ubiquitous and lethal human pathogens. The emer-
gence of Ebola virus, new human influenza viruses, severe acute respiratory syndrome coronavirus
(SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV) underscores the
capacity of RNA viruses to cause new human diseases. RNA viruses—notablyHIV and influenza—
also demonstrate emergence of resistance to antivirals and vaccines. Such adaptive potential results
from several characteristics of RNA viruses including rapid replication cycles, enormous popu-
lation size, and extensive genetic diversity. However, high adaptive potential is not without cost;
low-fidelity replication imposes genome size constraints such thatmost RNAvirus genomes do not
exceed∼15 kb (1–3). In this reviewwehighlight significant advances in understanding the determi-
nants of RNA virus replication fidelity and the implications of altered fidelity for virus replication,
fitness, and pathogenesis. We devote particular attention to the coronaviruses (CoVs), which en-
code genomes up to 32 kb long and thus are an exception to the constraint on RNA genome size
and complexity. Additionally, we summarize recent experimental data and comparative genomics
analyses demonstrating that CoVs have evolved a network of replicase proteins that increase the
efficiency of RNA replication and regulate replication fidelity through a novel RNA proofreading
activity. Finally, we discuss the possibility that CoVRNA replication involves a large multisubunit
polymerase similar in organization to replicative DNA polymerase complexes.
HUMAN CORONAVIRUSES: EMERGENCE, GENOME
ORGANIZATION, AND REPLICATION
Emergence and Human Disease
CoVs cause significant morbidity and mortality in humans (4), from mild common colds to lethal
respiratory and systemic diseases. Five CoVs are known to circulate in humans (HCoVs): HCoV-
NL63, HCoV-229E, HCoV-OC43, HCoV-HKU1, and MERS-CoV. Although SARS-CoV is
not known to be present in human populations, a SARS-like CoV recently was discovered in
Chinese horseshoe bats (Rhinolophidae) (5). This virus can use human ACE2 (angiotensin-
converting enzyme 2) as a receptor and is >99% identical to SARS-CoV, indicating that the
immediate SARS-CoV zoonotic precursor is likely present in bat populations. Molecular clock
analyses suggest that all endemic HCoVs originated as zoonotic infections and emerged into
humans over several hundred years: HCoV-NL63 between 1190 and 1449 CE (6), HCoV-229E
between 1501 and 1883 CE (7, 8), and HCoV-OC43 between 1866 and 1918 CE (9). The timing
of HCoV-HKU1 emergence remains unknown (10). SARS-CoV was identified in 2003 (11) and
MERS-CoV in 2012 (12), both within a year of entering the human population, emphasizing the
capacity of CoVs to cross species barriers and thrive in new host environments.
Though CoVs infect a large number of mammalian and avian species (13), the majority of the
identified diversity within alpha- and betacoronaviruses exists in bats (14). CoVs are predicted to
have coevolved with bats for millions of years, possibly since the evolutionary split between bats
and birds (15, 16). All known HCoVs have proposed bat origins with the exception of HCoV-
OC43, which emerged from a bovine CoV (6). However, movement of zoonotic CoVs into human
populations may require passage or coemergence with other mammalian species, as exemplified by
SARS-CoV emergence (17), which involved cyclical passage between civet cats and humans. The
closest known relative of HCoV-229E recently was discovered in alpacas, suggesting interspecies
transmission to humans might have been through alpacas (8) instead of directly from bats (7).
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(+)ssRNA:
positive-sense
single-stranded RNA
Nsp: nonstructural
protein
RdRp:
RNA-dependent RNA
polymerase
MERS-CoV is themost recently emergedHCoV, and its transmission history is still being defined.
MERS-CoV originally was isolated in June 2012, and new cases continue to be identified, with
more than 243 laboratory-confirmed cases as of April 2014 and more than 93 deaths. Emerging
data suggest the involvement of an additional species in maintenance of MERS-CoV transmission
to humans, and at present dromedary camels are the prime suspects (18, 19).There is clear evidence
for limited human-human transmission (20, 21), and the continued evidence for new infections
suggests the potential for further adaptation.
Genome Organization and Replication Strategy
The order Nidovirales contains four families: the Arteriviridae, Coronaviridae, Mesoniviridae,
and Roniviridae. CoVs comprise the Coronavirinae subfamily within the Coronaviridae family
and demonstrate a remarkable diversity across many animal species. All CoVs have positive-sense
single-stranded RNA [(+)ssRNA] genomes, which possess a 5′ cap structure and a 3′ poly(A)
tail and are contained within a pleomorphic host membrane–derived envelope (reviewed in 22).
The genome organization is similar for all CoVs, with the viral genome divided roughly into two
major regions: the nonstructural protein genes and the structural and accessory protein genes
(Figure 1a). Compared with other positive-strand RNA viruses, CoVs encode the most extensive
ensemble of replicase and transcriptase proteins, which can include up to 16 nonstructural
proteins (nsp1–16) (22). Proteins involved in viral replication and transcription compose the
first two-thirds of the viral genome and are contained in two open reading frames, ORF1a and
ORF1b. ORF1a is translated from genome RNA with every translational initiation, resulting
in the expression of polyprotein 1a (pp1a), which is composed of nsp1–11. Translation of
ORF1b requires a −1 ribosomal frameshift immediately following the nsp10 coding region,
which occurs less than 40% of the time and results in the fusion polyprotein 1ab (pp1ab), which
contains nsp1–16 (23, 24). Consequently, nsp1–11 are produced more abundantly than nsp12–16.
Processing of both polyproteins by two or three viral proteases yields 16 mature nsps and several
intermediate precursors, with the vast majority of these mature nsps known or predicted to
function in virus replication complex formation and RNA synthesis (22, 25, 26).
CoVRNAsynthesis can be divided into two general stages: genome replication and subgenomic
mRNA synthesis (22). Genome replication is initiated following translation of the viral genome
by host machinery and processing of replicase nsps by viral proteases. The (+)ssRNA genome
is transcribed into a full-length (−)ssRNA intermediate, which is then used as the template for
amplification of the (+)ssRNA genome (Figure 1b). Expression of the 3′ structural and accessory
proteins occurs from subgenomic mRNAs (sgmRNAs) initiated by a discontinuous transcription
mechanism. Negative-strand subgenomic RNA [(−)sgRNA] templates are generated from the 3′
end of the (+)ssRNA genome and are regulated by short transcriptional regulatory sequences
(TRSs) located in the 5′ untranslated region (UTR) of the (+)ssRNA genome, termed the leader
TRS, and by those present immediately upstream of each 3′ ORF (Figure 1b). Recognition of each
3′ TRS by the viral RNA-dependent RNA polymerase (RdRp) can result in either read-through
or dissociation of the (−)sgRNA template from the (+)ssRNA genome. The (−)sgRNA-RdRp
complex then reassociates with the 5′ leader TRS, thus generating a set of (−)sgRNAs that contain
one or more ORFs as well as 3′ and 5′ termini identical to the negative-strand genome template.
These (−)sgRNA templates are then used as the primary templates to generate sgmRNAs that
possess 5′ and 3′ sequences identical to each other and to the genome. This nested set of mRNAs
is the basis for the name of the order Nidovirales, of which CoVs are members. The sgmRNAs
also are used as amplification templates for subsequent rounds of (−)sgRNA synthesis (27).
www.annualreviews.org • RNA Virus Replication Fidelity 113
An
nu
al 
Re
vie
w 
of 
Vi
rol
og
y 2
01
4.1
:11
1-1
32
. D
ow
nlo
ad
ed
 fr
om
 w
ww
.an
nu
alr
ev
iew
s.o
rg
 A
cc
ess
 pr
ov
ide
d b
y V
an
de
rbi
lt U
niv
ers
ity
 on
 03
/31
/15
. F
or 
pe
rso
na
l u
se 
on
ly.
	 132	
 
VI01CH07-Denison ARI 19 August 2014 10:59
5'
Structural and accessory  proteinsPolyprotein 1a and 1ab nsps
An 3'
An 3'
5'
3'
3'
3'
3'
ORF1a ORF1b
–1 RFS
a
b
ExoN
N7-MT
ssRBP RdRp
Hel/NTPase NendoU
2'-OMT
ES
M
N
Polyprotein translation and processing
Leader 
TRS 
Body TRS 
Replication Negative-strand synthesis 
Leader added 
Synthesis of nested set
of  sgmRNA 
Translation of 
viral proteins 
Synthesis of (–)sgRNA 
Transfer to leader TRS Un 5'
3' Un 5'
Un 5'
Un 5'
Un 5'
DXE D HX4D DXG
ZnF N7-MT3' 5'  ExoN
1 2 3 4 5 6 7 9 13 1510 12 168 14
Motif II Motif IIIMotif I
5' An 3'
5' An 3'
Figure 1
Coronavirus genome organization and replication strategy. (a) Open reading frame (ORF) 1ab encompasses roughly two-thirds of the
genome and encodes the replicase nonstructural proteins (nsp1–16). Nsp11 is ∼15 amino acids long with no known function and thus is
not shown. The other one-third of the genome encodes structural and accessory proteins including the spike (S), envelope (E), matrix
(M), and nucleocapsid (N) proteins. The structural and accessory proteins are shown for a generic CoV, as the accessory proteins vary
both in number and in position between CoVs. The nonstructural proteins nsp1–11 are translated from ORF1a (blue), whereas
translation of the ORF1b proteins (nsp12–16) only occurs following a −1 ribosomal frameshift (RFS). Polypeptides containing nsp1–11
(pp1a) or nsp1–16 (pp1ab) are cleaved by up to three viral proteases to generate individual nsps. The functions of several nsps are noted:
nsp9, single-stranded RNA–binding protein (ssRBP); nsp12, RNA-dependent RNA polymerase (RdRp); nsp13, helicase (Hel) and
NTPase; nsp14, 3′→5′ exoribonuclease (ExoN) and N7-methyltransferase (N7-MT); nsp15, uridylate-specific endonuclease
(NendoU); nsp16, 2′-O-methyltransferase (2′-OMT). The active site residues of nsp14 involved in proofreading are distributed across
three motifs (I–III). Additionally, a zinc finger domain (ZnF) is encoded, which is unique among the DEDD superfamily of exonucleases
to which nsp14 ExoN belongs. (b) CoV replication (top) involves the production of full-length negative-strand intermediates (striped )
that are used to generate new positive-strand genomes (solid ). Transcription and translation (bottom) of the 3′ ORFs requires the
generation of negative-strand subgenomic RNAs [(−)sgRNAs] (striped ) that are then used to make viral subgenomic messenger RNA
(sgmRNA). Only the 5′-most ORF (checkered ) is translated for each sgmRNA. Abbreviation: TRS, transcriptional regulatory sequence.
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Replicase Proteins and Novel RNA-Modifying Functions
Studies of the CoV RNA synthesis machinery have focused on the identification and functions of
nsp1–16 (Figure 1a). Several CoVnsps have been shown to play prominent roles inRNA synthesis
and modification by harboring one or more enzymatic activities: the nsp8 primase (28, 29), nsp12
RdRp (30–32), nsp13 helicase (Hel) and NTPase (33, 34), nsp14N7-methyltransferase (N7-MT)
(35) and exoribonuclease (ExoN) (36), nsp15 uridylate-specific endoribonuclease (NendoU) (37),
and nsp16 RNA 2′-O-methyltransferase (2′-OMT) (38). Other viral proteins without predicted or
confirmed enzymatic activities also contribute to viral RNA synthesis and modification, including
nsp7, which interacts with nsp8 to form a large hexadecameric ring-like structure (39), and nsp10,
which is critical for viral RNA synthesis (40) and interacts with both nsp14 and nsp16 (41–44).
The nsp12 RdRp is the catalytic core of the CoV RNA synthesis machinery and consists of at least
two domains: an N-terminal domain unique to CoVs and a C-terminal catalytic domain that is
predicted to adopt a structure similar to other viral RdRps (45). CoVnsp12 contains an SDDactive
site motif that is conserved in all members of the Nidovirales order (46).Work by te Velthuis et al.
(30), using full-length nsp12 containing a native N terminus, demonstrated that nsp12 contains
weak primer-dependent RdRp activity; another group (32) has reported that nsp12 RdRp can
initiate de novo. Primase activity is likely provided by nsp8, which contains low-fidelity RdRp
activity similar to known DNA-dependent DNA primases (28, 29). Even less is known about the
unique N-terminal region, except that portions or all of the domain is required for in vitro RdRp
activity (31) and that it appears to lack homology to any protein identified to date. The encoding of
such a diverse repertoire of RNA-modifying functions suggests that CoVs have evolved a network
of proteins that might be more analogous to cellular RNA and/or DNA synthesis machinery. This
possibility, particularly relating to the mechanisms by which CoVs maintain the integrity of their
large RNA genomes, is discussed further below.
RNA VIRUS REPLICATION FIDELITY: DETERMINANTS AND THE
EFFECT ON VIRAL POPULATIONS
A Comparison with Cellular Organisms
Both cellular life forms and all viruses must faithfully replicate their genomes to ensure the trans-
mission of genetic information. For cellular organisms, faithful reproduction of genetic material
is mediated by a network of proteins tasked with detecting and repairing errors during or sub-
sequent to DNA synthesis. In its entirety, this process is referred to as replication fidelity, and
it encompasses at least three critical steps: (a) selection and extension of the correct nucleotide
onto the replicatingDNA strand by aDNA polymerase, (b) removal of mismatched nucleotides by
intrinsic 3′→5′ ExoN activity within theDNA polymerase or by a closely associated 3′→5′ ExoN–
containing subunit, and (c) correction by the cellular mismatch repair system of errors that have
escaped proofreading (Figure 2) (47–49). Each of these processes contributes to cellular DNA
replication fidelity, but the relative contributions of these steps toward the estimated error rate of
10−9 to 10−11, or one error per 109 to 1011 nucleotides, vary. Correct nucleotide selection, recog-
nition of a properly formed base pair, and extension by the DNA polymerase together provide
a greater contribution to fidelity (10−5) than either proofreading (10−2) or the mismatch repair
system (10−3), though the relative contributions are likely error type specific (47, 50, 51). The
fidelity of DNA and RNA polymerases likely results more from polymerase dynamics—such as
recognition of the shape of correct versus incorrect base pairs and conformational changes within
the polymerase active site—than from the capacity of the polymerase to selectively discriminate
between nucleotides (52–58). Beyond these mechanisms, DNA-based cellular organisms also have
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100 10 –1 10 –2 10 –3 10 –4 10 –5 10 –6 10 –7 10 –8 10 –9 10 –10 10 –11
Estimated mutation rate
(number of errors per nucleotide per replication cycle)
Low
fidelity
High
fidelity
RNA viruses
Coronaviruses Nsp14 ExoN
Cellular
DNA replication Base incorporation Proofreading Mismatch and excision repair
Base incorporation
Base incorporation
Figure 2
Replication fidelity in RNA viruses and DNA-based organisms. Shown is the estimated range of mutation rates (dashed arrows) for RNA
viruses, coronaviruses, and cellular DNA replication. The relative contributions of polymerase base incorporation (cyan), proofreading
( green), and mismatch and excision repair ( purple) toward the estimated mutation rates are shown. See the text for specific references
regarding the estimated mutation rates. Abbreviation: nsp14 ExoN, nonstructural protein 14 exoribonuclease.
MHV: murine
hepatitis virus
machinery dedicated to repairing damaged bases, removing UV-induced pyrimidine dimers, and
rejoining double-strand breaks. Overall, cellular DNA replication is orchestrated by numerous ac-
cessory proteins and by an ensemble of DNA polymerases: 5 for Escherichia coli, 8 for Saccharomyces
cerevisiae, and at least 16 for humans (recently reviewed in 47).
Compared with cellular organisms, RNA viruses areminimalists in terms of replication fidelity.
The primary determinant of RNA virus genome replication, with the exception of the retroviruses,
is the RdRp. Positive-strand RNA viruses with genomes <20 kb lack proofreading and other
postreplicative repair mechanisms (59) and therefore rely on the viral RdRp for maintenance of
genome sequence integrity. This reliance on the viral RdRp theoretically limits the fidelity of RNA
viruses to an upper limit in the range of∼10−5. In fact, most RNA viruses replicate with estimated
error rates between 10−3 and 10−5, which results in approximately one mutation per genome per
round of replication for a typical ∼10-kb genome (2, 60). This fidelity range is similar to that
observed with exonuclease-deficient DNA polymerases, and in fact, error-prone Y family DNA
polymerases polymerize with fidelities much lower than 10−5 (49, 61–63). Thus, the low fidelity
of RNA virus genome replication is likely not because RdRps polymerize RNA with significantly
lower fidelity than their DNA polymerase counterparts; rather, low fidelity is primarily a result
of the lack of proofreading activity (59, 64). This hypothesis is supported by the recent discovery
that CoVs and other members of the Nidovirales order with genomes >20 kb encode a 3′→5′
ExoN (36, 65) involved in maintaining CoV replication fidelity (66–69). The estimated mutation
rates of murine hepatitis virus (MHV) and SARS-CoV are approximately 2.5 × 10−6 and 9 ×
10−7 mutations per nucleotide per replication cycle, respectively (Figure 2). Genetic inactivation
of CoV ExoN activity reduces these estimated mutation rates to the range observed in other RNA
viruses and comparable to that of DNA polymerases lacking exonuclease activity (67, 68).
Diversity of RNA Virus Populations
RNA viruses are among the most diverse replicative units in existence (70), and they demonstrate
a remarkable capacity for adaptation due in part to high mutation rates during replication. RNA
viruses replicate exponentially, resulting in populations that can theoretically include a substitution
at every site in the genome (71). As a result of this replicative capacity, RNA viruses exist as
populations of heterogeneous yet genetically related viruses, often referred to as mutant swarms,
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mutant clouds, or quasispecies. The defining principle of viral quasispecies evolution is that viral
populations are composedof variants capable of interacting in a cooperative or antagonisticmanner
(see 71, 72 for recent reviews on viral quasispecies evolution). As a result, quasispecies evolution
posits that it is then the viral population, and not an individual variant, that is the subject of
natural selection. Mutant swarms have been shown to act as a collective during infection (73); one
of the most definitive examples of this phenomenon occurs during poliovirus infection. Poliovirus
is neurotropic in humans and mouse models. Poliovirus populations that have been genetically
bottlenecked with reduced diversity lose their neurotropism, whereas expanding diversity of the
poliovirus population by passage in the presence of RNAmutagen reestablishes neurotropism (74).
This cooperativity might allow initially deleterious mutations or less fit variants to be maintained
within a population, potentially facilitating more rapid adaptation under selective pressure or in
new host environments (73, 75).
Altered-Fidelity Variants
The replication fidelity of RNA viruses is likely evolutionarily constrained within a range that
balances genome stability with the generation of sufficient genetic diversity. Therefore, the mech-
anisms by which RNA virus replication fidelity is maintainedmust be evolutionarily finely tuned to
achieve these contrasting but important goals. A frequent misconception regarding viral mutation
rates, particularly in response to a perceived danger of mutator variants (69, 76), is that increasing
the mutation rate proportionally increases the rate at which viral populations adapt (77, 78). In
contrast to this supposition, although the normally high mutation rates of RNA virus replication
contribute to the adaptive capacity of RNA viruses, increasing the mutation rate beyond that of
the wild-type virus often results in a decrease in fitness (69, 76, 79). This is primarily due to the
probability that the majority of random mutations are deleterious (60, 71, 79). RNA viruses are
thought to replicate at an error threshold; thus, even marginal increases in mutation rates could
result in an excess of deleterious mutations within the population (see 72 for an excellent review).
On the other hand, increasing fidelity also results in decreased pathogenesis and spread, either
through a decrease in replication speed, an impaired ability to adapt, or both (71, 80–82).
Though many factors likely contribute to the high adaptive potential of RNA viruses, one of
the key contributors is the viral RdRp. Much like their DNA polymerase counterparts, RdRps
catalyze nucleotide polymerization and are the core machinery by which RNA viruses replicate
their genomes. The structural and dynamic aspects of RdRp fidelity remain an active area of
research, but early studies with the HIV reverse transcriptase and with E. coli and bacteriophage
T4 DNA polymerases demonstrated that point mutations can increase or decrease polymerase
fidelity, suggesting that changes to RdRp fidelity might be possible (83–85). The first example of
an RdRp with altered fidelity was the poliovirus RdRp G64S mutation (74, 86). This mutation
was identified independently by two groups following passage of poliovirus (PV) in the presence
of the antiviral nucleoside analog ribavirin, and it resulted in a ∼3-fold increase in replication
fidelity. Later studies by both groups demonstrated that this single mutation resulted in viral
attenuation in vivo, and that attenuation was likely the result of restricting the genetic diversity of
the virus population (80, 81). These studies provided the first evidence that increased fidelity was
attainable for an RNA virus. Subsequently, fidelity variants with mutations in viral RdRps have
been isolated for other picornaviruses and arboviruses (Figure 3 andTable 1) (67, 68, 74, 76, 80,
81, 86–99). Most reported altered-fidelity mutants deviate from the fidelity of the wild-type virus
by a maximum of 4- to 5-fold and often are attenuated in vivo (Figure 3). A recent study using
coxsackievirus B3 (CVB3) reported that mutations within the CVB3 RdRp that reduced fidelity
by more than ∼3-fold resulted in virus nonrecovery and suggested that this might represent the
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Figure 3
Fidelity variants of RNA viruses. Published RNA virus fidelity variants (excluding retroviruses) are shown. For each variant, the fold
change in replication fidelity was calculated using previously published data and compared with the wild type (dotted horizontal line). See
the text and Table 1 for specific references for each point. All points are colored according to whether or not the fidelity-altering
mutation resulted in attenuation in vivo: blue, not attenuated; orange, attenuated; gray, attenuation not tested. The two red points
denote mutations resulting in nonrecoverable viruses.
lower limit of RdRp fidelity for the picornaviruses (76). To our knowledge, no other group has
reported RdRp mutants with lower fidelity. An upper limit for alterations in RdRp fidelity has
yet to be described. These studies support the hypothesis that RNA viruses replicate within an
evolutionarily selected range of fidelity, and that deviation outside of this range profoundly impacts
virus fitness in vitro and in vivo.
The CoV Exoribonuclease in Replication Fidelity and Pathogenesis
In contrast to the picornaviruses and arboviruses, CoVs encode a 3′→5′ ExoN activity in nsp14
that is critical for replication fidelity. The larger members of the Nidovirales order (i.e., Coron-
aviridae and Roniviridae) with genomes of 26 to 32 kb encode ExoN, whereas it is absent in the
smaller Arteriviridae family members with genomes <16 kb (25, 65). The recent identification
of the Nam Dinh virus (NDiV), an insect nidovirus that encodes ExoN in its 20-kb genome,
provides an important link in the transition from small to large nidoviruses (100, 101). CoV nsp14
is approximately 530 amino acids long and contains two enzymatic activities (Figure 1a): N-
terminal ExoN activity and C-terminal N7-MT activity (35). The ExoN domain contains four
acidic residues, DEDD, in three motifs, which are a defining characteristic of the DEDD super-
family of RNA and DNA exonucleases (102). In addition to these four invariant residues, CoV
nsp14 ExoN contains a highly conserved histidine residue within motif III resulting in an HX4D
arrangement (25, 36). Members of this DEDDh subgroup include proofreading enzymes such
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Table 1 Fidelity variants of RNA viruses
Virus Reference(s) Mutation(s) Protein Systema Methodb
Fold
changec Attenuatedd
CVB3 76 L241I 3Dpol Virus Fragment sequencing −1.5 No
I230F, M145L,
S299T
3Dpol Virus Fragment sequencing −1.5 –
S299T, A372V 3Dpol Virus Fragment sequencing −1.5 –
S164P 3Dpol Virus Fragment sequencing −1.6 No
P48K 3Dpol Virus Fragment sequencing −1.6 Yes
I230F, S299T 3Dpol Virus Fragment sequencing −1.6 –
F232Y, S299T 3Dpol Virus Fragment sequencing −1.6 –
F232Y, S299T,
A372V
3Dpol Virus Fragment sequencing −1.6 –
I230F, M145L 3Dpol Virus Fragment sequencing −1.8 –
A239G 3Dpol Virus Fragment sequencing −1.9 Yes
Y268W 3Dpol Virus Fragment sequencing −2.1 Yes
Y268H 3Dpol Virus Fragment sequencing −2.1 Yes
F232Y 3Dpol Virus Fragment sequencing −2.6 Yes
I230F 3Dpol Virus Fragment sequencing −2.6 Yes
F232V 3Dpol Protein Kinetic parameters −2.7 –
F232L 3Dpol Protein Kinetic parameters −3.6 –
88, 98 S299T 3Dpol Virus/protein Multiple methods −1.5 –
A372V 3Dpol Virus/protein Multiple methods 1.8 –
PV 74, 80, 81,
86, 89
G64V 3Dpol Virus Fragment sequencing 1.8 Yes
G64L 3Dpol Virus Fragment sequencing 1.8 Yes
G64A 3Dpol Virus Fragment sequencing 2.0 Yes
G64S 3Dpol Virus/protein Multiple methods 2.0–4.0 Yes
G64T 3Dpol Virus Fragment sequencing 2.5 Yes
93 T362I 3Dpol Virus/protein Kinetic parameters −1.5 Yes
96 K359R 3Dpol Virus/protein Kinetic parameters 5.0 Yes
HEV71 94, 95 G64N 3Dpol Virus Fragment sequencing −1.1 –
G64T 3Dpol Virus Fragment sequencing 4.7 –
G64R 3Dpol Virus Fragment sequencing 14.0 –
S264L 3Dpol Virus Fragment sequencing 14.0 Yes
FMDV 97 M296I 3Dpol Virus/protein Multiple methods −2.5 –
91 R84H 3Dpol Virus Fragment sequencing 1.4 No
92 D5N 3Dpol Virus Fragment sequencing 1.5 No
A38V 3Dpol Virus Fragment sequencing 1.7 Yes
D5N, A38V,
M194I,
M296V
3Dpol Virus Fragment sequencing 1.9 Yes
CHIKV 87 C483Y Nsp4 Virus Fragment sequencing 1.4 Yes
90 C483A Nsp4 Virus Fragment sequencing −1.4 Yes
C483W Nsp4 Virus Fragment sequencing −1.5 Yes
C483G Nsp4 Virus Fragment sequencing −1.9 Yes
(Continued )
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Table 1 (Continued)
Virus Reference(s) Mutation(s) Protein Systema Methodb
Fold
changec Attenuatedd
MHV 67 D89A, E91A Nsp14 Virus Full-genome
sequencing
−15.0 –
SARS-
CoV
68 D90A, E92A Nsp14 Virus Full-genome
sequencing
−20.7 –
69 D90A, E92A Nsp14 Virus Full-genome
sequencing
−14.0 Yes
Abbreviations: CHIKV, chikungunya virus; CVB3, coxsackievirus B3; FMDV, foot-and-mouth disease virus; HEV71, human enterovirus 71;
MHV, murine hepatitis virus; PV, poliovirus; SARS-CoV, severe acute respiratory syndrome coronavirus.
a“Virus” denotes the recovery of virus, whereas “protein” denotes recombinantly expressed protein.
bSequencing was performed on either viral supernatants, viable plaques, or total intracellular viral RNA.
cFold change was calculated using values reported in each reference. A range is reported if values were independently reported by more than one group.
dDashes indicate that the attenuation phenotype is unknown.
as the ε subunit of E. coli DNA polymerase III (Pol III). This similarity early on suggested a
role for nsp14 ExoN in proofreading and/or other aspects of RNA processing (25). In contrast
with its cellular counterparts, CoV ExoN also contains a unique zinc finger domain of unknown
function between motifs I and II. Biochemical confirmation of ExoN activity using bacterially
expressed nsp14 from HCoV-229E demonstrated that ExoN is capable of cleaving both ssRNA
and dsRNA in a 3′→5′ direction (36). Recombinant HCoV-229E genomes containing mutations
that inactivated ExoN activity did not allow recovery of replication-competent virus and exhibited
profound defects in viral RNA synthesis. In contrast, MHV and SARS-CoV containing mutations
in motifs I and III were replication competent, albeit with reductions in viral RNA synthesis (67,
68). Alanine substitution of the DEDDh residues does not impair N7-MT activity of purified
nsp14 in vitro (35, 103); however, other mutations within nsp14 ExoN have been demonstrated
to affect N7-MT activity in vitro, indicating that ExoN and N7-MT functions are evolutionarily
linked or potentially serve a novel function in CoV RNA synthesis (103).
RecombinantMHV lackingExoNactivity (ExoN−) accumulated 15-foldmoremutations com-
pared with wild-type MHV with intact ExoN (ExoN+) (67). Recombinant SARS-CoV ExoN−
also demonstrated an almost identical mutator phenotype in culture and during mouse infection
using ExoN− variants of virulent mouse-adapted SARS-CoV (MA-SARS) (68, 69). In both cases,
between 14- and 20-fold more mutations were present within the ExoN− viruses as compared
with ExoN+ viruses (Table 1 and Figure 3). ExoN inactivation profoundly attenuated the patho-
genesis of MA-SARS in young, aged, and immunocompromised mice (67, 69). Both the genotype
and phenotype of ExoN− MHV and SARS-CoV were stable over extended passage in culture
and in mice. Furthermore, MA-SARS ExoN− did not revert to virulence even during persistent
infection of SCID (severe combined immunodeficient) mice. Although the precise mechanism
of fidelity regulation by ExoN remains to be defined, all available biochemical and virological
evidence supports the conclusion that nsp14 ExoN provides a critical proofreading function dur-
ing CoV replication (36, 42, 66–69, 104). Both MHV ExoN− and SARS-CoV ExoN− viruses
demonstrated increased sensitivity to the RNA mutagen 5-fluorouracil (5-FU) as compared with
ExoN+ viruses (66). Next-generation sequencing of SARS-CoV RNA following treatment with
5-FU indicated that the ExoN− virus populations accumulated 40-fold more mutations compared
with untreated ExoN− population, and 24-fold more mutations compared with 5-FU-treated
wild-type ExoN+ virus (66). These results together demonstrate a role for ExoN in maintaining
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CoV replication fidelity, establish a link between CoV fidelity and pathogenesis, and provide the
most direct evidence that ExoN is the first known proofreading enzyme encoded by an RNA virus.
It remains to be determined whether nsp14 ExoNmediates other functions in virus replication
or host interactions. Arenaviruses such as Lassa fever virus (LASV) are the only other mammalian
RNA viruses known to encode a 3′→5′ ExoN (105). LASV nucleoprotein (NP) is a DEDDh
ExoN that specifically degrades double-stranded RNA (dsRNA) and thus is a critical component
of immune evasion (105). SARS-CoV nsp1 has been shown to induce endonucleolytic cleavage
of host mRNAs (106); however, there is as yet no direct evidence that nsp14 ExoN degrades
host mRNAs. CoV ExoN was shown to cleave both dsRNA and ssRNA in vitro (36), and ExoN-
mediated cleavage of ssRNA resulted in larger cleavage products as compared with cleavage of
dsRNA.These data suggest that nsp14 ExoN could potentially exert differential activity on diverse
RNA species (36). More recent work demonstrated that the small nonenzymatic CoV protein
nsp10 can stimulate ExoN activity by almost 35-fold and renders ExoN capable of cleaving 3′
mismatched residues (42). Thus, the specificity and activity of ExoN on various viral or host RNA
substrates conceivably could be determined through interactions with other viral proteins. Aside
from nsp10, CoV nsp14 ExoN could also function in tandem with the viral endonuclease nsp15
NendoU to degrade RNA targets. In fact, CoV nsp15 NendoU has an uncharacterized interferon
antagonist activity, and the arterivirus homolog of nsp15 was recently shown to inhibit interferon
β induction (107, 108). The capacity of ExoN to cleave a variety of RNA substrates and the
uncharacterized interferon antagonist activity identified for nsp15 NendoU suggest that these
two proteins could be important for suppression of anti-CoV immune responses (108). If so, such
a function for ExoN could contribute to the attenuation of MA-SARS ExoN− observed in vivo.
CORONAVIRUS GENOME SIZE: SOLVING THE EIGEN PARADOX
RNA Virus Genome Size and the Eigen Paradox
Unlike in DNA viruses and DNA-based organisms, the genome size distribution of ssRNA
genomes from different virus families is quite narrow; the largest ssRNA virus genomes are∼32 kb
in length (65). Excluding the nidoviruses, (+)ssRNA viruses range in size from∼2,300 to∼20,000
bases, with the majority of ssRNA virus genomes measuring ∼10 kb (Figure 4a) (65). Assuming
near-equivalent error rates, RNA viruses with larger genomes would be predicted to accumulate
more mutations per genome during replication, and would in turn be predicted to accumulate
more deleterious mutations, leading to virus extinction. This has led to a theoretical limitation
to RNA virus genome size termed the Eigen paradox or Eigen trap, after Manfred Eigen’s work
describing self-replicating molecules (1, 109, 110). In an analysis of CoV evolution, Nga et al.
(100) depicted the Eigen trap as a triangle on which genome size, replication fidelity, and genome
complexity are located at the apices (Figure 4b). In the center of this triangle are the RNA viruses,
which due to their low-fidelity replication are confined within the Eigen trap. Because they are
unable to increase replication fidelity, RNA viruses are evolutionarily constrained to have genomes
of relatively low complexity and small size.
However, a growing body of work suggests that CoVs have found a way to escape this trap.
Recent comparative genomics studies of complete nidovirus genomes proposed that acquisition
of ExoN allowed expansion of the smaller ancestor nidovirus genome (65, 100, 111). Once CoVs
acquired mechanisms to increase their fidelity and limit the accumulation of deleterious muta-
tions, increases in both genome size and complexity were possible. The acquisition of additional
replicase proteins likely allowed both the continued expansion and the divergence of nidoviruses
into present-day CoVs (Figure 4c) (111). Conceptually, expansion of ORF1a could have allowed
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Figure 4
Size of positive-sense single-stranded RNA [(+)ssRNA] virus genomes and expansion of the coronavirus (CoV) genome. (a) Median
genome size for (+)ssRNA viruses, excluding the nidoviruses, in comparison with each family within the order Nidovirales. Full-length
genomes were obtained from the National Center for Biotechnology Information (NCBI) Viral Genomes Resource. Each bar depicts
the median genome size and extends from the 25th to 75th percentile; the whiskers show the minimum and maximum values. Genomes
containing ( green) and lacking (cyan) 3′→5′ exoribonuclease (ExoN) activity are shown. (b) The relationship between replication
fidelity, genome complexity, and genome size. Fidelity, complexity, and size increase as the arrows move from the center to the edges of
the triangle. RNA viruses have low replication fidelity, low genomic complexity, and small genomes and thus are constrained within the
small Eigen triangle (or trap). Acquisition of ExoN likely helped CoVs ( green) escape this trap by increasing replication fidelity. Panel b
adapted with permission from Nga et al. (100). (c) A schematic of the CoV genome (top) depicts open reading frame (ORF) 1a in blue,
ORF1b in orange, and the 3′ ORFs in red. The order in which these regions are thought to have expanded—ORF1b→ORF1a→3′
ORFs—is shown (bottom). The relative contribution to overall CoV genome size, as defined by the total number of bases added, is
denoted by the height of the triangle. See Lauber et al. (111) for additional details. Some predicted activities and functions likely
acquired as a result of genomic expansion are also shown.
for increased replication efficiency, possibly through the regulation of ORF1b proteins (111). This
hypothesis is supported by studies showing the association of ORF1a products such as nsp7–10
with the ORF1b proteins (38, 41–44, 112–114). Furthermore, the lack of homologous nsp7–10
sequences outside of the coronaviruses and toroviruses suggests that acquisition of these pro-
teins might have also facilitated genomic expansion of the “large” nidoviruses (65). Acquisition of
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Processivity: the
average number of
consecutive
nucleotides a
polymerase is capable
of adding during a
single template-
binding event
several 3′ accessory ORFs, excluding essential structural proteins, was shown to have contributed
the most to CoV genomic expansion, as defined by the total number of nucleotides added. Both
the number and the function of these 3′ ORFs vary tremendously among CoVs.
A Model for a Putative Multisubunit Polymerase Complex
Whereas the simplest of RNA viruses encode only an RdRp, other RNA viruses encode a variety
of RNA-modifying enzymes, such as RNA capping (or cap snatching) machinery and helicase
activity. Due to their large genomes (65, 111), unique RNA-modifying functions, and putative
proofreading capability (25, 65–69, 111), CoVs may have more complex RNA replication systems
than those described for many other RNA viruses. Additionally, the limited polymerase activity
observed for nsp12RdRp (30–32) alone likely reflects the need for additional viral proteins in order
to faithfully and rapidly replicate the CoV genome during infection. These observations suggest
the possibility thatCoVs employ amultisubunit polymerase complex for viral RNA synthesis. Such
a complex has yet to be described experimentally, likely due to challenges of recapitulating in vitro a
complex containing nsp12 RdRp and six or more additional replicase proteins. Although detailed
biochemical and structural studies will be essential in understanding how the CoV replicase is
assembled, a model can be proposed (104, 115) on the basis of known and predicted activities and
by analogy to DNA polymerase complexes (Figure 5), specifically DNA Pol III.
One of the most extensively studied multisubunit polymerases is E. coli DNA Pol III, which is
the major polymerase during chromosomal replication (recently reviewed in 116). E. coliDNAPol
III is a holoenzyme (DNAPol III HE) that contains a catalytic core (αεθ), a processivity factor (β2
sliding clamp), and a multisubunit clamp loader that loads β2 onto the DNA template (116). The
catalytic core contains three subunits: the polymerase (α); the 3′→5′ exonuclease (ε); and the small
nonenzymatic θ subunit, which stabilizes and stimulates ε (116–118). Much like the Pol III core,
CoV nsp12 RdRp likely interacts with nsp14 ExoN, as both proteins would need to be in close
proximity for error removal and repair (Figure 5). The viral helicase nsp13 is likely upstream but
closely associated with nsp12 RdRp (33) to ensure the availability of a single-stranded template.
This model is consistent with previous studies describing that a large majority of CoV RNA
is present as partially double-stranded RNA, suggesting that multiple RNA templates are being
synthesized for each negative-strand template (119).Nsp15 andnsp16 could also be associatedwith
this complex; however, given the undefined role of nsp15 during replication and the role of nsp16
in RNA capping, these proteins might form distinct complexes. Other proteins, particularly those
from ORF1a, likely interact with the CoV polymerase core (112–114), which would be consistent
with the hypothesis that some ORF1a proteins were acquired to regulate ORF1b proteins and/or
to increase the efficiency of replicating an increasingly large CoV genome (111).
Though the functions of several of the ORF1a proteins are just beginning to be defined, sev-
eral studies support the hypothesis that nsp7–10 are associated with this polymerase core. CoV
nsp8 was shown to harbor RdRp and primase activity (28) and to interact with nsp7 to form a
large toroidal hexadecamer structure (39). The ∼30-A˚ central pore of the SARS-CoV nsp7-nsp8
hexadecamer is lined with positively charged amino acids, which allow the supercomplex to bind
dsRNA. These data suggest that the nsp7-nsp8 hexadecamer could function as a processivity fac-
tor for the CoV polymerase during RNA replication, much like the β2 clamp within the E. coli
Pol III HE (reviewed in 120) and other processivity factors. The small nonenzymatic nsp10 asso-
ciates with both CoV methyltransferases: nsp14 N7-MT and nsp16 2′-OMT (41–44). Binding of
nsp10 to nsp16 is required for 2′-OMT activity, an enzymatic activity that is critical in mitigating
detection of CoV RNA by the innate immune system (121). Nsp10 also stimulates nsp14 ExoN
activity in vitro (42), though the significance of an nsp10-nsp14 interaction during virus replication
www.annualreviews.org • RNA Virus Replication Fidelity 123
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Figure 5
Model of the putative coronavirus multisubunit polymerase. The viral genome is shown in light gray and negative-sense template RNA
in dark gray. The viral helicase and NTPase (nsp13 Hel/NTPase; green) is shown removing a newly synthesized viral genome, and the
viral single-stranded RNA–binding protein (nsp9 ssRBP; cyan) is shown protecting the single-stranded RNA. The remaining portions
of the model are based on known structures (nsp7 and nsp8) and/or reported protein-protein interactions. The polymerase core is
predicted to include the viral RNA-dependent RNA polymerase (nsp12 RdRp; red ), the 3′→5′ exoribonuclease and
N7-methyltransferase (nsp14 ExoN and N7-MT; blue), and the nonenzymatic protein nsp10 (orange). This core is shown tightly
associated with the putative processivity factor (nsp7 and nsp8; yellow and purple, respectively). Figure adapted with permission from
Smith et al. (104).
has yet to be described. Nsp9 appears to function as an ssRNA-binding protein (122), suggest-
ing that its function is to protect the single-stranded template as well as single-stranded newly
synthesized RNA, a function analogous that of the SSB protein during DNA replication. Indeed,
interactions between nsp9 and other replicase proteins have been observed (122). The continued
elucidation of the functions of ORF1a proteins will be essential in establishing their importance
during replication and their potential evolutionary linkage to specific ORF1b proteins.
CONCLUDING REMARKS
RNA virus replication fidelity is emerging as a new field of study that incorporates polymerase
biochemistry, in vitro evolution experiments, virus fitness studies, and bioinformatic analyses.
The studies are yielding surprising insights that have important implications for how we think
about virus replication, pathogenesis, and evolution, as well as translational approaches to virus
inhibition and attenuation.
Impact of Decreased Fidelity on Virus Fitness
Consider the following statement: An increased mutation rate favors the virus. This widely held
view is based on two clear observations: (a) RNA viruses replicate with much lower fidelity than
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DNA-based organisms, and (b) RNA viruses demonstrate rapid adaptation and emergence of
resistance to antivirals and vaccines. The assumption built on these observations is that if decreased
fidelity is beneficial for the virus, further decreases in fidelity are even better. Yet the data presented
here for several virus families suggest that decreasing fidelity results in impaired replication,
decreased competitive fitness, and attenuated virulence. Although only a few virus families have
been investigated for the effect of decreased fidelity, it is certainly possible that examples will be
identified where decreased fidelity favors the virus under specific circumstances, such as selection
of resistance mutants to antivirals or revertants of conditional mutants.
New Models for RNA Synthesis and Regulation of Fidelity
Data presented in this review support the hypothesis thatCoVs use amultiprotein replication com-
plex that incorporates a processivity factor, a proofreading exoribonuclease, an RNA-dependent
RNA polymerase, and a helicase, as well as predicted stimulatory cofactors and capping activities.
These data and models argue that CoV RNA synthesis, modification, and fidelity might be more
akin to those of DNA-based organisms with multiprotein DNA replication complexes. This has
significant implications for understanding CoV replication but also for investigating the interface
between DNA- and RNA-based life. The fact that CoVs are the largest known replicating RNA-
based organisms suggests the possibility that they may exist at the boundary of what is possible in
an RNA virus that has to balance genome stability with the population diversity required for adap-
tation. Alternatively, the demonstrated capacity of CoVs for zoonotic infections and host-species
movement might argue that CoVs use a much larger range of fidelity and genome complexity to
explore a greatly expanded sequence and phenotype space.
Goldilocks? Maybe
The Goldilocks metaphor is often used in cosmology and evolution to describe the fortuitous
conditions that allowed the emergence and evolution of life. One is tempted to apply a similar
metaphor to virus replication fidelity. Certainly the available data as presented in this review
indicate that increasing or decreasing the fidelity of a number of divergent RNA viruses impairs
fitness and is attenuating. However, the fact that fidelity can be moved off center—notably by at
least 20-fold for CoVs—suggests that a range of fidelity is available to RNA viruses, potentially
allowing for selection of more or less diverse populations. If Goldilocks is applicable, it would
be to a range rather than a single optimal fidelity set point. CoVs represent the most obvious
opportunity to explore this possibility, because they at minimum require the interaction of RdRp
with a proofreading ExoN. This would represent at least two possible fidelity states, one high-
fidelity state during RdRp-ExoN interaction and one low-fidelity state where RdRp interaction
with ExoN is altered.
Fidelity as a Target for Inhibition and Attenuation
Could altered-fidelity viruses be used as live attenuated vaccine candidates? The best data for the
effect of altered fidelity are presented here and show that either increased or decreased fidelity
is attenuating in a range of RNA virus families. Thus it is possible that fidelity regulation is so
central to all aspects of virus replication and pathogenesis that altering fidelity may be a broadly
applicable approach to stable attenuation. For CoVs it appears that genetic inactivation of ExoN
results in both a genotype and a phenotype that are attenuated and are resistant to reversion in
vitro and in vivo during passage or persistent infection. Further, inactivation of ExoN results in a
profound increase in sensitivity to RNAmutagens for SARS-CoV.Thus, the process of replication
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fidelity may be a new target for virus family–wide attenuation and inhibition of virus replication
and pathogenesis.
SUMMARY POINTS
1. RNA viruses replicate with lower fidelity than DNA-based organisms due to the lack of
mechanisms for error recognition and repair.
2. RNA viruses exist as populations of genetically related variants, also known as mutant
swarms or quasispecies, that are the units of selection.
3. To date, small RNA viruses are thought to regulate fidelity principally through the
RNA-dependent RNA polymerase.
4. The tolerated range of increased or decreased fidelity for RNA viruses lacking proof-
reading may be very narrow.
5. Incorporation of a proofreading exoribonuclease allowed expansion of nidovirus genome
size and complexity, as observed in coronaviruses.
6. Coronaviruses tolerate a 20-fold decrease in fidelity; the limits of increased or decreased
replication fidelity for CoVs have not been defined.
7. Coronaviruses may assemble a multiprotein complex containing RNA-dependent RNA
polymerase and proofreading activities.
8. Fidelity determinants may represent highly conserved and nonredundant targets for viral
inhibition and live-virus attenuation.
FUTURE ISSUES
1. For coronaviruses, identifying all of the components of a multiprotein replication com-
plex by in vitro reconstitution and structural studies will allow prediction and testing of
our model for assembly and function of the replication complex in RNA synthesis and
fidelity.
2. It will be exciting to test whether RNA viruses explore the range of fidelity under different
selective pressures, and even during the course of a single infectious cycle.
3. The contributions of host cell proteins to RNA virus replication fidelity should be ex-
plored to define whether different environments stimulate or impair virus replication
fidelity.
4. It will be important to define the multiple contributing factors to replication fidelity for
CoVs and other RNA viruses, particularly robustness to mutations and RNA-dependent
RNA polymerase selectivity and speed.
5. Studies of other families of RNA viruses, including negative-strand segmented genomes
such as that of influenza virus, are needed to better understand common and divergent
mechanisms and ranges of tolerated replication fidelity.
6. The availability of increased-fidelity and decreased-fidelity strains of multiple RNA
viruses will allow testing of the impact of fidelity on host-range expansion, adaption,
and experimental evolution.
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7. Increasing availability and affordability of next-generation sequencingwill allow in-depth
analysis of the effects of fidelity and virus population diversity on virus replication, patho-
genesis, and fitness.
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